N-acyl amino acid compounds and methods of use

ABSTRACT

The invention relates to compounds of formula (I): 
     
       
         
         
             
             
         
       
     
     or a salt thereof, wherein R 1 , A, L, and R 2  and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority benefit of U.S. Provisional PatentApplication No. 62/384,682, filed Sep. 7, 2016. The entire contents ofthat application are hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

Fibrosis, a pathologic feature of many diseases, is caused by adysfunction in the body's natural ability to repair damaged tissues. Ifleft untreated, fibrosis can result in scarring of vital organs causingirreparable damage and eventual organ failure.

Patients with nonalcoholic fatty liver disease (NAFLD) may progress fromsimple steatosis to nonalcoholic steatohepatitis (NASH) and thenfibrosis. While liver fibrosis is reversible in its initial stages,progressive liver fibrosis can lead to cirrhosis.

Fibrosis in the kidney, characterized by glomerulosclerosis andtubulointerstitial fibrosis, is the final common manifestation of a widevariety of chronic kidney diseases (CKD). Irrespective of the initialcauses, progressive CKD often results in widespread tissue scarring thatleads to destruction of kidney parenchyma and end-stage renal failure, adevastating condition that requires dialysis or kidney replacement.

Scleroderma encompasses a spectrum of complex and variable conditionsprimarily characterized by fibrosis, vascular alterations, andautoimmunity. The scleroderma spectrum of disorders share the commonfeature of fibrosis, resulting in hardening or thickening of the skin.For some patients, this hardening occurs only in limited areas, but forothers, it can spread to other major organs.

Following myocardial infarction, cardiac structural remodeling isassociated with an inflammatory reaction, resulting in scar formation atthe site of the infarction. This scar formation is a result of fibrotictissue deposition which may lead to reduced cardiac function anddisruption of electrical activity within the heart.

Crohn's Disease is a chronic disease of unknown etiology tending toprogress even in the setting of medical or surgical treatment.Intestinal fibrosis is among the most common complications of Crohn'sdisease, resulting in stricture formation in the small intestine andcolon.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosingdisease of unknown etiology, occurring in adults and limited to thelungs. In IPF, the lung tissue becomes thickened, stiff, and scarred. Aslung fibrosis progresses, it becomes more difficult for the lungs totransfer oxygen into the bloodstream and the organs do not receive theoxygen needed to function properly. IPF currently affects approximately200,000 people in the U.S., resulting in 40,000 deaths per year.Patients diagnosed with IPF experience progressive breathlessness andeventually, complete respiratory failure.

Available courses of treatment are scarce, as there are currently nooptions on the market proven to have an effect on long-term patientsurvival or symptomatology. There remains a need for treatment offibrotic diseases.

The αvβ1 integrin, which is highly expressed on activated fibroblasts,directly binds to the latency-associated peptide of transforming growthfactor-β1 (TGFβ1) and mediates TGFβ1 activation; it plays a critical invivo role in tissue fibrosis. The present disclosure provides for αvβ1integrin inhibitors that may be useful for tissue-specific treatment offibrosis.

BRIEF SUMMARY OF THE INVENTION

Disclosed are N-acyl amino acid compounds that are αvβ1 integrininhibitors, compositions containing these compounds and methods fortreating diseases mediated by αvβ1 integrin such as a fibrotic disease.

In one aspect, provided is a compound of formula (I), or any variationthereof, or a salt thereof (e.g., a pharmaceutically acceptable saltthereof), as detailed herein.

Further provided is a pharmaceutical composition comprising a compoundof formula (I), or any variation thereof detailed herein, or a saltthereof (e.g., a pharmaceutically acceptable salt thereof), and apharmaceutically acceptable carrier or excipient.

In another aspect, provided is a method of treating a fibrotic diseasein an individual (such as a human) in need thereof comprisingadministering to the individual a therapeutically effective amount of acompound of formula (I), or any variation thereof detailed herein, or apharmaceutically acceptable salt thereof. In some embodiments, thefibrotic disease is pulmonary fibrosis, liver fibrosis, skin fibrosis,cardiac fibrosis, kidney fibrosis, or gastrointestinal fibrosis.

In another aspect, provided is a method of delaying the onset and/ordevelopment of a fibrotic disease in an individual (such as a human) whois at risk for developing a fibrotic disease.

Also provided is a compound of formula (I), or any variation thereofdetailed herein, or a pharmaceutical composition thereof, for thetreatment of a fibrotic disease.

Also provided is use of a compound of formula (I), or any variationthereof detailed herein, or a pharmaceutically acceptable salt thereof,in the manufacture of a medicament for the treatment of a fibroticdisease.

Further provided is a kit comprising a compound of formula (I), or anyvariation thereof detailed herein, or a pharmaceutically acceptable saltthereof. In some embodiments, the kit comprises instructions for useaccording to a method described herein, such as a method of treating afibrotic disease in an individual.

In another aspect, provided is a method of making a compound of formula(I) or any variation thereof. Also provided are compound intermediatesuseful in synthesis of a compound of formula (I), or any variationthereof.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides, inter alia, compounds of formula (I), andvariations thereof, pharmaceutical compositions comprising compounds offormula (I), and methods of using such compounds and compositions intreating fibrotic diseases.

Definitions

For use herein, unless clearly indicated otherwise, use of the terms“a”, “an” and the like refers to one or more.

Reference to “about” a value or parameter herein includes (anddescribes) embodiments that are directed to that value or parameter perse. For example, description referring to “about X” includes descriptionof “X”.

“Alkyl” as used herein refers to and includes, unless otherwise stated,a saturated linear (i.e., unbranched) or branched univalent hydrocarbonchain or combination thereof, having the number of carbon atomsdesignated (i.e., C₁-C₁₀ means one to ten carbon atoms). Particularalkyl groups are those having 1 to 20 carbon atoms (a “C₁-C₂₀ alkyl”),having 1 to 10 carbon atoms (a “C₁-C₁₀ alkyl”), having 6 to 10 carbonatoms (a “C₆-C₁₀ alkyl”), having 1 to 6 carbon atoms (a “C₁-C₆ alkyl”),having 2 to 6 carbon atoms (a “C₂-C₆ alkyl”), or having 1 to 4 carbonatoms (a “C₁-C₄ alkyl”). Examples of alkyl groups include, but are notlimited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl,t-butyl, isobutyl, sec-butyl, homologs and isomers of, for example,n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

“Alkylene” as used herein refers to the same residues as alkyl, buthaving bivalency. Particular alkylene groups are those having 1 to 20carbon atoms (a “C₁-C₂₀ alkylene”), having 1 to 10 carbon atoms (a“C₁-C₁₀ alkylene”), having 6 to 10 carbon atoms (a “C₆-C₁₀ alkylene”),having 1 to 6 carbon atoms (a “C₁-C₆ alkylene”), 1 to 5 carbon atoms (a“C₁-C₅ alkylene”), 1 to 4 carbon atoms (a “C₁-C₄ alkylene”) or 1 to 3carbon atoms (a “C₁-C₃ alkylene”). Examples of alkylene include, but arenot limited to, groups such as methylene (—CH₂—), ethylene (—CH₂CH₂—),propylene (—CH₂CH₂CH₂—), isopropylene (—CH₂CH(CH₃)—), butylene(—CH₂(CH₂)₂CH₂—), isobutylene (—CH₂CH(CH₃)CH₂—), pentylene(—CH₂(CH₂)₃CH₂—), hexylene (—CH₂(CH₂)₄CH₂—), heptylene (—CH₂(CH₂)₅CH₂—),octylene (—CH₂(CH₂)₆CH₂—), and the like.

“Alkenyl” as used herein refers to and includes, unless otherwisestated, an unsaturated linear (i.e., unbranched) or branched univalenthydrocarbon chain or combination thereof, having at least one site ofolefinic unsaturation (i.e., having at least one moiety of the formulaC═C) and having the number of carbon atoms designated (i.e., C₂-C₁₀means two to ten carbon atoms). An alkenyl group may have “cis” or“trans” configurations, or alternatively have “E” or “Z” configurations.Particular alkenyl groups are those having 2 to 20 carbon atoms (a“C₂-C₂₀ alkenyl”), having 6 to 10 carbon atoms (a “C₆-C₁₀ alkenyl”),having 2 to 8 carbon atoms (a “C₂-C₈ alkenyl”), having 2 to 6 carbonatoms (a “C₂-C₆ alkenyl”), or having 2 to 4 carbon atoms (a “C₂-C₄alkenyl”). Examples of alkenyl group include, but are not limited to,groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl),2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl,buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, homologs and isomers thereof,for example, pent-1-enyl, pent-2-enyl, hex-1-enyl, hex-2-enyl,hex-3-enyl, and the like.

“Alkenylene” as used herein refers to the same residues as alkenyl, buthaving bivalency. Particular alkylene groups are those having 2 to 20carbon atoms (a “C₂-C₂₀ alkenylene”), having 2 to 10 carbon atoms (a“C₂-C₁₀ alkenylene”), having 6 to 10 carbon atoms (a “C₆-C₁₀alkenylene”), having 2 to 6 carbon atoms (a “C₂-C₆ alkenylene”), 2 to 4carbon atoms (a “C₂-C₄ alkenylene”) or 2 to 3 carbon atoms (a “C₂-C₃alkenylene”). Examples of alkenylene include, but are not limited to,groups such as ethenylene (or vinylene) (—CH═CH—), propenylene(—CH═CHCH₂—), 1,4-but-1-enylene (—CH═CH—CH₂CH₂—), 1,4-but-2-enylene(—CH₂CH═CHCH₂—), 1,6-hex-1-enylene (—CH═CH—(CH₂)₃CH₂—), and the like.

“Alkynyl” as used herein refers to and includes, unless otherwisestated, an unsaturated linear (i.e., unbranched) or branched univalenthydrocarbon chain or combination thereof, having at least one site ofacetylenic unsaturation (i.e., having at least one moiety of the formulaC≡C) and having the number of carbon atoms designated (i.e., C₂-C₁₀means two to ten carbon atoms). Particular alkynyl groups are thosehaving 2 to 20 carbon atoms (a “C₂-C₂₀ alkynyl”), having 6 to 10 carbonatoms (a “C₆-C₁₀ alkynyl”), having 2 to 8 carbon atoms (a “C₂-C₈alkynyl”), having 2 to 6 carbon atoms (a “C₂-C₆ alkynyl”), or having 2to 4 carbon atoms (a “C₂-C₄ alkynyl”). Examples of alkynyl groupinclude, but are not limited to, groups such as ethynyl (or acetylenyl),prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl,but-3-ynyl, homologs and isomers thereof, and the like.

“Alkynylene” as used herein refers to the same residues as alkynyl, buthaving bivalency. Particular alkylene groups are those having 2 to 20carbon atoms (a “C₂-C₂₀ alkynylene”), having 2 to 10 carbon atoms (a“C₂-C₁₀ alkynylene”), having 6 to 10 carbon atoms (a “C₆-C₁₀alkynylene”), having 2 to 6 carbon atoms (a “C₂-C₆ alkynylene”), 2 to 4carbon atoms (a “C₂-C₄ alkynylene”) or 2 to 3 carbon atoms (a “C₂-C₃alkynylene”). Examples of alkynylene include, but are not limited to,groups such as ethynylene (or acetylenylene) (—C≡C—), propynylene(—C≡CCH₂—), and the like.

“Cycloalkyl” as used herein refers to and includes, unless otherwisestated, saturated cyclic univalent hydrocarbon structures, having thenumber of carbon atoms designated (i.e., C₃-C₁₀ means three to tencarbon atoms). Cycloalkyl can consist of one ring, such as cyclohexyl,or multiple rings, such as adamantyl. A cycloalkyl comprising more thanone ring may be fused, spiro or bridged, or combinations thereof.Particular cycloalkyl groups are those having from 3 to 12 annularcarbon atoms. A preferred cycloalkyl is a cyclic hydrocarbon having from3 to 8 annular carbon atoms (a “C₃-C₈ cycloalkyl”), having 3 to 6 carbonatoms (a “C₃-C₆ cycloalkyl”), or having from 3 to 4 annular carbon atoms(a “C₃-C₄ cycloalkyl”). Examples of cycloalkyl include, but are notlimited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, norbornyl, and the like.

“Cycloalkylene” as used herein refers to the same residues ascycloalkyl, but having bivalency. Cycloalkylene can consist of one ringor multiple rings which may be fused, spiro or bridged, or combinationsthereof. Particular cycloalkylene groups are those having from 3 to 12annular carbon atoms. A preferred cycloalkylene is a cyclic hydrocarbonhaving from 3 to 8 annular carbon atoms (a “C₃-C₈ cycloalkylene”),having 3 to 6 carbon atoms (a “C₃-C₆ cycloalkylene”), or having from 3to 4 annular carbon atoms (a “C₃-C₄ cycloalkylene”). Examples ofcycloalkylene include, but are not limited to, cyclopropylene,cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene,norbornylene, and the like. A cycloalkylene may attach to the remainingstructures via the same ring carbon atom or different ring carbon atoms.When a cycloalkylene attaches to the remaining structures via twodifferent ring carbon atoms, the connecting bonds may be cis- or trans-to each other. For example, cyclopropylene may include1,1-cyclopropylene and 1,2-cyclopropylene (e.g., cis-1,2-cyclopropyleneor trans-1,2-cyclopropylene), or a mixture thereof.

“Cycloalkenyl” refers to and includes, unless otherwise stated, anunsaturated cyclic non-aromatic univalent hydrocarbon structure, havingat least one site of olefinic unsaturation (i.e., having at least onemoiety of the formula C═C) and having the number of carbon atomsdesignated (i.e., C₂-C₁₀ means two to ten carbon atoms). Cycloalkenylcan consist of one ring, such as cyclohexyl, or multiple rings, such asnorbornenyl. A preferred cycloalkenyl is an unsaturated cyclichydrocarbon having from 3 to 8 annular carbon atoms (a “C₃-C₈cycloalkenyl”). Examples of cycloalkenyl groups include, but are notlimited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl,norbornenyl, and the like.

“Cycloalkenylene” as used herein refers to the same residues ascycloalkenyl, but having bivalency.

“Aryl” or “Ar” as used herein refers to an unsaturated aromaticcarbocyclic group having a single ring (e.g., phenyl) or multiplecondensed rings (e.g., naphthyl or anthryl) which condensed rings may ormay not be aromatic. Particular aryl groups are those having from 6 to14 annular carbon atoms (a “C₆-C₁₄ aryl”). An aryl group having morethan one ring where at least one ring is non-aromatic may be connectedto the parent structure at either an aromatic ring position or at anon-aromatic ring position. In one variation, an aryl group having morethan one ring where at least one ring is non-aromatic is connected tothe parent structure at an aromatic ring position.

“Arylene” as used herein refers to the same residues as aryl, but havingbivalency. Particular arylene groups are those having from 6 to 14annular carbon atoms (a “C₆-C₁₄ arylene”).

“Heteroaryl” as used herein refers to an unsaturated aromatic cyclicgroup having from 1 to 14 annular carbon atoms and at least one annularheteroatom, including but not limited to heteroatoms such as nitrogen,oxygen and sulfur. A heteroaryl group may have a single ring (e.g.,pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl,benzothienyl) which condensed rings may or may not be aromatic.Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12annular carbon atoms and 1 to 6 annular heteroatoms independentlyselected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independentlyselected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered ringshaving 1 to 5 annular carbon atoms and 1 to 4 annular heteroatomsindependently selected from nitrogen, oxygen and sulfur. In onevariation, particular heteroaryl groups are monocyclic aromatic 5-, 6-or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4annular heteroatoms independently selected from nitrogen, oxygen andsulfur. In another variation, particular heteroaryl groups arepolycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1to 6 annular heteroatoms independently selected from nitrogen, oxygenand sulfur. A heteroaryl group having more than one ring where at leastone ring is non-aromatic may be connected to the parent structure ateither an aromatic ring position or at a non-aromatic ring position. Inone variation, a heteroaryl group having more than one ring where atleast one ring is non-aromatic is connected to the parent structure atan aromatic ring position. A heteroaryl group may be connected to theparent structure at a ring carbon atom or a ring heteroatom.

“Heteroarylene” as used herein refers to the same residues asheteroaryl, but having bivalency.

“Heterocycle”, “heterocyclic”, or “heterocyclyl” as used herein refersto a saturated or an unsaturated non-aromatic cyclic group having asingle ring or multiple condensed rings, and having from 1 to 14 annularcarbon atoms and from 1 to 6 annular heteroatoms, such as nitrogen,sulfur or oxygen, and the like. A heterocycle comprising more than onering may be fused, bridged or spiro, or any combination thereof. Infused ring systems, one or more of the fused rings can be cycloalkyl,aryl or heteroaryl. The heterocyclyl group may be optionally substitutedindependently with one or more substituents described herein. Particularheterocyclyl groups are 3 to 14-membered rings having 1 to 13 annularcarbon atoms and 1 to 6 annular heteroatoms independently selected fromnitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11annular carbon atoms and 1 to 6 annular heteroatoms independentlyselected from nitrogen, oxygen and sulfur, 3 to 10-membered rings having1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independentlyselected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independentlyselected from nitrogen, oxygen and sulfur, or 3 to 6-membered ringshaving 1 to 5 annular carbon atoms and 1 to 4 annular heteroatomsindependently selected from nitrogen, oxygen and sulfur. In onevariation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-memberedrings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annularcarbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatomsindependently selected from nitrogen, oxygen and sulfur. In anothervariation, heterocyclyl includes polycyclic non-aromatic rings havingfrom 1 to 12 annular carbon atoms and 1 to 6 annular heteroatomsindependently selected from nitrogen, oxygen and sulfur.

“Heterocyclylene” as used herein refers to the same residues asheterocyclyl, but having bivalency.

“Halo” or “halogen” refers to elements of the Group 17 series havingatomic number 9 to 85. Preferred halo groups include the radicals offluorine, chlorine, bromine and iodine. Where a residue is substitutedwith more than one halogen, it may be referred to by using a prefixcorresponding to the number of halogen moieties attached, e.g.,dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkylsubstituted with two (“di”) or three (“tri”) halo groups, which may bebut are not necessarily the same halogen; thus 4-chloro-3-fluorophenylis within the scope of dihaloaryl. An alkyl group in which each hydrogenis replaced with a halo group is referred to as a “perhaloalkyl.” Apreferred perhaloalkyl group is trifluoroalkyl (—CF₃). Similarly,“perhaloalkoxy” refers to an alkoxy group in which a halogen takes theplace of each H in the hydrocarbon making up the alkyl moiety of thealkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy(—OCF₃).

“Carbonyl” refers to the group C═O.

“Thiocarbonyl” refers to the group C═S.

“Oxo” refers to the moiety ═O.

“Optionally substituted” unless otherwise specified means that a groupmay be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or5) of the substituents listed for that group in which the substituentsmay be the same of different. In one embodiment, an optionallysubstituted group has one substituent. In another embodiment, anoptionally substituted group has two substituents. In anotherembodiment, an optionally substituted group has three substituents. Inanother embodiment, an optionally substituted group has foursubstituents. In some embodiments, an optionally substituted group has 1to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents.

Unless clearly indicated otherwise, “an individual” as used hereinintends a mammal, including but not limited to a primate, human, bovine,horse, feline, canine, or rodent. In one variation, the individual is ahuman.

As used herein, “treatment” or “treating” is an approach for obtainingbeneficial or desired results including clinical results. For purposesof this invention, beneficial or desired results include, but are notlimited to, one or more of the following: decreasing one more symptomsresulting from the disease, diminishing the extent of the disease,stabilizing the disease (e.g., preventing or delaying the worsening ofthe disease), preventing or delaying the spread of the disease, delayingthe occurrence or recurrence of the disease, delay or slowing theprogression of the disease, ameliorating the disease state, providing aremission (whether partial or total) of the disease, decreasing the doseof one or more other medications required to treat the disease,enhancing effect of another medication, delaying the progression of thedisease, increasing the quality of life, and/or prolonging survival.Also encompassed by “treatment” is a reduction of pathologicalconsequence of fibrosis. The methods of the invention contemplate anyone or more of these aspects of treatment.

As used herein, the term “effective amount” intends such amount of acompound of the invention which should be effective in a giventherapeutic form. As is understood in the art, an effective amount maybe in one or more doses, i.e., a single dose or multiple doses may berequired to achieve the desired treatment endpoint. An effective amountmay be considered in the context of administering one or moretherapeutic agents (e.g., a compound, or pharmaceutically acceptablesalt thereof), and a single agent may be considered to be given in aneffective amount if, in conjunction with one or more other agents, adesirable or beneficial result may be or is achieved. Suitable doses ofany of the co-administered compounds may optionally be lowered due tothe combined action (e.g., additive or synergistic effects) of thecompounds.

A “therapeutically effective amount” refers to an amount of a compoundor salt thereof sufficient to produce a desired therapeutic outcome.

As used herein, “unit dosage form” refers to physically discrete units,suitable as unit dosages, each unit containing a predetermined quantityof active ingredient calculated to produce the desired therapeuticeffect in association with the required pharmaceutical carrier. Unitdosage forms may contain a single or a combination therapy.

As used herein, the term “controlled release” refers to adrug-containing formulation or fraction thereof in which release of thedrug is not immediate, i.e., with a “controlled release” formulation,administration does not result in immediate release of the drug into anabsorption pool. The term encompasses depot formulations designed togradually release the drug compound over an extended period of time.Controlled release formulations can include a wide variety of drugdelivery systems, generally involving mixing the drug compound withcarriers, polymers or other compounds having the desired releasecharacteristics (e.g., pH-dependent or non-pH-dependent solubility,different degrees of water solubility, and the like) and formulating themixture according to the desired route of delivery (e.g., coatedcapsules, implantable reservoirs, injectable solutions containingbiodegradable capsules, and the like).

As used herein, by “pharmaceutically acceptable” or “pharmacologicallyacceptable” is meant a material that is not biologically or otherwiseundesirable, e.g., the material may be incorporated into apharmaceutical composition administered to a patient without causing anysignificant undesirable biological effects or interacting in adeleterious manner with any of the other components of the compositionin which it is contained. Pharmaceutically acceptable carriers orexcipients have preferably met the required standards of toxicologicaland manufacturing testing and/or are included on the Inactive IngredientGuide prepared by the U.S. Food and Drug administration.

“Pharmaceutically acceptable salts” are those salts which retain atleast some of the biological activity of the free (non-salt) compoundand which can be administered as drugs or pharmaceuticals to anindividual. Such salts, for example, include: (1) acid addition salts,formed with inorganic acids such as hydrochloric acid, hydrobromic acid,sulfuric acid, nitric acid, phosphoric acid, and the like; or formedwith organic acids such as acetic acid, oxalic acid, propionic acid,succinic acid, maleic acid, tartaric acid and the like; (2) salts formedwhen an acidic proton present in the parent compound either is replacedby a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or analuminum ion; or coordinates with an organic base. Acceptable organicbases include ethanolamine, diethanolamine, triethanolamine and thelike. Acceptable inorganic bases include aluminum hydroxide, calciumhydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, andthe like. Pharmaceutically acceptable salts can be prepared in situ inthe manufacturing process, or by separately reacting a purified compoundof the invention in its free acid or base form with a suitable organicor inorganic base or acid, respectively, and isolating the salt thusformed during subsequent purification.

The term “excipient” as used herein means an inert or inactive substancethat may be used in the production of a drug or pharmaceutical, such asa tablet containing a compound of the invention as an active ingredient.Various substances may be embraced by the term excipient, includingwithout limitation any substance used as a binder, disintegrant,coating, compression/encapsulation aid, cream or lotion, lubricant,solutions for parenteral administration, materials for chewable tablets,sweetener or flavoring, suspending/gelling agent, or wet granulationagent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.;coatings include, e.g., cellulose acetate phthalate, ethylcellulose,gellan gum, maltodextrin, enteric coatings, etc.;compression/encapsulation aids include, e.g., calcium carbonate,dextrose, fructose dc (dc=“directly compressible”), honey dc, lactose(anhydrate or monohydrate; optionally in combination with aspartame,cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.;disintegrants include, e.g., croscarmellose sodium, gellan gum, sodiumstarch glycolate, etc.; creams or lotions include, e.g., maltodextrin,carrageenans, etc.; lubricants include, e.g., magnesium stearate,stearic acid, sodium stearyl fumarate, etc.; materials for chewabletablets include, e.g., dextrose, fructose dc, lactose (monohydrate,optionally in combination with aspartame or cellulose), etc.;suspending/gelling agents include, e.g., carrageenan, sodium starchglycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame,dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulationagents include, e.g., calcium carbonate, maltodextrin, microcrystallinecellulose, etc.

Compounds

In one aspect, provided is a compound of formula (I):

or a salt thereof, wherein:

-   -   R¹ is C₆-C₁₄ aryl or 5- to 10-membered heteroaryl, wherein the        C₆-C₁₄ aryl and 5- to 10-membered heteroaryl of R¹ are        independently optionally substituted by R¹⁰;    -   R² is        -   5- to 10-membered heteroaryl containing at least 2 ring            nitrogen atoms,        -   3- to 12-membered heterocyclyl containing at least 2 ring            nitrogen atoms,        -   —NH—R³,        -   —R³-R¹⁰, or        -   —R³—NR^(3a)R^(3b),        -   wherein the 5- to 10-membered heteroaryl and 3- to            12-membered heterocyclyl of        -   R² are independently optionally substituted by R¹⁰;    -   R³ is 5- to 10-membered heteroaryl containing at least 1 ring        nitrogen atom, or 3- to 12-membered heterocyclyl containing at        least 1 ring nitrogen atom, wherein the 5- to 10-membered        heteroaryl and 3- to 12-membered heterocyclyl of R³ are        independently optionally substituted by R¹⁰;    -   -A-L- is -A¹-L¹-, -A²-L²-, or A³;    -   A¹ is C₃-C₈ cycloalkylene, C₃-C₈ cycloalkenylene, C₆-C₁₄        arylene, 5- to 10-membered heteroarylene or 3- to 12-membered        heterocyclylene, wherein the C₃-C₈ cycloalkylene, C₃-C₈        cycloalkenylene, C₆-C₁₄ arylene, 5- to 10-membered heteroarylene        and 3- to 12-membered heterocyclylene of A¹ are independently        optionally substituted by R¹⁰;    -   A² is C₃-C₈ alkylene or C₃-C₈ alkenylene, wherein the C₃-C₈        alkylene and C₃-C₈ alkenylene of A² are independently optionally        substituted by R⁹;    -   A³ is C₅-C₁₀ alkylene or C₅-C₁₀ alkenylene, wherein the C₅-C₁₀        alkylene and C₅-C₁₀ alkenylene of A³ are independently        optionally substituted by R⁹;    -   L¹ is —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Y¹—X¹—, —O—Z—Y¹—, —O—Z—Y¹—X¹—,        —O—Z—X¹—Y¹—, —O—Z—X¹—Y¹—X¹—, —Z—O—Z—, —X¹—Z—O—Z—, —Z—O—Z—X¹—,        —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, —Z—O—Y¹—X¹—, —X¹—Z—O—Y¹—X¹—Z—O—Y¹—X¹—,        —N(R⁴)—Z—, —N(R⁴)—Z—X¹—, X², —X²—Y¹—, Y², or —Y²—X²—.    -   L² is C₃-C₆ cycloalkylene optionally substituted by R¹⁰;    -   each X¹ is independently C₁-C₆ alkylene or C₂-C₆ alkenylene,        wherein the C₁-C₆ alkylene and C₂-C₆ alkenylene of X¹ are        independently optionally substituted by R¹⁰;    -   each X² is independently C₁-C₆ alkylene or C₂-C₆ alkenylene,        wherein the C₁-C₆ alkylene and C₂-C₆ alkenylene of X² are        independently optionally substituted by R⁹;    -   each Y¹ is independently C₃-C₆ cycloalkylene optionally        substituted by R¹⁰;    -   each Y² is independently saturated 3- to 4-membered        heterocyclylene optionally substituted by R¹⁰;    -   each Z is independently —CR^(5a)R^(5b)—;    -   each R^(3a), R^(3b), R⁴, R^(5a) and R^(5b) is independently H or        C₁-C₆ alkyl;    -   each R⁹ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, halogen, —CN, —OR¹¹, —SR¹¹, —NR¹²R¹¹, —NO₂,        —C═NH(OR¹¹), —C(O)R¹¹, —OC(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹²R¹³,        —NR¹¹C(O)R¹², —NR¹¹C(O)OR¹², —NR¹¹C(O)NR¹²R¹³, —S(O)R¹¹,        —S(O)₂R¹¹, —NR¹¹ S(O)R¹², —NR¹¹S(O)₂R¹², —S(O)NR¹²R¹³,        —S(O)₂NR¹²R¹³, —P(O)(OR¹²) (OR¹³), C₃-C₈ cycloalkyl, 3- to        12-membered heterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄        aryl, wherein each R⁹ is independently optionally substituted by        halogen,        oxo, —OR¹⁴, —NR¹⁴R¹⁵, —C(O)R¹⁴, —CN, —S(O)R¹⁴, —S(O)₂R¹⁴,        —P(O)(OR¹⁴)(OR¹⁵), C₃-C₈ cycloalkyl, 3- to 12-membered        heterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄ aryl, or        C₁-C₆ alkyl optionally substituted by oxo, —OH or halogen;    -   each R¹⁰ is independently oxo or R⁹;    -   R¹¹ is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄ aryl, 5- to 6-membered        heteroaryl or 3- to 6-membered heterocyclyl, wherein the C₁-C₆        alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄        aryl, 5- to 6-membered heteroaryl and 3- to 6-membered        heterocyclyl are independently optionally substituted by        halogen, oxo, —CN, —OR¹⁶, —NR¹⁶R¹⁷, —P(O)(OR¹⁶)(OR¹⁷), or C₁-C₆        alkyl optionally substituted by halogen, —OH or oxo;    -   R¹² and R¹³ are each independently hydrogen, C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄ aryl, 5- to        6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein        the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl,        C₆-C₁₄ aryl, 5- to 6-membered heteroaryl and 3- to 6-membered        heterocyclyl are independently optionally substituted by        halogen, oxo, —CN, —OR¹⁶, —NR¹⁶R¹⁷ or C₁-C₆ alkyl optionally        substituted by halogen, —OH or oxo;        -   or R¹² and R¹³ are taken together with the atom to which            they attached to form a 3- to 6-membered heterocyclyl            optionally substituted by halogen, oxo, —OR¹⁶, —NR¹⁶R¹⁷ or            C₁-C₆ alkyl optionally substituted by halogen, oxo or —OH;    -   R¹⁴ and R¹⁵ are each independently hydrogen, C₁-C₆ alkyl        optionally substituted by halogen or oxo, C₂-C₆ alkenyl        optionally substituted by halogen or oxo, or C₂-C₆ alkynyl        optionally substituted by halogen or oxo;        -   or R¹⁴ and R¹⁵ are taken together with the atom to which            they attached to form a 3- to 6-membered heterocyclyl            optionally substituted by halogen, oxo or C₁-C₆ alkyl            optionally substituted by halogen or oxo; and    -   R¹⁶ and R¹⁷ are each independently hydrogen, C₁-C₆ alkyl        optionally substituted by halogen or oxo, C₂-C₆ alkenyl        optionally substituted by halogen or oxo, or C₂-C₆ alkynyl        optionally substituted by halogen or oxo;        -   or R¹⁶ and R¹⁷ are taken together with the atom to which            they attached to form a 3-6 membered heterocyclyl optionally            substituted by halogen, oxo or C₁-C₆ alkyl optionally            substituted by oxo or halogen.

In another embodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰. In another embodiment, R² is —NH-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound is other than a compound in Table 1Xand salts thereof. In some embodiments, the compound herein, such as acompound of formula (I), is other than a compound selected from one ormore of Compound Nos. 1x-164x in Table 1X. In some embodiments, thecompounds of the disclosure, and methods of using the compounds detailedherein, encompass any of the compounds of formula (I), including thoselisted Table 1X and salts thereof.

TABLE 1X No. Chemical Name ¹  1x L-Tyrosine,N-[(2-methyl-1-naphthalenyl)carbonyl]- O-[4-(2-pyridinylamino)butyl]- 2x L-Tyrosine, N-[(5-chloro-1,3-benzodioxol-4-yl)carbonyl]-O-[3-(2-pyridinylamino)propyl]-  3x L-Tyrosine,N-[(5-chloro-1,3-benzodioxol-4-yl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl]-  4xL-Tyrosine, N-[(3-chloro-1-methyl-1H-indol-2-yl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl]-  5xL-Tyrosine, N-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]-O-(1H-tetrazol-5-ylmethyl)-  6x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methyl]-  7x L-Tyrosine,N-(2-chloro-4-methoxybenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  8x L-Tyrosine,N-(2-chloro-6-methylbenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  9x L-Tyrosine,N-(2-fluoro-6-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  10x L-Tyrosine,N-[(2-ethyl-3-thienyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  11x L-Tryptophan,N-benzoyl-5-[4-(1-piperazinyl)butoxy]-  12x L-Tyrosine,N-(2-chlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  13x L-Tyrosine,N-[(3-chloro-2-thienyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  14x2-Pyridinepropanoic acid, a-[(2,6-dichlorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  15x L-Tyrosine,N-(2-chloro-6-fluorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  16x L-Tyrosine,N-[(3-chloro-4-pyridinyl)carbonyl]-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  17x L-Tyrosine,O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-N-(2,4,6-trimethylbenzoyl)-  18x L-Tyrosine,N-[(3,5-dichloro-4-pyridinyl)carbonyl]-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  19xL-Tyrosine, N-(2,4-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  20x 2-Pyridinepropanoic acid,α-[(2-chloro-4- methoxybenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  21x2-Pyridinepropanoic acid, α-[(2-chlorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  22x L-Tyrosine,N-(2-chloro-6-fluoro-3- methylbenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  23x 3-Pyridinepropanoic acid,α-[(2- chlorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  24x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  25x L-Tyrosine,N-(2-chloro-6-fluorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  26x L-Tyrosine,N-(2-chloro-5-fluorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  27x2-Naphthalenepropanoic acid, α-(benzoylamino)-6-[2-(1-piperazinyl)ethoxy]-  28x L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2-ethyl-4-fluorobenzoyl)-  29x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-5-methyl-1,8-naphthyridin-2-yl)ethyl]-  30x2-Pyridinepropanoic acid, α-[[(3-chloro-2-thienyl)carbonyl]amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  31x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(1,2,3,4-tetrahydro-1-methylpyrido[2,3-b]pyrazin-6-yl)ethyl]-  32x L-Tryptophan,N-benzoyl-5-[3-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]propoxy]-  33x L-Tyrosine,N-(2,6-dimethylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  34x L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-[(3-methyl-4-pyridinyl)carbonyl]-  35xL-Tyrosine, N-(2-chloro-6-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  36x L-Tyrosine,N-[(3-chloro-2-thienyl)carbonyl]-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  37x2-Thiophenepropanoic acid, α-[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  38x L-Tyrosine,N-(2-chloro-3,6-difluorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  39x2-Pyridinepropanoic acid, α-[(2-fluoro-4-methylbenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  40x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-4-methyl-1,8-naphthyridin-2-yl)ethyl]-  41x2-Pyridinepropanoic acid, α-[(2-chloro-4-fluorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  42x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  43x3-Pyridinepropanoic acid, α-[(2-chloro-4-fluorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  44x L-Tyrosine,N-(2-chlorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  45x L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2-ethyl-5-fluorobenzoyl)-  46x1-Piperazinecarboxylic acid, 4-[2-[[6-[2-(benzoylamino)-2-carboxyethyl]-2- naphthalenyl]oxy]ethyl]-,1-(1,1-dimethylethyl) ester  47x L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2,4,6-trimethylbenzoyl)-  48x L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2,6-dimethylbenzoyl)-  49x 3-Pyridinepropanoicacid, α-[[(3-chloro-2- thienyl)carbonyl]amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  50x L-Tryptophan,N-benzoyl-5-[4-[4-[(1,1- dimethylethoxy)carbonyl]-1-piperazinyl]butoxy]- 51x L-Tyrosine, N-(2-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  52x L-Tyrosine,N-[(3,5-dichloro-4-pyridinyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  53xL-Tryptophan, N-benzoyl-5-[3-(1-piperazinyl)propoxy]-  54x L-Tyrosine,N-(6-chloro-2-fluoro-3-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  55x L-Tyrosine,N-[(4-methoxy-3-thienyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  56x L-Tyrosine,N-(2-chloro-4-fluorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  57x L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-  58xL-Tyrosine, N-(2-chloro-5-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-  59x2-Pyridinepropanoic acid, α-[(2-ethyl-4-fluorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  60x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-7-methyl-1,8-naphthyridin-2-yl)ethyl]-  61x2-Pyridinepropanoic acid, α-[(2-chloro-6-fluorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  62x 3-Pyridinepropanoic acid,α-[(2-chloro-6- fluorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  63x L-Tyrosine,N-(2-chloro-4-fluorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-  64x3-Pyridinepropanoic acid, α-[(2,6-dichlorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-, (αS)-  65xL-Tyrosine, N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-  66x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-  67x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(2- pyridinylamino)ethyl]-  68x D-Tyrosine,N-benzoyl-O-[3-(2-pyridinylamino)propyl]-  69x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[3-[(4,6- dimethyl-2-pyridinyl)amino]propyl]- 70x L-Tyrosine, N-(2,6-dimethylbenzoyl)-O-[3-(2-pyridinylamino)propyl]-  71x L-Tyrosine,N-(3,5-dimethylbenzoyl)-O-[3-(2- pyridinylamino)propyl]-  72xL-Tyrosine, N-(2,6-dichlorobenzoyl)-O-[3-[(4-methyl-2-pyridinyl)amino]propyl]-  73x L-Phenylalanine,N-(2,6-dichlorobenzoyl)-3-[4-(2- pyridinylamino)butoxy]-  74xL-Tyrosine, N-(2-chloro-3,6-difluorobenzoyl)-O-[3-(2-pyridinylamino)propyl]-  75x L-Tyrosine,O-[3-[(1,4,5,6-tetrahydro-2-pyridinyl)amino]propyl]-N-(2,4,6-trimethylbenzoyl)-  76x L-Tyrosine,N-(2-chloro-6-fluoro-3-methylbenzoyl)- O-[3-(2-pyridinylamino)propyl]- 77x L-Tyrosine, O-[3-(4-pyrimidinylamino)propyl]-N-(2,4,6-trimethylbenzoyl)-  78x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[3-[(4- methoxy-2-pyridinyl)amino]propyl]- 79x L-Tyrosine, N-(2,4-dichlorobenzoyl)-O-[3-(2-pyridinylamino)propyl]-  80x L-Tyrosine,O-[4-(2-pyridinylamino)butyl]-N- (2,4,6-trimethylbenzoyl)-  81xL-Tyrosine, N-benzoyl-O-[4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]butyl]-  82x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[3-(2- pyridinylamino)propyl]-  83xL-Tyrosine, N-(4-methoxy-2,6-dimethylbenzoyl)-O-[3-(2-pyridinylamino)propyl]-  84x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[3- [(4-ethyl-2-pyridinyl)amino]propyl]-  85xL-Tyrosine, N-(4-methylbenzoyl)-O-[3- (2-pyridinylamino)propyl]-  86xD-Tyrosine, O-[3-(2-pyridinylamino)propyl]- N-(2,4,6-trimethylbenzoyl)- 87x L-Tyrosine, N-(2,6-dichlorobenzoyl)-O-[3-[(6-methyl-2-pyridinyl)amino]propyl]-  88x L-Phenylalanine,N-(2,6-dichlorobenzoyl)- 3-[2-(2-pyridinylamino)ethoxy]-  89xL-Tyrosine, O-[2-(2-benzothiazolylamino)ethyl]- N-(2,6-dichlorobenzoyl)- 90x L-Tyrosine, N-(2-chloro-4-fluorobenzoyl)-O-[3-(2-pyridinylamino)propyl]-  91x L-Tyrosine,N-(2-methylbenzoyl)-O-[3-(2- pyridinylamino)propyl]-  92x L-Tyrosine,N-(6-chloro-2-fluoro-3-methylbenzoyl)- O-[3-(2-pyridinylamino)propyl]- 93x L-Tyrosine, O-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]-N-(2,4,6- trimethylbenzoyl)-  94x L-Tyrosine,N-(2-chloro-5-methylbenzoyl)-O-[3- (2-pyridinylamino)propyl]-  95xL-Tyrosine, O-[3-(2-pyrimidinylamino)propyl]-N-(2,4,6-trimethylbenzoyl)-  96x L-Tyrosine,O-[2-(1H-benzimidazol-2-ylamino)ethyl]- N-(2,6-dichlorobenzoyl)-  97xL-Tyrosine, N-[2,6-dimethyl-4-(1-methylethoxy)benzoyl]-O-[4-(2-pyridinylamino)butyl]-  98x L-Tyrosine,N-benzoyl-O-[4-(2-pyrimidinylamino)butyl]-  99x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[4-(2- pyridinylamino)butyl]- 100x L-Tyrosine,O-[3-(2-pyridinylamino)propyl]-N-(2,4,6- trichlorobenzoyl)- 101xL-Tyrosine, N-[2,6-dimethyl-4-(1-methylethoxy)benzoyl]-O-[3-(2-pyridinylamino)propyl]- 102x L-Tyrosine,O-[3-(2-pyridinylamino)propyl]-N-[(2,4,6-trimethyl-3-pyridinyl)carbonyl]- 103x L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[3-[(3- methyl-2-pyridinyl)amino]propyl]- 104xL-Tyrosine, N-(2,6-dichlorobenzoyl)-O-[3-[(5-methyl-2-pyridinyl)amino]propyl]- 105x L-Tyrosine,N-(2-bromo-6-chlorobenzoyl)-O-[3- (2-pyridinylamino)propyl]- 106xL-Tyrosine, N-(2,6-dichloro-3-methylbenzoyl)-O-[3-(2-pyridinylamino)propyl]- 107x L-Tyrosine,N44-(1-methylethoxy)benzoyl]-O- [3-(2-pyridinylamino)propyl]- 108xL-Tyrosine, N-(3-chloro-2-methylbenzoyl)-O-[3-(2-pyridinylamino)propyl]- 109x L-Tyrosine,O-[3-[(1,4,5,6-tetrahydro-2-pyrazinyl)amino]propyl]-N-(2,4,6-trimethylbenzoyl)- 110x L-Tyrosine,N-(2-chloro-6-fluorobenzoyl)-O-[3-(2- pyridinylamino)propyl]- 111xL-Tyrosine, O-[3-(2-pyrazinylamino)propyl]-N- (2,4,6-trimethylbenzoyl)-112x L-Tyrosine, N-(2,6-dichlorobenzoyl)-O-[3-[(5-methoxy-2-pyridinyl)amino]propyl]- 113x L-Tyrosine,N-(2-chlorobenzoyl)-O-[3-(2- pyridinylamino)propyl]- 114x L-Tyrosine,N-(2,6-diethylbenzoyl)-O-[4-(2- pyridinylamino)butyl]- 115x L-Tyrosine,N-benzoyl-O-[4-(2-pyridinylamino)butyl]- 116x2-(2,6-dichlorobenzamido)-3-(3-(3-(pyridin-2-ylamino)propoxy)phenyl)propanoic acid 117x2-(4-isopropoxybenzamido)-3-(4-(3-(pyridin-2-ylamino)propoxy)phenyl)propanoic acid 118x Phenylalanine,4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]-N-(2,4,6-trimethylbenzoyl)- 119x Phenylalanine,N-(4-chloro-2-ethyl-6-methylbenzoyl)-4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]- 120x Phenylalanine,N-[2-ethyl-4-(1H-imidazol-1-yl)-6-methylbenzoyl]-4-[3-[(2-pyridinylamino)methyl]- 1-azetidinyl]- 121xPhenylalanine, N-(4-acetyl-2-ethyl-6-methylbenzoyl)-4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]- 122x Phenylalanine,N-(2-ethyl-4-fluoro-6-methylbenzoyl)-4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]- 123x Phenylalanine,N-[2-ethyl-6-methyl-4- (trifluoromethyl)benzoyl]-4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]- 124x Phenylalanine,N-(4-cyano-2-ethyl-6-methylbenzoyl)-4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]- 125x Phenylalanine,N-(2-ethyl-6-methylbenzoyl)-4-[3-[(2-pyridinylamino)methyl]-1-azetidinyl]- 126x 2-Thiophenepropanoic acid,α-[(2-chloro-4- fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 127x 2-Pyridinepropanoic acid,α-[(2-chlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 128x3-Pyridinepropanoic acid, α-[(2-chloro-4-fluorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 129x 2-Thiophenepropanoic acid,α-[[(3,5-dichloro-4- pyridinyl)carbonyl]amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 130x L-Phenylalanine,N-(2-chloro-4-fluorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]- 131x2-Thiophenepropanoic acid, α-[(2-chloro-6-fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 132x 2-Pyridinepropanoic acid,α-[(2-fluoro-6- methylbenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 133x 3-Pyridinepropanoic acid,α-[(2-chloro-6- fluorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 134x L-Phenylalanine,N-(2,6-dichlorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]- 135x2-Thiophenepropanoic acid, α-[(2,6-dichlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 136x 2-Pyridinepropanoic acid,α-[(2-chloro-4- fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 137x 2-Pyridinepropanoic acid,α-[[(3-chloro-2- thienyl)carbonyl]amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 138x L-Phenylalanine,N-(2-chlorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]- 139x L-Phenylalanine,N-(2-chloro-6-fluorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]- 140x2-Pyridinepropanoic acid, α-[(2-chloro-6-fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 141x 2-Pyridinepropanoic acid,α-[(2,6- dichlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 142x L-Phenylalanine,N-(2,6-dichlorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]- 143x3-Pyridinepropanoic acid, α-[(2,6- dichlorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 144x L-Phenylalanine,N-[(3,5-dimethyl-4- isoxazolyl)carbonyl]-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]- 145x L-Phenylalanine,N-(2-chlorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]- 146x2-Thiophenepropanoic acid, α-[[3-[(dimethylamino)methyl]benzoyl]amino]-5-[(8-methyl-6,10-dioxo-7,9-diazaspiro[4.5]dec-7-en-9-yl)methyl]- 147x2-Thiophenepropanoic acid, α-[(2-chlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 148xL-Phenylalanine, N-(2-chloro-4-fluorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]- 149x3-Pyridinepropanoic acid, α-[(2-chlorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 150x2-Thiophenepropanoic acid, α-[[(3,5-dimethyl-4-isoxazolyl)carbonyl]amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 151x L-Phenylalanine,N-(2-chloro-6-fluorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]- 152x3-Pyridinepropanoic acid, α-[[(3-chloro-2-thienyl)carbonyl]amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-, (αS)- 153x L-Phenylalanine,N-(2,6-dichlorobenzoyl)-4-[3- (2-pyridinylamino)propyl]- 154xL-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-[4- (2-pyridinylamino)butyl]-155x 5-Benzofuranpropanoic acid, α-[(2,6-dichlorobenzoyl)amino]-2-[2-(2-pyridinylamino)ethyl]-, (αS)- 156x2-(2,6-dichlorobenzamido)-3-(4-(4-(pyridin-2-ylamino)butyl)-1H-imidazol-1-yl)propanoic acid 157x2-(2,6-dichlorobenzamido)-3-(5-(4-(pyridin-2-ylamino)butyl)oxazol-2-yl)propanoic acid 158x2-(2,6-dichlorobenzamido)-3-(4-(5-(pyridin-2-ylamino)pentyl)phenyl)propanoic acid 159x2-(2,6-dichlorobenzamido)-3-(4-(2-(pyridin-2-ylamino)ethyl)-1H-1,2,3-triazol-1-yl)propanoic acid 160x2-(2,6-dichlorobenzamido)-3-(4-(3-(pyridin-2-ylamino)propyl)-1H-1,2,3-triazol-1-yl)propanoic acid 161x2-(2,6-dichlorobenzamido)-3-(4-(4-(pyridin-2-ylamino)butyl)-1H-1,2,3-triazol-1-yl)propanoic acid 162x2-(2,6-dichlorobenzamido)-3-(4-(5-(pyridin-2-ylamino)pentyl)-1H-1,2,3-triazol-1-yl)propanoic acid 163x2-(2,6-dichlorobenzamido)-3-(2-((4-(pyridin-2-ylamino)butyl)amino)pyrimidin-5-yl)propanoic acid 164x1,8-Naphthyridine-2-nonanoic acid, α-(benzoylamino)-5,6,7,8-tetrahydro-, (αS)- ¹ Chemical names are either index names forthe compound as in CAS Registry ® database or generated using theChemBioDraw ® Ultra version 14.0.0.117 software.

In some embodiments, the compound of the formula (I) is a derivative of(S)-2-acylaminopropionic acid, having the formula (I-A):

or a salt thereof, wherein R¹, A, L and R² are as defined for formula(I).

In some embodiments, the compound of the formula (I) is a derivative of(R)-2-acylaminopropionic acid, having the formula (I-B):

or a salt thereof, wherein R¹, A, L and R² are as defined for formula(I).

In some embodiments of the compound of formula (I), (I-A) or (I-B), or asalt thereof, R¹ is C₆-C₁₄ aryl or 5- to 10-membered heteroaryl, whereinthe C₆-C₁₄ aryl and 5- to 10-membered heteroaryl of R¹ are independentlyoptionally substituted by R¹⁰. In one variation, R¹ is a monocyclic arylor heteroaryl. In another variation, R¹ is bicyclic aryl or heteroaryl.

In some embodiments, R¹ is a fused bicyclic C₉-C₁₄ aryl optionallysubstituted by R¹⁰ or a fused bicyclic 7- to 10-membered heteroaryloptionally substituted by R¹⁰. In one variation, the compound is otherthan any applicable compounds in Table 1X, e.g., Compound Nos. 1x-5x inTable 1X, and salts thereof.

In some embodiments, R¹ is a fused bicyclic 7- to 10-membered heteroaryloptionally substituted by R¹⁰. In some embodiments, R¹ is indazolyl(e.g., 1H-indazolyl or 2H-indazolyl, more specifically 1H-indazol-5-yl,1H-indazol-6-yl, 2H-indazol-5-yl or 2H-indazol-6-yl) optionallysubstituted by R¹⁰. In some embodiments, R¹ is benzimidazolyl (e.g.,1H-benzo[d]imidazolyl, more specifically 1H-benzo[d]imidazol-5-yl or1H-benzo[d]imidazol-6-yl) optionally substituted by R¹⁰. In someembodiments, R¹ is a benzoxazolyl (e.g., benzo[d]oxazol-5-yl) optionallysubstituted by R¹⁰. In one variation, R¹ is a fused bicyclic 7- to10-membered heteroaryl optionally substituted by R¹⁰, provided that thefused bicyclic 7- to 10-membered heteroaryl R¹ is not an indolyl (e.g.,indol-2-yl) or 1,3-benzodioxolyl (e.g., 1,3-benzodioxol-4-yl). Inanother variation, R¹ is other than a 1H-benzimidazolyl (e.g.,1H-benzo[d]imidazol-5-yl).

In some embodiments, R¹ is a fused bicyclic C₉-C₁₄ aryl optionallysubstituted by R¹⁰. In some embodiments, R¹ is a naphthalenyl optionallysubstituted by R¹⁰.

In some embodiments, R¹ is phenyl optionally substituted by R¹⁰. In someembodiments, R¹ is phenyl. In some embodiments, R¹ is phenyl substitutedby 1 to 5 substituents independently selected from the group consistingof F, Cl, —CN, methyl, —CHF₂, —CF₃, cyclopropylmethyl, tert-butyl,cyclopropyl and phenyl.

In some embodiments, R¹ is a monocyclic 5- or 6-membered heteroaryloptionally substituted by R¹⁰. In some embodiments, R¹ is a monocyclic5- or 6-membered heteroaryl optionally substituted by R¹⁰. In someembodiments, R¹ is a monocyclic 5-membered heteroaryl optionallysubstituted by R¹⁰. In some embodiments, R¹ is a monocyclic 6-memberedheteroaryl (e.g., pyridinyl, pyrimidinyl and pyrazinyl) optionallysubstituted by 1 to 3 substituents independently selected from the groupconsisting of F, Cl, —CN, methyl, —CHF₂, —CF₃, cyclopropylmethyl,tert-butyl, cyclopropyl and phenyl.

In some of these embodiments, R¹ is selected from the group consistingof phenyl, 2,6-dichlorophenyl, 2,6-dichloro-4-cyanophenyl,2,6-difluorophenyl, 2-trifluoromethyl-6-fluorophenyl,3-amino-4-hydroxylphenyl, 3-formamido-4-hydroxyphenyl, 6-1H-indazolyl,1-methyl-1H-6-indazolyl, 5-1H-indazolyl, 1-methyl-1H-5-indazolyl,2-methyl-2H-6-indazolyl, 2-methyl-2H-5-indazolyl, 3-pyridinyl,4-pyridinyl, 3,5-dichloro-4-pyridinyl, 2-methyl-4-pyrimidinyl,5-phenyl-2-pyrazinyl, 4-difluoromethyl-2-pyrazinyl,2-chloro-5-fluorophenyl, 3,5-dichlorophenyl, 5-benzo[d]oxazolyl,1-methyl-1H-5-benzo[d]imidazolyl, and 1-methyl-1H-6-benzo[d]imidazolyl.

In some embodiments of the compound of formula (I), (I-A) or (I-B), or asalt thereof, the -A-L- moiety is -A¹-L¹-, -A²-L²-, or A³. In someembodiments, the -A-L-moiety is -A¹-L¹-, wherein A¹ is a cyclic moietyand L¹ is a linker moiety linking A¹ and R². In some embodiments, the-A-L- moiety is -A²-L²-, wherein A² is an acyclic moiety and L² is acyclic moiety linking A² and R². In some embodiments, the -A-L- moietyis A³, which is directly attached to the R² group. In one variation, thecompound is other than any applicable compounds in Table 1X, and saltsthereof.

In some embodiments, A¹ is C₃-C₈ cycloalkylene, C₃-C₈ cycloalkenylene,C₆-C₁₄ arylene, 5- to 10-membered heteroarylene or 3- to 12-memberedheterocyclylene, wherein the C₃-C₈ cycloalkylene, C₃-C₈ cycloalkenylene,C₆-C₁₄ arylene, 5- to 10-membered heteroarylene and 3- to 12-memberedheterocyclylene of A¹ are independently optionally substituted by R¹⁰.

In some of these embodiments, A¹ is C₆-C₁₄ arylene optionallysubstituted by R⁹. In one variation, A¹ is phenylene (e.g.,1,4-phenylene or 1,3-phenylene) optionally substituted by R⁹. In oneparticular variation, A¹ is 1,4-phenylene. In another particularvariation, A¹ is 1,3-phenylene.

In some of these embodiments, A¹ is C₃-C₈ cycloalkylene optionallysubstituted by R¹⁰. In one variation, A¹ is C₃-C₆ cycloalkyleneoptionally substituted by R¹⁰. In one variation, A¹ is C₃-C₅cycloalkylene optionally substituted by R¹⁰. In another variation, A¹ isC₃-C₄ cycloalkylene optionally substituted by R¹⁰. In another variation,A¹ is C₃-C₄ cycloalkylene optionally substituted by R⁹. In oneparticular variation, A¹ is 1,2-cyclopropylene or 1,1-cyclopropylene. Inanother particular variation, A¹ is 1,3-cyclobutylene, 1,2-cyclobutyleneor 1,1-cyclobutylene. In one particular variation, A¹ is1,4-cyclohexylene.

In some of these embodiments, A¹ is 5- to 10-membered heteroaryleneoptionally substituted by R¹⁰. In one variation, A¹ is 5- to 10-memberedheteroarylene optionally substituted by R⁹. In one variation, A¹ is 5-to 6-membered heteroarylene optionally substituted by R⁹. In onevariation, A¹ is 7- to 10-membered bicyclic heteroarylene optionallysubstituted by R⁹. In one particular variation, A¹ is2,5-benzo[d]oxazolylene.

In some of these embodiments, A¹ is 3- to 12-membered heterocyclyleneoptionally substituted by R¹⁰. In some of these embodiments, A¹ is 3- to12-membered heterocyclylene optionally substituted by R⁹. In some ofthese embodiments, A¹ is 3- to 6-membered heterocyclylene optionallysubstituted by R¹⁰. In one particular variation, A¹ is1,3-azetidinylene. In another particular variation, A¹ is1,3-pyrrolidinylene.

In some of these embodiments, A¹ is selected from the group consistingof 1,4-phenylene, 1,3-phenylene, 1,1-cyclopropylene, 1,2-cyclopropylene,1,3-cyclobutylene, 1,4-cyclohexylene, 1,3-azetidinylene,1,3-pyrrolidinylene, and 2,5-benzo[d]oxazolylene.

In some embodiments, L¹ is a linker moiety defined as —O—Z—, —O—Z—X¹—,—O—Y¹—, —O—Y¹—X¹—, —O—Z—Y¹—, —O—Z—Y¹—X¹—, —O—Z—X¹—Y¹—, —O—Z—X¹—Y¹—X¹—,—Z—O—Z—, —X¹—Z—O—Z—, —Z—O—Z—X¹—, —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, —Z—O—Y¹—X¹—,—X¹—Z—O—Y¹—, —X¹—Z—O—Y¹—X¹—, —N(R⁴)—Z—, —N(R⁴)—Z—X¹—, X², —X²—Y¹—, Y²,or —Y²—X²—.

In some embodiments, L¹ is a linker moiety comprising an ether group,which is further defined as —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Y¹—X¹—,—O—Z—Y¹—, —O—Z—Y¹—X¹—, —O—Z—X¹—Y¹—, —O—Z—X¹—Y¹—X¹—, —Z—O—Z—, —X¹—Z—O—Z—,—Z—O—Z—X¹—, —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, —Z—O—Y¹—X¹—, —X¹—Z—O—Y¹—, or—X¹—Z—O—Y¹—X¹—. In some embodiments, L¹

is —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Z—Y¹—, —O—Z—X¹—Y¹—, —Z—O—Z—, —X¹—Z—O—Z—,—Z—O—Z—X¹—, —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, or —X¹—Z—O—Y¹—. In someembodiments, L¹is —O—Y¹—X¹—, —O—Z—Y¹—X¹—, —O—Z—X¹—Y¹—X¹—, —Z—O—Y¹—X¹—, or—X¹—Z—O—Y¹—X¹—. In some of these embodiments, X¹ is C₁-C₆ alkyleneoptionally substituted by R¹⁰. In one variation, X¹ is C₁-C₆ alkyleneoptionally substituted by R⁹. In one variation, X¹ is C₁-C₆ alkylene. Insome of these embodiments, X¹ is C₂-C₆ alkenylene optionally substitutedby R¹⁰. In one variation, X¹ is C₂-C₆ alkenylene optionally substitutedby R⁹. In one variation, X¹ is C₂-C₆ alkenylene. In some of theseembodiments, Y¹ is C₃-C₆ cycloalkylene optionally substituted by R¹⁰. Inone variation, Y¹ is C₃-C₆ cycloalkylene optionally substituted by R⁹.In one variation, Y¹ is C₃-C₆ cycloalkylene. In some of theseembodiments, Z is —CR^(5a)R^(5b)— where each R^(5a) and R^(5b) isindependently H or C₁-C₆ alkyl. In one variation, each of R^(5a) andR^(5b) is H.

In some embodiments, L¹ is selected from the group consisting of—O—(CH₂)₃—, —O—(CH₂)₄—, —CH₂—O—(CH₂)₃—, —CH₂—O—(CH₂)₂—,—CH(CH₃)—O—(CH₂)₂—, —CH₂—O—(C H₂)₃—,

wherein the wavy lines denote attachment points to the parent molecule.

Unless indicated otherwise, when the structure or formula of a bivalentgroup is shown, the orientation of the bivalent group is intended to bein alignment with the orientation of the parent structure. For example,when an L¹ group which is part of an -A¹-L¹- moiety is shown as theformula —O—(CH₂)₃—, it is intended that the oxygen atom on the left sideof —O—(CH₂)₃— is attached to the A¹ moiety, the terminal carbon atom onthe right side of —O—(CH₂)₃— is attached to the parent structure to theright of the -A¹-L¹- moiety.

In some embodiments, L¹ is a linker moiety comprising an amino group,which is further defined as —N(R⁴)—Z— or —N(R⁴)—Z—X¹—. In some of theseembodiments, Z is —CR^(5a)R^(5b). In some of these embodiments, eachR^(3a), R^(3b), R⁴, R^(5a) and R^(5b) is independently H or C₁-C₆ alkyl.In one variation, R⁴ is H. In one variation, each of R^(5a) and R^(5b)is H. In some of these embodiments, X¹ is C₁-C₆ alkylene optionallysubstituted by R¹⁰. In one variation, X¹ is C₁-C₆ alkylene optionallysubstituted by R⁹. In one variation, X¹ is C₁-C₆ alkylene. In someembodiments, L¹ is —N(R⁴)—Z—X¹— where R⁴ is H, Z is —CR^(5a)R^(5b)—where each of R^(5a) and R^(5b) is H, and X¹ is C₁-C₆ alkylene.

In some embodiments, L¹ is —NH—C(CH₃)₂—(CH₂)₂—.

In some embodiments, X¹ is C₁-C₆ alkylene, i.e., —(CH₂)_(n)—, where n is1 to 6. In some embodiments, X¹ is —(CH₂)_(n)—, where n is 1 to 5, 1 to4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to4, 4 to 6, 4 to 5, or 5 to 6. In some embodiments, X¹ is —(CH₂)_(n)—,where n is 1, 2, 3, 4, 5 or 6. In some embodiments, Z is —CH₂—. In someembodiments, the —Z—X¹— moiety is —(CH₂)_(m)—, where m is 2 to 7. Insome embodiments, L¹ is —O—Z—X¹—, which is further defined as—O—(CH₂)_(m)—, where m is 2 to 7. In some embodiments, L¹ is —Z—O—Z—X¹—,which is further defined as —CR^(5a)R^(5b)—O—(CH₂)_(m)—, where m is 2 to6. In one variation, L¹ is —CH₂—O—(CH₂)_(m)—. In another variation, L¹is —CH(CH₃)—O—(CH₂)_(m)—. In some embodiments, L¹ is —N(R⁴)—Z—X¹—, whichis further defined as —N(R⁴)—(CH₂)_(m)—, where m is 2 to 7. In someembodiments, R⁴ is H. In some embodiments, m is 2, 3, 4, 5, 6 or 7. Insome embodiments, m is 2, 3 or 4.

In some embodiments, L¹ is —O—Z—, —O—Z—X¹—, —Z—O—Z—, —X¹—Z—O—Z—,—Z—O—Z—X¹—, or —X¹—Z—O—Z—X¹—, which is further defined as—(CH₂)_(n)—O—(CH₂)_(m)—, where n is 0, 1, 2, 3, 4, 5 or 6 and m is 1, 2,3, 4, 5 or 6. In some embodiments, one or more of the methylene groupsof L¹ is independently optionally substituted by R⁹. In one variation, nis 0 or 1 and m is 2, 3 or 4. In one variation, n is 0 and m is 2, 3 or4. In another variation, n is 1 and m is 2, 3 or 4.

In some embodiments, L¹

is —O—Y¹—, —O—Y¹—X¹—, —O—Z—Y¹—, —O—Z—Y¹—X¹—, —O—Z—X¹—Y¹—,—O—Z—X¹—Y¹—X¹—, —Z—O—Y¹—, —Z—O—Y¹—X¹—, —X¹—Z—O—Y¹—, or —X¹—Z—O—Y¹—X¹—,which is further defined as —(CH₂)_(r)—O—(CH₂)_(s)—Y¹—(CH₂)_(t)—, wherer, s and t are independently 0, 1, 2, 3, 4, 5 or 6, and Y¹ is C₃-C₆cycloalkylene optionally substituted by R¹⁰. In some embodiments, one ormore of the methylene groups of L¹ is independently optionallysubstituted by R⁹. In one variation, Y¹ is C₃-C₆ cycloalkyleneoptionally substituted by R⁹. In one variation, Y¹ is cyclopropylene(e.g., 1,2-cyclopropylene and 1,1-cyclopropylene), cyclobutylene (e.g.,1,3-cyclobutylene) or cyclohexylene (e.g., 1,4-cyclohexylene). In onevariation, r, s and t are independently 0 or 1. In one variation, eachr, s and t is 0. In another variation, r is 0, s is 1 and t is 1. Inanother variation, r is 1, s is 0 and t is 0. In another variation, r is0, s is 1 and t is 0. In one particular variation, r, s and t areindependently 0 or 1 and Y¹ is cyclopropylene (e.g., 1,2-cyclopropyleneand 1,1-cyclopropylene), cyclobutylene (e.g., 1,3-cyclobutylene) orcyclohexylene (e.g., 1,4-cyclohexylene).

In some embodiments, L¹ comprising a hydrocarbon group, which is furtherdefined as X² or —X²—Y¹—. In some of these embodiments, X² is C₁-C₆alkylene optionally substituted by R⁹. In one variation, X² is C₁-C₆alkylene. In another variation, X² is C₁-C₆ alkylene optionallysubstituted by fluoro. In some of these embodiments, X² is C₂-C₆alkenylene optionally substituted by R⁹. In one variation, X² is C₂-C₆alkenylene. In some of these embodiments, Y¹ is C₃-C₆ cycloalkyleneoptionally substituted by R¹⁰. In one variation, Y¹ is C₃-C₆cycloalkylene optionally substituted by R⁹. In one variation, Y¹ isC₃-C₆ cycloalkylene. In some embodiments, L¹ is —X²—Y¹— where X² isC₁-C₆ alkenylene and Y¹ is C₃-C₆ cycloalkylene.

In some embodiments, L¹ is selected from the group consisting of—(CH₂)₂—, —(CH₂)₄—, —(CH₂)₅—, —CF₂—(CH₂)₃— and

wherein the wavy lines denote attachment points to the parent molecule.

In some embodiments, L¹ is a linker moiety comprising a heterocyclylgroup, which is further defined as Y² or —Y²—X²—. In some of theseembodiments, Y² is a saturated 3- to 4-membered heterocyclyleneoptionally substituted by R¹⁰. In some embodiments, Y² is a saturated4-membered heterocyclylene optionally substituted by R¹⁰. In onevariation, Y² is a saturated 3- to 4-membered heterocyclylene optionallysubstituted by R⁹. In one variation, Y² is a saturated 3- to 4-memberedheterocyclylene. In one variation, Y² is a saturated 4-memberedheterocyclylene (e.g., 1,3-azetidinylene). In some embodiments, L¹ is—Y²—X²— where Y² is a saturated 3- to 4-membered heterocyclylene (e.g.,1,3-azetidinylene) and X² is C₁-C₆ alkylene (e.g., methylene).

In some embodiments, L¹ is selected from the group consisting of

wherein the wavy lines denote attachment points to the parent molecule.

In some embodiments, the -A-L- moiety is -A¹-L¹-, wherein A¹ and L¹ areas detailed herein. It is intended and understood that each and everyvariation of A¹ described herein, where applicable, may be combined witheach and every variation of L¹ described herein, the same as if each andevery combination is individually and specifically described. Forexample, in some embodiments of the compound of formula (I), (I-A) or(I-B), or a salt thereof, A¹ is phenylene (e.g., 1,4-phenylene) and L¹is —O—(CH₂)_(m)—, where m is 2, 3 or 4.

In some embodiments, A² is C₃-C₈ alkylene optionally substituted by R⁹or C₃-C₈ alkenylene optionally substituted by R⁹. In some embodiments,A² is C₃-C₈ alkylene optionally substituted by R⁹. In some embodiments,A² is C₄-C₈ alkylene optionally substituted by R⁹. In some embodiments,A² is C₃-C₆ alkylene optionally substituted by R⁹. In some embodiments,A² is C₃, C₄, C₅, or C₆, C₇, C₈ alkylene optionally substituted by R⁹.In some embodiments, A² is C₃-C₈ alkylene, C₄-C₈ alkylene or C₄-C₆alkylene. In one variation, A² is C₃, C₄, C₅, C₆, C₇, or C₈ alkylene. Insome embodiments, A² is C₃-C₈ alkenylene optionally substituted by R⁹.In some embodiments, A² is C₄-C₈ alkenylene optionally substituted byR⁹. In some embodiments, A² is C₄-C₄ alkenylene optionally substitutedby R⁹. In some embodiments, A² is C₃, C₄, C₅, C₆, C₇, or C₈ alkenyleneoptionally substituted by R⁹. In some embodiments, A² is C₃-C₈alkenylene, C₄-C₈ alkenylene or C₄-C₆ alkenylene. In one variation, A²is C₃, C₄, C₅, C₆, C₇, or C₈ alkenylene.

In some embodiments, L² is C₃-C₆ cycloalkylene optionally substituted byR¹⁰. In some embodiments, L² is C₃-C₆ cycloalkylene optionallysubstituted by R⁹. In some embodiments, L² is C₃-C₆ cycloalkylene. Insome embodiments, L² is C₃, C₄, C₅ or C₆ cycloalkylene optionallysubstituted by R¹⁰. In some embodiments, L² is C₃, C₄, C₅ or C₆cycloalkylene optionally substituted by R⁹. In one variation, L² is C₃,C₄, C₅ or C₆ cycloalkylene.

In some embodiments, the -A-L- moiety is -A²-L²-, wherein A² and L² areas detailed herein. It is intended and understood that each and everyvariation of A² described herein, where applicable, may be combined witheach and every variation of L² described herein, the same as if each andevery combination is individually and specifically described. Forexample, in some embodiments, A² is C₄-C₆ alkenylene (e.g., —(CH₂)₄—)and L² is C₃-C₆ cycloalkylene (e.g., 1,2-cyclopropylene).

In some embodiments, A³ is C₅-C₁₀ alkylene optionally substituted by R⁹or C₅-C₁₀ alkenylene optionally substituted by R⁹. In some embodiments,A³ is C₅-C₁₀ alkylene optionally substituted by R⁹. In some embodiments,A³ is C₆-C₁₀ alkylene optionally substituted by R⁹. In some embodiments,A³ is C₆-C₈ alkylene optionally substituted by R⁹. In some embodiments,A³ is C₅, C₆, C₇, C₈, C₉, or C₁₀ alkylene optionally substituted by R⁹.In some embodiments, A³ is C₅-C₁₀ alkylene, C₆-C₁₀ alkylene or C₆-C₈alkylene. In one variation, A³ is C₅, C₆, C₇, C₈, C₉, or C₁₀ alkylene.In some embodiments, A³ is C₅-C₁₀ alkenylene optionally substituted byR⁹. In some embodiments, A³ is C₆-C₁₀ alkenylene optionally substitutedby R⁹. In some embodiments, A³ is C₆-C₈ alkenylene optionallysubstituted by R⁹. In some embodiments, A³ is C₅, C₆, C₇, C₈, C₉, or C₁₀alkenylene optionally substituted by R⁹. In some embodiments, A³ isC₅-C₁₀ alkenylene, C₆-C₁₀ alkenylene or C₆-C₈ alkenylene. In onevariation, A³ is C₅, C₆, C₇, C₈, C₉, or C₁₀ alkenylene.

In some embodiments, the -A-L- moiety is selected from the groupconsisting of —CH₂(CH₂)₅CH₂—, —CH₂(CH₂)₄CH₂—, —CH═CH—(CH₂)₃CH₂—, and

wherein the wavy lines denote attachment points to the parent molecule.

It is intended and understood that each and every variation of R¹described herein, may be combined with each and every variation of the-A-L- moiety described herein, the same as if each and every combinationis individually and specifically described. For example, in someembodiments of the compound of formula (I), (I-A) or (I-B), or a saltthereof, R¹ is fused bicyclic 7- to 10-membered heteroaryl optionallysubstituted by R¹⁰ and the -A-L- moiety is -A¹-L¹- where A¹ is1,4-phenylene and L¹ is —O—(CH₂)_(m)—, where m is 2, 3 or 4. In someembodiments, R¹ is monocyclic 5- to 6-membered heteroaryl optionallysubstituted by R⁹ and the -A-L- moiety is -A¹-L¹- where A¹ is1,4-phenylene and L¹ is —O—(CH₂)_(m)—, where m is 2, 3 or 4. In someembodiments, R¹ is phenyl optionally substituted by R⁹ and the -A-L-moiety is -A¹-L¹- where A¹ is 1,4-phenylene and L¹ is —O—(CH₂)_(m)—,where m is 2, 3 or 4. In some embodiments, R¹ is phenyl optionallysubstituted by R⁹ or monocyclic 5- to 6-membered heteroaryl optionallysubstituted by R⁹ and the -A-L- moiety is -A¹-L¹- where A¹ is1,4-phenylene and L¹ is —O—(CH₂)_(m)—, where m is 2, 3 or 4. In someembodiments, R¹ is phenyl optionally substituted by R⁹ and the -A-L-moiety is -A¹-L¹- where A¹ is 3- to 6-membered heterocyclylene (e.g.,1,3-azetidinylene or 1,3-pyrrolidinylene) optionally substituted by R¹⁰and L¹ is —O—(CH₂)_(m)—, where m is 2, 3 or 4. In some embodiments, R¹is phenyl optionally substituted by R⁹ and the -A-L- moiety is -A¹-L¹-where A¹ is C₃-C₆ cycloalkylene (e.g., 1,4-cyclohexylene or1,3-cyclobutylene) optionally substituted by R¹⁰ and L¹ is—O—(CH₂)_(m)—, where m is 2, 3 or 4.

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A¹-L¹- where A¹ is 1,4-phenylene and L¹ is—(CH₂)_(n)—O—(CH₂)_(m) where n is 0 or 1 and m is 2, 3 or 4. In someembodiments, R¹ is phenyl optionally substituted by R⁹ and the -A-L-moiety is -A¹-L¹- where A¹ is 1,4-phenylene and L¹ is—(CH₂)_(r)—O—(CH₂)_(s)—Y¹—(CH₂)_(t)—, where r, s and t are independently0 or 1 and Y¹ is cyclopropylene (e.g., 1,2-cyclopropylene and1,1-cyclopropylene), cyclobutylene (e.g., 1,3-cyclobutylene) orcyclohexylene (e.g., 1,4-cyclohexylene).

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A¹-L¹- where A¹ is 1,4-phenylene and L¹ is—N(R⁴)—(CH₂)_(m) where m is 2, 3 or 4. In one variation, R⁴ is H.

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A¹-L¹- where A¹ is 1,4-phenylene and L¹ is C₁-C₆alkylene optionally substituted by fluoro. In some embodiments, R¹ isphenyl optionally substituted by R⁹ and the -A-L- moiety is -A¹-L¹-where A¹ is 1,4-phenylene and L¹ is —X²—Y¹— where X² is C₁-C₆ alkenyleneand Y¹ is C₃-C₆ cycloalkylene.

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A¹-L¹- where A¹ is C₃-C₄ cycloalkylene (e.g.,cyclopropylene) optionally substituted by R¹⁰ and L¹ is C₁-C₆ alkylene(e.g., C₂-C₄ alkylene). In some embodiments, R¹ is phenyl optionallysubstituted by R⁹ and the -A-L- moiety is -A¹-L¹- where A¹ is 5- to10-membered heteroarylene (e.g., 2,5-benzo[d]oxazolylene) optionallysubstituted by R⁹ and L¹ is C₁-C₆ alkylene (e.g., C₂-C₄ alkylene).

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A¹-L¹- where A¹ is C₃-C₄ cycloalkylene optionallysubstituted by R¹⁰ and L¹ is C₁-C₆ alkylene.

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A¹-L¹- where A¹ is C₃-C₄ cycloalkylene optionallysubstituted by R¹⁰ and L¹ is C₁-C₆ alkylene.

In some embodiments, R¹ is phenyl optionally substituted by R⁹ and the-A-L- moiety is -A²-L²- where A² is C₄-C₆ alkenylene (e.g., —(CH₂)₄—)and L² is C₃-C₆ cycloalkylene (e.g., 1,2-cyclopropylene).

In some embodiments, R¹ is a fused bicyclic 7- to 10-membered heteroaryl(e.g., indazolyl) optionally substituted by R¹⁰ and the -A-L- moiety isC₆-C₈ alkylene or C₆-C₈ alkenylene.

In one variation of any of the preceding embodiments or any otherembodiment or variation detailed herein, the compound is other than anyapplicable compounds in Table 1X and salts thereof.

In some embodiments of the compound of formula (I), (I-A) or (I-B), or asalt thereof, R² is 5- to 10-membered heteroaryl containing at least 2ring nitrogen atoms, 3- to 12-membered heterocyclyl containing at least2 ring nitrogen atoms, or —NH—R³, wherein the 5- to 10-memberedheteroaryl and 3- to 12-membered heterocyclyl of R² are independentlyoptionally substituted by R¹⁰.

In some embodiments, R² is 5- to 10-membered heteroaryl containing atleast 2 ring nitrogen atoms optionally substituted by R¹⁰, or 3- to12-membered heterocyclyl containing at least 2 ring nitrogen atomsoptionally substituted by R¹⁰.

In some embodiments, R² is selected from the group consisting of5,6,7,8-tetrahydro-naphthyridinyl,1,2,3,4-tetrahydro-1,8-naphthyridinyl,3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, and2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl.

In some embodiments, R² is —NH—R³, where R³ is 5- to 10-memberedheteroaryl containing at least 1 ring nitrogen atom, or 3- to12-membered heterocyclyl containing at least 1 ring nitrogen atom,wherein the 5- to 10-membered heteroaryl and 3- to 12-memberedheterocyclyl of R³ are independently optionally substituted by R¹⁰.

In some embodiments, R³ is 5- to 10-membered heteroaryl containing atleast 1 ring nitrogen atom optionally substituted by R¹⁰.

In some embodiments, R³ is a pyridinyl.

In some embodiments, R³ is a 3- to 12-membered heterocyclyl containingat least 1 ring nitrogen atom optionally substituted by R¹⁰.

In some embodiments, R³ is selected from the group consisting of4,5-dihydro-1H-imidazolyl, 5,6-dihydro-4H-1,3-oxazinyl,4,5-dihydrothiazolyl, 3,4,5,6-tetrahydropyrazinyl, and5,6-dihydro-4H-1,3-thiazinyl.

In some embodiments, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰.

In some embodiments, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰.

In some embodiments, R² is

In some embodiments, R² is

In some embodiments, R² is —R³—NR^(3a)R^(3b).

In some embodiments, R² is —R³—NHR^(3a)

In some embodiments, R³ is pyridyl optionally substituted by R¹⁰.

In some embodiments, R² is

In some embodiments, R² is

It is intended and understood that each and every variation of R¹ and/or-A-L- described herein, may be combined with each and every variation ofR² described herein, the same as if each and every combination isindividually and specifically described. For example, in someembodiments, R¹ is a fused bicyclic 7- to 10-membered heteroaryloptionally substituted by R¹⁰, the -A-L- moiety is -A¹-L¹- where A¹ is1,4-phenylene and L¹ is —O—(CH₂)_(m) where m is 2, 3 or 4, and R² is10-membered heteroaryl containing 2 ring nitrogen atoms (e.g.,5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl).

In some embodiments, the compound of formula (I) is of the formula (II):

or a salt thereof, wherein R¹, L¹ and R² are as defined for formula (I)or any embodiment or variation thereof.

In some embodiments of the compound of formula (II), or a salt thereof,R² is 5- to 10-membered heteroaryl containing at least 2 ring nitrogenatoms, or 3- to 12-membered heterocyclyl containing at least 2 ringnitrogen atoms, wherein the 5- to 10-membered heteroaryl and 3- to12-membered heterocyclyl of R² are independently optionally substitutedby R¹⁰. In another embodiment, R² is —NR^(3a)-pyridyl, wherein pyridylis optionally substituted by R¹⁰. In another embodiment, R² is—NH-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (II) is of the formula(II-1):

or a salt thereof, wherein R¹, L¹ and R² are as defined for formula (I)or any embodiment or variation thereof.

In some embodiments, the compound of formula (I) is of the formula(III):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof, and m is 1, 2, 3, 4, 5 or 6. In onevariation, m is 2, 3 or 4. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (III) is of the formula(III-1):

or a salt thereof, wherein R¹ and R³ are as defined for formula (I) orany embodiment or variation thereof, and m is 1, 2, 3, 4, 5 or 6. In onevariation, m is 3, 4 or 5.

In some embodiments, the compound of formula (III) is of the formula(III-2):

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof; R⁸ is as defined for R¹⁰ of formula (I)or any embodiment or variation thereof; Y is O, S, or NR⁶; R⁶ is H orC₁-C₆ alkyl; m is 1, 2, 3, 4, 5 or 6; and q is 0, 1, 2 or 3. In onevariation, m is 3, 4 or 5. In one variation, q is 0.

In some embodiments, the compound of formula (I) is of the formula (IV):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof, and p is 4, 5, 6, 7, 8 or 9. In onevariation, p is 5, 6 or 7. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (IV) is of the formula(IV-1):

or a salt thereof, wherein R¹ and R³ are as defined for formula (I) orany embodiment or variation thereof, and p is 4, 5, 6, 7, 8 or 9. In onevariation, p is 5, 6, 7 or 8.

In some embodiments, the compound of formula (IV) is of the formula(IV-2):

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof; R⁸ is as defined for R¹⁰ of formula (I)or any embodiment or variation thereof; Y is O, S, or NR⁶; R⁶ is H orC₁-C₆ alkyl; p is 4, 5, 6, 7, 8 or 9; and q is 0, 1, 2 or 3. In onevariation, p is 5, 6, 7 or 8. In one variation, q is 0.

In some embodiments, each optional substituent R⁹ is independently C₁-C₆alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, —CN, —OR¹¹, —SR¹¹,—NR¹²R¹¹, —NO₂, —C═NH(OR¹¹), —C(O)R¹¹, —OC(O)R¹¹, —C(O)OR¹¹,—C(O)NR¹²R¹³, —NR¹¹C(O)R¹², —NR¹¹C(O)OR¹², —NR¹¹C(O)NR¹²R¹³, —S(O)R¹¹,—S(O)₂R¹¹, —NR¹¹ S(O)R¹², —NR¹¹S(O)₂R¹², —S(O)NR¹²R¹³, —S(O)₂NR¹²R¹³,—P(O)(OR¹²) (OR¹³), C₃-C₈ cycloalkyl, 3- to 12-membered heterocyclyl, 5-to 10-membered heteroaryl or C₆-C₁₄ aryl, wherein each R⁹ isindependently optionally substituted by halogen, oxo, —OR¹⁴, —NR¹⁴R¹⁵,—C(O)R¹⁴, —CN, —S(O)R¹⁴, —S(O)₂R¹⁴, —P(O)(OR¹⁴)(OR¹⁵), C₃-C₈ cycloalkyl,3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄aryl, or C₁-C₆ alkyl optionally substituted by oxo, —OH or halogen.

In some embodiments, R⁹ is independently C₁-C₆ alkyl, halogen, —CN,—OR¹¹, —NR¹²R¹³, —C(O)R¹¹, C₃-C₈ cycloalkyl, 3- to 12-memberedheterocyclyl, 5- to 10-membered heteroaryl or C₆-C₁₄ aryl, wherein eachR⁹ is independently optionally substituted by halogen, oxo, —OR¹⁴,—NR¹⁴R¹⁵, —C(O)R¹⁴, —CN, C₃-C₈ cycloalkyl, 3- to 12-memberedheterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄ aryl, or C₁-C₆ alkyloptionally substituted by oxo, —OH or halogen. In some embodiments, R⁹is independently selected from F, Cl, —CN, methyl, —CHF₂, —CF₃,cyclopropylmethyl, tert-butyl, cyclopropyl and phenyl.

In some embodiments, R¹⁰ is independently oxo or any variation detailedherein for R⁹. In some embodiments, R¹⁰ is independently oxo, C₁-C₆alkyl, halogen, —CN, —OR¹¹, —NR¹²R¹³, —C(O)R¹¹, C₃-C₈ cycloalkyl, 3- to12-membered heterocyclyl, 5- to 10-membered heteroaryl or C₆-C₁₄ aryl,wherein each R⁹ is independently optionally substituted by halogen, oxo,—OR¹⁴, —NR¹⁴R¹⁵, —C(O)R¹⁴, —CN, C₃-C₈ cycloalkyl, 3- to 12-memberedheterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄ aryl, or C₁-C₆ alkyloptionally substituted by oxo, —OH or halogen. In some embodiments, R¹⁰is independently selected from oxo, F, Cl, —CN, methyl, —CHF₂, —CF₃,cyclopropylmethyl, tert-butyl, cyclopropyl and phenyl.

In some embodiments, R¹¹, R¹² and R¹³ are each independently hydrogen orC₁-C₆ alkyl. In some embodiments, R¹¹ is hydrogen. In some embodiments,R¹² and R¹³ are each hydrogen.

In some embodiments, R¹⁴ and R¹⁵ are each independently hydrogen orC₁-C₆ alkyl.

In some embodiments, the compound of formula (I) is of the formula (V):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof, each R¹⁰ is independently R⁹ andq is 0, 1, 2, 3, 4, or 5. In one variation, q is 0, 1, 2, or 3. Inanother embodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰. In another embodiment, R² is —NH-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In one variation of formula (V), each R¹⁰ is independently F, Cl, —CN,—OR¹¹, —NH₂, —NH(CO)H, —CF₃, cyclopropyl, pyridinyl, thiazolyl,imidazolyl, or substituted pyrazolyl. In one variation, q is 1, 2, or 3and each R¹⁰ is independently F, Cl, —CN, —OR, —NH2, —NH(CO)H, —CF₃,cyclopropyl, pyridinyl, thiazolyl, imidazolyl, or substituted pyrazolyl.It is understood that the embodiments of formula (V) may employ any ofthe A-L-R² embodiments or variations provided herein the same as if eachand every combination were specifically and individually listed. Forexample, in one embodiment, -A-L- is -phenylene-O—(CH2)3-:

In another embodiment, -A-L- is C₆ alkylene:

In another embodiment, -A-L- is -phenylene-(CH₂)—O—(CH₂)₃—:

for example, where R² is —NH-pyridyl such as the following:

In another embodiment, -A-L- is -phenylene-(CH₂)—O—(CH₂)₂—:

In some embodiments, the compound of formula (I) is of the formula (VI):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof; X is —O—, —S—, or —N(R¹⁰)—; andR¹⁰ is H or C₁-C₆ alkyl optionally substituted by halogen or C₃-C₆cycloalkyl. In another embodiment, R² is —NR^(3a)-pyridyl, whereinpyridyl is optionally substituted by R¹⁰. In another embodiment, R² is—NH-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (VI) is of the formula(VI-1):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof and R¹⁰ is H or C₁-C₆ alkyloptionally substituted by halogen or C₃-C₆ cycloalkyl. In someembodiments, the compound of formula (VI-1) is of the formula (VI-1-A):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

In some embodiments, the compound of formula (VI-1) is of the formula(VI-1-B):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

In some embodiments, the compound of formula (VI-1) is of the formula(VI-1-C):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

In some embodiments, the compound of formula (VI-1) is of the formula(VI-1-D):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

It is understood that the embodiments of formula (VI), (VI-1), (VI-1-A),(VI-1-B), (VI-1-C) and (VI-1-D) may employ any of the A-L-R² embodimentsor variations provided herein the same as if each and every combinationwere specifically and individually listed.

In some embodiments, the compound of formula (I) is of the formula(VII):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof; X is —O—, —S—, or —N(R¹⁰)—; andR¹⁰ is C₁-C₆ alkyl optionally substituted by halogen. In anotherembodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is —NH-pyridyl, whereinpyridyl is optionally substituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (VII) is of the formula(VII-1):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

In some embodiments, the compound of formula (VII-1) is of the formula(VII-1-A):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

In some embodiments, the compound of formula (VII-1) is of the formula(VII-1-B):

or a salt thereof, wherein R², A, L, and R¹⁰ are as defined for formula(I) or any embodiment or variation thereof.

It is understood that the embodiments of formula (VII), (VII-1),(VII-1-A) and (VII-1-B) may employ any of the A-L-R² embodiments orvariations provided herein the same as if each and every combinationwere specifically and individually listed.

In some embodiments, the compound of formula (I) is of the formula(VIII):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof; X is —O—, —S—, or —N(R¹⁰)—; andR¹⁰ is C₁-C₆ alkyl. In another embodiment, R² is —NR^(3a)-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is —NH-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (VIII) is of the formula(VIII-1):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof; X is —O—, —S—, or —N(R¹⁰)—; andR¹⁰ is C₁-C₆ alkyl.

In some embodiments, the compound of formula (VIII) is of the formula(VIII-2):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof; X is —O—, —S—, or —N(R¹⁰)—; andR¹⁰ is C₁-C₆ alkyl.

It is understood that the embodiments of formula (VIII) and (VIII-1) mayemploy any of the A-L-R² embodiments or variations provided herein thesame as if each and every combination were specifically and individuallylisted.

In some embodiments, the compound of formula (I) is of the formula (IX):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof, each R¹⁰ is independently R⁹ andq is 0, 1, 2, 3, or 4. In one variation, q is 0, 1, or 2. In onevariation, each R¹⁰ is Cl. In one variation, q is 1, or 2 and each R¹⁰is Cl. It is understood that the embodiments of formula (IX) may employany of the A-L-R² embodiments or variations provided herein the same asif each and every combination were specifically and individually listed.In another embodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰. In another embodiment, R² is —NH-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula (X):

or a salt thereof, wherein R², A and L are as defined for formula (I) orany embodiment or variation thereof, each R¹⁰ is independently R⁹ and qis 0, 1, 2, or 3. In one variation, q is 0, or 1. In one variation, eachR¹⁰ is independently C₁-C₆ alkyl or phenyl, wherein the C₁-C₆ alkyl ofR¹⁰ is optionally substituted by halogen. In one variation, q is 1, or 2and each R¹⁰ is independently C₁-C₆ alkyl or phenyl, wherein the C₁-C₆alkyl of R¹⁰ is optionally substituted by halogen. It is understood thatthe embodiments of formula (X) may employ any of the A-L-R² embodimentsor variations provided herein the same as if each and every combinationwere specifically and individually listed. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula (XI):

or a salt thereof, wherein R², A, and L are as defined for formula (I)or any embodiment or variation thereof; Y is —N—, —CH—, or C(R¹⁰), eachR¹⁰ is independently R⁹ and q is 0, 1, 2, or 3. In one variation, q is0, 1, or 2. In one variation, each R¹⁰ is independently halogen, C₁-C₆alkyl or phenyl, wherein the C₁-C₆ alkyl is optionally substituted byone to eight halogen atoms. In one variation, q is 1, or 2 and each R¹⁰is independently halogen, C₁-C₆ alkyl or phenyl, wherein the C₁-C₆ alkylof R¹⁰ is optionally substituted by one to eight halogen atoms. In onevariation, Y is —N—, q is 1, and each R¹⁰ is independently C₁-C₆ alkyloptionally substituted by one to eight halogen atoms or phenyl. It isunderstood that the embodiments of formula (XI) may employ any of theA-L-R² embodiments or variations provided herein the same as if each andevery combination were specifically and individually listed. In anotherembodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is —NH-pyridyl, whereinpyridyl is optionally substituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula(III-4)

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof.

In some embodiments, the compound of formula (I) is of the formula(III-5)

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof; m is 1, 2, 3, 4, 5, or 6; and n is 1 or2. In one variation, m is 2, 3, or 4.

In some embodiments, the compound of formula (I) is of the formula(III-1-A)

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof;

-   -   R⁸ is as defined for R¹⁰ of formula (I) or any embodiment or        variation thereof; Y is —O—, —S—, or —N(R⁶)—; R⁶ is H, C₁-C₆        alkyl, or —C(═O)CH₃; m is 1, 2, 3, 4, 5, or 6; n is an integer        from 0-8; p is 0 or 1; and q is 0, 1, 2 or 3. In one variation,        m is 3, 4 or 5. In one variation, q is 0. In one variation, n is        1 or 2.

In some embodiments, the compound of formula (I) is of the formula(XII):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof; m is an integer from 0-7; and

is C₃-C₅ cycloalkylene optionally substituted by one to six R⁹ groupswhere R⁹ is as defined for formula (I). In one variation, m is 1 and

is cyclobutylene. In one variation, m is 1 and

is cyclohexylene. In another embodiment, R² is —NR^(3a)-pyridyl, whereinpyridyl is optionally substituted by R¹⁰. In another embodiment, R² is—NH-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula(XIII):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof; m is 0 or 1; and

is C₃-C₅ cycloalkylene optionally substituted by one to six R⁹ groupswhere R⁹ is as defined for formula (I). In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula(XIV):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof, and m is 0, 1, 2, 3, 4, 5, or 6. Inone variation, m is 0 or 1. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (III-1) is of the formula(III-1-B):

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof, and m is 1, 2, 3, 4, 5, or 6. In onevariation, m is 3, 4, or 5. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula (XV):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof;

is C₃-C₈ cycloalkylene or C₃-C₈ cycloalkenylene optionally substitutedby one to six R¹⁰ groups where R¹⁰ is as defined for formula (I); m is0, 1, 2, 3, 4, 5, 6, or 7; and n is 1, 2, 3, 4, 5, 6, or 7. In onevariation, m is 0 or 1. In one variation, n is 3, 4, or 5. In onevariation,

is 1,3-cyclobutylene or 1,4-cyclohexylene. In one particular variation,m is 1, n is 3, and

is 1,3-cyclobutylene:

In another embodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰. In another embodiment, R² is —NH-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b),

where pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another particular variation, m is 0, n is 3, and

is 1,3-cyclobutylene:

In another embodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰. In another embodiment, R² is —NH-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In yet another particular variation, m is 0, n is 3, and

is 1,4-cyclohexylene:

In another embodiment, R² is —NR^(3a)-pyridyl, wherein pyridyl isoptionally substituted by R¹⁰. In another embodiment, R² is —NH-pyridyl,wherein pyridyl is optionally substituted by R¹⁰. In another embodiment,R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (I) is of the formula(XVI):

or a salt thereof, wherein R¹ and R² are as defined for formula (I) orany embodiment or variation thereof, and m is 1, 2, 3, 4, 5 or 6. In onevariation, m is 2, 3 or 4. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (III) is of the formula(III-1):

or a salt thereof, wherein R¹ and R³ are as defined for formula (I) orany embodiment or variation thereof, and m is 1, 2, 3, 4, 5 or 6. In onevariation, m is 3, 4 or 5. In another embodiment, R² is—NR^(3a)-pyridyl, wherein pyridyl is optionally substituted by R¹⁰. Inanother embodiment, R² is —NH-pyridyl, wherein pyridyl is optionallysubstituted by R¹⁰. In another embodiment, R² is

In another embodiment, R² is

In another embodiment, R² is —R³—NR^(3a)R^(3b). In another embodiment,R² is —R³—NHR^(3a). In another embodiment, R² is-(pyridyl)-NR^(3a)R^(3b), where pyridyl is optionally substituted byR¹⁰. In another embodiment, R² is

In another embodiment, R² is

In some embodiments, the compound of formula (III) is of the formula(III-2):

or a salt thereof, wherein R¹ is as defined for formula (I) or anyembodiment or variation thereof; R⁸ is as defined for R¹⁰ of formula (I)or any embodiment or variation thereof; Y is O, S, or NR⁶; R⁶ is H orC₁-C₆ alkyl; m is 1, 2, 3, 4, 5 or 6; and q is 0, 1, 2 or 3. In onevariation, m is 3, 4 or 5. In one variation, q is 0.

Also provided is a compound of formula (I), or a salt thereof, or anyembodiment or variation thereof, wherein R¹ is selected from the groupconsisting of:

In one embodiment, when R¹ is optionally substituted phenyl, -A-L- isselected from the group consisting of:

wherein m is 0 or 1; and the wavy lines denote attachment points to theparent molecule; and R² is selected from the group consisting of:

wherein R⁸ is as defined for R¹⁰ of formula (I) or any embodiment orvariation thereof; J is —O—, —S—, —N(R⁶)—, or —CH₂—; R⁶ is H, C₁-C₆alkyl, or —C(═O)CH₃; w is 0 or 1; n is 0, 1, 2, 3, 4, 5, 6, or 7; p is 0or 1; q is 0, 1, 2 or 3; and the wavy lines denote attachment points tothe parent molecule. In one variation n is 1 or 2.

In one variation of the preceding embodiment, p is 0 and n is 1:

In another variation of the preceding embodiment, p is 0 and n is 2:

In another variation of the preceding embodiment, p is 1 and n is 1:

In another variation of the preceding embodiment, -A-L-R² is selectedfrom the group consisting of:

wherein R⁸ is as defined for R¹⁰ of formula (I) or any embodiment orvariation thereof; J is —O—, —S—, —N(R⁶)—, or —CH₂—; R⁶ is H, C₁-C₆alkyl, or —C(═O)CH₃; w is 0 or 1; n is 0, 1, 2, 3, 4, 5, 6, or 7; p is 0or 1; q is 0, 1, 2 or 3; and the wavy lines denote attachment points tothe parent molecule. In one variation, A-L-R² is selected from the groupconsisting of:

In one variation, -A-L- is

and R² is

wherein J is —N(R⁶)—, p is 1, and n is 1:

wherein R¹⁰ is as defined for formula (I) or any embodiment or variationthereof; R⁸ is as defined for R¹⁰ of formula (I) or any embodiment orvariation thereof; R⁶ is H, C₁-C₆ alkyl, or —C(═O)CH₃; q is 0, 1, 2, or3; and r is 0, 1, 2, 3, 4, or 5.

Representative compounds are listed in Table 1 and Table 2.

TABLE 1 Com- pound No. Structure Chemical Name¹  1

2-benzamido-3-(4-(3-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoic acid  1a (S)-2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  1b(R)-2-benzamido-3-(4-(3-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoic acid  2

2-(1-methyl-1H-benzo[d]imidazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  2a(S)-2-(1-methyl-1H-benzo[d]imidazole- 6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  2b(R)-2-(1-methyl-1H-benzo[d]imidazole- 6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  3

2-(5-(difluoromethyl)pyrazine-2- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  3a(S)-2-(5-(difluoromethyl)pyrazine-2- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  3b(R)-2-(5-(difluoromethyl)pyrazine-2- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  4

2-(6-phenylpyrazine-2-carboxamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  4a(S)-2-(6-phenylpyrazine-2- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  4b(R)-2-(6-phenylpyrazine-2- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  5

2-(2,6-dichloro-4-cyanobenzamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  5a(S)-2-(2,6-dichloro-4-cyanobenzamido)- 3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  5b(R)-2-(2,6-dichloro-4-cyanobenzamido)- 3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  6

2-(2-fluoro-6- (trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 6a (S)-2-(2-fluoro-6- (trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 6b (R)-2-(2-fluoro-6- (trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 7

2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 7a (S)-2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 7b (R)-2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 8

2-(2-methylpyrimidine-4-carboxamido)- 3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  8a(S)-2-(2-methylpyrimidine-4- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  8b(R)-2-(2-methylpyrimidine-4- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  9

2-(1-methyl-1H-benzo[d]imidazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  9a(S)-2-(1-methyl-1H-benzo[d]imidazole- 5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid  9b(R)-2-(1-methyl-1H-benzo[d]imidazole- 5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 10

2-(benzo[d]oxazole-5-carboxamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 10a(S)-2-(benzo[d]oxazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 10b(R)-2-(benzo[d]oxazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 11

2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 11a (S)-2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)propoxy)phenyl)propanoic acid 11b (R)-2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)propoxy)phenyl)propanoic acid 12

2-(3-formamido-4-hydroxybenzamido)- 3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 12a(S)-2-(3-formamido-4- hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 12b(R)-2-(3-formamido-4- hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 13

2-(isonicotinamido)-3-(4-(3-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoic acid 13a (S)-2-(isonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid13b (R)-2-(isonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid14

2-(nicotinamido)-3-(4-(3-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoic acid 14a(S)-2-(nicotinamido)-3-(4-(3-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoic acid 14b(R)-2-(nicotinamido)-3-(4-(3-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoic acid 15

2-(3,5-dichloroisonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 15a (S)-2-(3,5-dichloroisonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)propoxy)phenyl)propanoic acid 15b(R)-2-(3,5-dichloroisonicotinamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 16

2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid16a (S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid16b (R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid17

2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoic acid 17a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2- yl)amino)butoxy)phenyl)propanoic acid 17b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2- yl)amino)butoxy)phenyl)propanoic acid 18

2-(2,6-dichlorobenzamido)-3-(4-(3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2- yl)propoxy)phenyl)propanoic acid 18a(S)-2-(2,6-dichlorobenzamido)-3-(4-(3- ((S)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2- yl)propoxy)phenyl)propanoic acid 18b(R)-2-(2,6-dichlorobenzamido)-3-(4-(3- ((R)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2- yl)propoxy)phenyl)propanoic acid 18c(S)-2-(2,6-dichlorobenzamido)-3-(4-(3- ((R)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2- yl)propoxy)phenyl)propanoic acid 18d(R)-2-(2,6-dichlorobenzamido)-3-(4-(3- ((S)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2- yl)propoxy)phenyl)propanoic acid 19

2-(2,6-dichlorobenzamido)-9-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 19a (S)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)nonanoic acid 19b(R)-2-(2,6-dichlorobenzamido)-9- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 20

(E)-2-(2,6-dichlorobenzamido)-9- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)non-4-enoic acid 20a (S, E)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)non-4-enoic acid 20b (R,E)-2-(2,6-dichlorobenzamido)-9- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)non-4-enoic acid 21

2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)methyl)azetidin-1-yl)phenyl)propanoic acid 21a (S)-2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)methyl)azetidin-1-yl)phenyl)propanoic acid 21b (R)-2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)methyl)azetidin-1-yl)phenyl)propanoic acid 22

2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoic acid 22a(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoic acid 22b(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoic acid 23

2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)cyclobutyl)methoxy)phenyl) propanoic acid 23a(S)-2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)cyclobutyl)methoxy)phenyl) propanoic acid 23b(R)-2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)cyclobutyl)methoxy)phenyl) propanoic acid 24

(E)-2-(2,6-dichlorobenzamido)-3-(4-(2- (4-(pyridin-3-ylamino)cyclohexyl)vinyl)phenyl) propanoic acid 24a (S,E)-2-(2,6-dichlorobenzamido)-3-(4- (2-(4-(pyridin-3-ylamino)cyclohexyl)vinyl)phenyl) propanoic acid 24b (R,E)-2-(2,6-dichlorobenzamido)-3-(4- (2-(4-(pyridin-3-ylamino)cyclohexyl)vinyl)phenyl) propanoic acid 25

2-(2,6-dichlorobenzamido)-3-(4-((4- (pyridin-2-ylamino)cyclohexyl)methoxy)phenyl) propanoic acid 25a(S)-2-(2,6-dichlorobenzamido)-3-(4-((4- (pyridin-2-ylamino)cyclohexyl)methoxy)phenyl) propanoic acid 25b(R)-2-(2,6-dichlorobenzamido)-3-(4-((4- (pyridin-2-ylamino)cyclohexyl)methoxy)phenyl) propanoic acid 26

2-(2,6-dichlorobenzamido)-3-(4-((2- methyl-4-(pyridin-2-ylamino)butan-2-yl)amino)phenyl)propanoic acid 26a(S)-2-(2,6-dichlorobenzamido)-3-(4-((2-methyl-4-(pyridin-2-ylamino)butan-2- yl)amino)phenyl)propanoic acid 26b(R)-2-(2,6-dichlorobenzamido)-3-(4-((2-methyl-4-(pyridin-2-ylamino)butan-2- yl)amino)phenyl)propanoic acid 27

2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid27a (2S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid27b (2R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 28

(+/−)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoic acid 28a(S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoic acid 28b(R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoic acid 29

2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoic acid 29a(S)-2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoic acid 29b(R)-2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoic acid 30

2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)propoxy)methyl)phenyl) propanoic acid 30a(S)-2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)propoxy)methyl)phenyl) propanoic acid 30b(R)-2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)propoxy)methyl)phenyl) propanoic acid 31

2-(2,6-dichlorobenzamido)-3-(4-(((4- (pyridin-2-ylamino)cyclohexyl)oxy)methyl)phenyl) propanoic acid (substituents incis orientation on cyclohexyl ring) 31a(S)-2-(2,6-dichlorobenzamido)-3-(4- (((4-(pyridin-2-ylamino)cyclohexyl)oxy)methyl)phenyl) propanoic acid (substituents incis orientation on cyclohexyl ring) 31b(R)-2-(2,6-dichlorobenzamido)-3-(4- (((4-(pyridin-2-ylamino)cyclohexyl)oxy)methyl)phenyl) propanoic acid (substituents incis orientation on cyclohexyl ring) 32

2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)cyclobutoxy)methyl)phenyl) propanoic acid (substituents in cisorientation on cyclobutyl ring) 32a(S)-2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)cyclobutoxy)methyl)phenyl) propanoic acid (substituents in cisorientation on cyclobutyl ring) 32b(R)-2-(2,6-dichlorobenzamido)-3-(4-((3- (pyridin-2-ylamino)cyclobutoxy)methyl)phenyl) propanoic acid (substituents in cisorientation on cyclobutyl ring) 33

2-(2,6-dichlorobenzamido)-3-(4-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)ethoxy)ethyl)phenyl)propanoicacid 33a (2S)-2-(2,6-dichlorobenzamido)-3-(4-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)phenyl)propanoic acid 33b(2R)-2-(2,6-dichlorobenzamido)-3-(4- (1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)ethoxy)ethyl)phenyl)propanoic acid 34

2-(4-cyclopropylbenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid34a (2S)-2-(4-cyclopropylbenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 34b (2R)-2-(4-cyclopropylbenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 35

2-(3,5-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid35a (2S)-2-(3,5-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid35b (2R)-2-(3,5-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 36

2-(2-chloro-5-fluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 36a (2S)-2-(2-chloro-5-fluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)propoxy)phenyl)propanoic acid 36b(2R)-2-(2-chloro-5-fluorobenzamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 37

2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid37a (2S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid37b (2R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)propoxy)phenyl)propanoicacid 38

2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4- cis-(2-pyridylamino)cyclohexoxy]phenyl] propanoic acid 38a(2S)-2-[(2,6-dichlorobenzoyl)amino]-3- [4-[4-cis-(2-pyridylamino)cyclohexoxy]phenyl] propanoic acid 38b(2R)-2-[(2,6-dichlorobenzoyl)amino]-3- [4-[4-cis-(2-pyridylamino)cyclohexoxy]phenyl] propanoic acid 39

2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4- trans-(2-pyridylamino)cyclohexoxy]phenyl] propanoic acid 39a(2S)-2-[(2,6-dichlorobenzoyl)amino]-3- [4-[4-trans-(2-pyridylamino)cyclohexoxy]phenyl] propanoic acid 39b(2R)-2-[(2,6-dichlorobenzoyl)amino]-3- [4-[4-trans-(2-pyridylamino)cyclohexoxy]phenyl] propanoic acid 40

2-(1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid40a (2S)-2-(1H-indazole-6-carboxamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 40b(2R)-2-(1H-indazole-6-carboxamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 41

2-(1-methyl-1H-indazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 41a(2S)-2-(1-methyl-1H-indazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 41b(2R)-2-(1-methyl-1H-indazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 42

2-(1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid42a (2S)-2-(1H-indazole-5-carboxamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 42b(2R)-2-(1H-indazole-5-carboxamido)-3- (4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 43

2-(1-methyl-1H-indazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 43a(2S)-2-(1-methyl-1H-indazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 43b(2R)-2-(1-methyl-1H-indazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 44

2-(2-methyl-2H-indazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 44a(2S)-2-(2-methyl-2H-indazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 44b(2R)-2-(2-methyl-2H-indazole-6- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 45

2-(2-methyl-2H-indazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 45a(2S)-2-(2-methyl-2H-indazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 45b(2R)-2-(2-methyl-2H-indazole-5- carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid 46

2-(2,6-dichlorobenzamido)-3-(4-((1- ((pyridin-2-ylamino)methyl)cyclopropyl)methoxy) phenyl)propanoic acid 46a(2S)-2-(2,6-dichlorobenzamido)-3-(4- ((1-((pyridin-2-ylamino)methyl)cyclopropyl)methoxy) phenyl)propanoic acid 46b(2R)-2-(2,6-dichlorobenzamido)-3-(4- ((1-((pyridin-2-ylamino)methyl)cyclopropyl)methoxy) phenyl)propanoic acid 47

2-(2,6-dichlorobenzamido)-10-((3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoic acid 47a(S)-2-(2,6-dichlorobenzamido)-10- ((3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoic acid 47b (R)-2-(2,6-dichlorobenzamido)-10-((3,4,5,6-tetrahydropyrazin-2- yl)amino)decanoic acid 48

2-(2,6-dichlorobenzamido)-10-((4,5- dihydrooxazol-2-yl)amino)decanoicacid 48a (S)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrooxazol-2-yl)amino)decanoic acid 48b(R)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrooxazol-2-yl)amino)decanoic acid 49

2-(2,6-dichlorobenzamido)-10-((4,5- dihydrothiazol-2-yl)amino)decanoicacid 49a (S)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrothiazol-2-yl)amino)decanoic acid 49b(R)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrothiazol-2-yl)amino)decanoic acid 50

2-(2,6-dichlorobenzamido)-10-((1- methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)decanoic acid 50a (S)-2-(2,6-dichlorobenzamido)-10-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol- 2-yl)amino)decanoic acid 50b(R)-2-(2,6-dichlorobenzamido)-10-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol- 2-yl)amino)decanoic acid 51

2-(2,6-dichlorobenzamido)-10-((5,6- dihydro-4H-1,3-oxazin-2-yl)amino)decanoic acid 51a (S)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-oxazin-2- yl)amino)decanoic acid 51b(R)-2-(2,6-dichlorobenzamido)-10-((5,6- dihydro-4H-1,3-oxazin-2-yl)amino)decanoic acid 52

2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin- 2-yl)amino)decanoic acid 52a(S)-2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin- 2-yl)amino)decanoic acid 52b(R)-2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin- 2-yl)amino)decanoic acid 53

2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin- 2-yl)amino)decanoic acid 53a(S)-2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin- 2-yl)amino)decanoic acid 53b(R)-2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin- 2-yl)amino)decanoic acid 54

2-(2,6-dichlorobenzamido)-10-((5,6- dihydro-4H-1,3-thiazin-2-yl)amino)decanoic acid 54a (S)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-thiazin-2- yl)amino)decanoic acid 54b(R)-2-(2,6-dichlorobenzamido)-10-((5,6- dihydro-4H-1,3-thiazin-2-yl)amino)decanoic acid 55

3-(4-(4-((4-acetyl-3,4,5,6- tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6- dichlorobenzamido)propanoic acid 55a(S)-3-(4-(4-((4-acetyl-3,4,5,6- tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6- dichlorobenzamido)propanoic acid 55b(R)-3-(4-(4-((4-acetyl-3,4,5,6- tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6- dichlorobenzamido)propanoic acid 56

2-(2,6-dichlorobenzamido)-3-(4-(4- ((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoic acid 56a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoic acid 56b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoic acid 57

2-(2,6-dichlorobenzamido)-3-(4-(4-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol- 2-yl)amino)butoxy)phenyl)propanoicacid 57a (S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((1-methyl-5-oxo-4,5-dihydro-1H- imidazol-2-yl)amino)butoxy)phenyl)propanoic acid 57b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2- yl)amino)butoxy)phenyl)propanoic acid 58

2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoic acid 58a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2- yl)amino)butoxy)phenyl)propanoic acid 58b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2- yl)amino)butoxy)phenyl)propanoic acid 59

2-(2,6-dichlorobenzamido)-3-(4-(4- ((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoic acid 59a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoic acid 59b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoic acid 60

2-(2,6-dichlorobenzamido)-3-(4-(4- ((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoic acid 60a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoic acid 60b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoic acid 61

2-(2,6-dichlorobenzamido)-3-(4-(4- ((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoic acid 61a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoic acid 61b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoic acid 62

2-(2,6-dichlorobenzamido)-3-(4-(4- ((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoic acid 62a(S)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoic acid 62b(R)-2-(2,6-dichlorobenzamido)-3-(4-(4- ((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoic acid 63

2-(2,6-dichlorobenzamido)-3-(4-(3-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3- yl)propoxy)phenyl)propanoic acid63a (2S)-2-(2,6-dichlorobenzamido)-3-(4-(3- (3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3- yl)propoxy)phenyl)propanoic acid 63b(2R)-2-(2,6-dichlorobenzamido)-3-(4-(3- (3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3- yl)propoxy)phenyl)propanoic acid 64

2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid64a (2S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid64b (2R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2- yl)propoxy)phenyl)propanoic acid65

2-(2,6-dichlorobenzamido)-9-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 65a (S)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)nonanoic acid 65b(R)-2-(2,6-dichlorobenzamido)-9- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 66

2-(2,6-dichlorobenzamido)-9-(3,4- dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)nonanoic acid 66a (2S)-2-(2,6-dichlorobenzamido)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3- yl)nonanoic acid 66b(2R)-2-(2,6-dichlorobenzamido)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3- yl)nonanoic acid 67

2-(2,6-dichlorobenzamido)-7-(2- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)cyclopropyl)heptanoic acid 67a (2S)-2-(2,6-dichlorobenzamido)-7-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)cyclopropyl)heptanoic acid67b (2R)-2-(2,6-dichlorobenzamido)-7-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)cyclopropyl)heptanoic acid 68

2-(2,6-dichlorobenzamido)-3-(2-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butyl)cyclopropyl)propanoicacid 68a (2S)-2-(2,6-dichlorobenzamido)-3-(2-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butyl)cyclopropyl)propanoicacid 68b (2R)-2-(2,6-dichlorobenzamido)-3-(2-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butyl)cyclopropyl)propanoicacid 69

2-(2,6-dichlorobenzamido)-3-(1-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)pentyl)cyclopropyl)propanoicacid 69a (S)-2-(2,6-dichlorobenzamido)-3-(1-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)pentyl)cyclopropyl)propanoicacid 69b (R)-2-(2,6-dichlorobenzamido)-3-(1-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)pentyl)cyclopropyl)propanoicacid 70

2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)cyclobutyl)propanoicacid 70a (S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)cyclobutyl)propanoicacid 70b (R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)cyclobutyl)propanoicacid 71

2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)cyclobutyl)propanoic acid 71a(S)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)methyl)cyclobutyl)propanoic acid 71b (R)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)methyl)cyclobutyl)propanoic acid 72

2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)cyclohexyl)propanoicacid 72a (S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)cyclohexyl)propanoicacid 72b (R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)cyclohexyl)propanoicacid 73

2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)methyl)azetidin-1-yl)propanoic acid 73a (S)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)methyl)azetidin-1-yl)propanoic acid 73b (R)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)propoxy)methyl)azetidin-1-yl)propanoic acid 74

2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoic acid 74a(S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoic acid 74b(R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoic acid 75

2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)propanoic acid 75a(2S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)propanoic acid 75b(2R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)propanoic acid 76

2-(2,6-dichlorobenzamido)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)benzo[d]oxazol-5-yl)propanoic acid 76a(S)-2-(2,6-dichlorobenzamido)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)benzo[d]oxazol-5-yl)propanoic acid 76b(R)-2-(2,6-dichlorobenzamido)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)benzo[d]oxazol-5-yl)propanoic acid 77

2-(2,6-dichlorobenzamido)-3-(4-(1,1- difluoro-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butyl)phenyl)propanoic acid 77a(S)-2-(2,6-dichlorobenzamido)-3-(4-(1,1-difluoro-4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butyl)phenyl)propanoic acid 77b (R)-2-(2,6-dichlorobenzamido)-3-(4-(1,1-difluoro-4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butyl)phenyl)propanoic acid 78

9-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-5-carboxamido)nonanoic acid 78a(2S)-9-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-5-carboxamido)nonanoic acid 78b(2R)-9-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-5-carboxamido)nonanoic acid 79

2-(1-methyl-1H-indazole-5- carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 79a (2S)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid79b (2R)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid80

9-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-6-carboxamido)nonanoic acid 80a(2S)-9-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-6-carboxamido)nonanoic acid 80b(2R)-9-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-6-carboxamido)nonanoic acid 81

2-(1-methyl-1H-indazole-6- carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 81a (S)-2-(1-methyl-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid81b (R)-2-(1-methyl-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid82

2-(1-methyl-1H-indazole-5- carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 82a (S)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid82b (R)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid83

2-(1-(tert-butyl)-1H-indazole-6- carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 83a (S)-2-(1-(tert-butyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid83b (R)-2-(1-(tert-butyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid84

2-(1-(cyclopropylmethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro- 1,8-naphthyridin-2-yl)nonanoicacid 84a (S)-2-(1-(cyclopropylmethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 84b (R)-2-(1-(cyclopropylmethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 85

2-(2-methyl-2H-indazole-5- carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 85a (2S)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid85b (2R)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid86

2-(2-methyl-2H-indazole-5- carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid 86a (S)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid86b (R)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)nonanoic acid¹Chemical names are generated using the ChemBioDraw ® Ultra version14.0.0.117 software.

TABLE 2 Compound No. Structure  87

 88

 89

 90

 91

 92

 93

 94

 95

 96

 97

 98

 99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

121

122

123

124

125

126

In some embodiments, provided is a compound selected from Compound Nos.1-62 in Table 1, or a salt thereof. In some embodiments, provided is acompound selected from Compound Nos. 1-86 in Table 1, or a salt thereof.In some embodiments, provided is a compound selected from Compound Nos.87-126 in Table 2, or a salt thereof. In some embodiments, provided is acompound selected from Compound Nos. 1-62 in Table 1 or Compound Nos.87-126 in Table 2, or a salt thereof. In some embodiments, the compoundis selected from the group consisting of one or more of Compound Nos.1-62 in Table 1, or a salt thereof. In some embodiments, the compound isselected from the group consisting of one or more of Compound Nos. 1-86in Table 1, or a salt thereof. In some embodiments, the compound isselected from the group consisting of one or more of Compound Nos.87-126 in Table 2, or a salt thereof. In some embodiments, the compoundis selected from the group consisting of one or more of Compound Nos.1-86 in Table 1 or Compound Nos. 87-126 in Table 2, or a salt thereof.

The invention also includes all salts of compounds referred to herein,such as pharmaceutically acceptable salts. The invention also includesany or all of the stereochemical forms, including any enantiomeric ordiastereomeric forms, and any tautomers or other forms of the compoundsdescribed. Unless stereochemistry is explicitly indicated in a chemicalstructure or name, the structure or name is intended to embrace allpossible stereoisomers of a compound depicted. In addition, where aspecific stereochemical form is depicted, it is understood that otherstereochemical forms are also embraced by the invention. All forms ofthe compounds are also embraced by the invention, such as crystalline ornon-crystalline forms of the compounds. It is also understood thatprodrugs, solvates and metabolites of the compounds are embraced by thisdisclosure. Compositions comprising a compound of the invention are alsointended, such as a composition of substantially pure compound,including a specific stereochemical form thereof. Compositionscomprising a mixture of compounds of the invention in any ratio are alsoembraced by the invention, including mixtures of two or morestereochemical forms of a compound of the invention in any ratio, suchthat racemic, non-racemic, enantioenriched and scalemic mixtures of acompound are embraced.

Compounds described herein are αvβ1 integrin inhibitors. In someinstances, it is desirable for the compound to inhibit other integrinsin addition to αvβ1 integrin. In some embodiments, the compound inhibitsαvβ1 integrin and one or more of αvβ6, αvβ3, αvβ5, α2β1, α3β1 and α6β1integrin. In some embodiments, the compound inhibits αvβ1 integrin andαvβ6 integrin. In some embodiments, the compound inhibits αvβ1 integrin,αvβ3 integrin and αvβ5 integrin. In some embodiments, the compoundinhibits αvβ1 integrin and α2β1 integrin. In some embodiments, thecompound inhibits αvβ1 integrin, α2β1 integrin and 301 integrin. In someembodiments, the compound inhibits αvβ1 integrin and α6β1 integrin.

In some instances, it is desirable to avoid inhibition of otherintegrins. In some embodiments, the compound is a selective αvβ1integrin inhibitor. In some embodiments, the compound does not inhibitsubstantially α4β1, αvβ8 and/or α2β3 integrin. In some embodiments, thecompound inhibits αvβ1 integrin but does not inhibit substantially α4β1integrin. In some embodiments, the compound inhibits αvβ1 integrin butdoes not inhibit substantially αvβ8 integrin. In some embodiments, thecompound inhibits αvβ1 integrin but does not inhibit substantially α2β3integrin.

General Synthetic Methods

The compounds of the invention may be prepared by a number of processesas generally described below and more specifically in the Exampleshereinafter. In the following process descriptions, the symbols whenused in the formulae depicted are to be understood to represent thosegroups described above in relation to the formulae herein.

Where it is desired to obtain a particular enantiomer of a compound,this may be accomplished from a corresponding mixture of enantiomersusing any suitable conventional procedure for separating or resolvingenantiomers. Thus, for example, diastereomeric derivatives may beproduced by reaction of a mixture of enantiomers, e.g., a racemate, andan appropriate chiral compound. The diastereomers may then be separatedby any convenient means, for example by crystallization, and the desiredenantiomer recovered. In another resolution process, a racemate may beseparated using chiral High Performance Liquid Chromatography.Alternatively, if desired a particular enantiomer may be obtained byusing an appropriate chiral intermediate in one of the processesdescribed.

Chromatography, recrystallization and other conventional separationprocedures may also be used with intermediates or final products whereit is desired to obtain a particular isomer of a compound or tootherwise purify a product of a reaction.

Solvates and/or polymorphs of a compound provided herein or apharmaceutically acceptable salt thereof are also contemplated. Solvatescontain either stoichiometric or non-stoichiometric amounts of asolvent, and are often formed during the process of crystallization.Hydrates are formed when the solvent is water, or alcoholates are formedwhen the solvent is alcohol. Polymorphs include the different crystalpacking arrangements of the same elemental composition of a compound.Polymorphs usually have different X-ray diffraction patterns, infraredspectra, melting points, density, hardness, crystal shape, optical andelectrical properties, stability, and/or solubility. Various factorssuch as the recrystallization solvent, rate of crystallization, andstorage temperature may cause a single crystal form to dominate.

Compounds of the formula (III) can be prepared according to Scheme 1,wherein R¹ and R² are as defined for formula (III), or any variationthereof detailed herein; P¹ is an amine protecting group (e.g., Cbz); P⁰is a carboxylic acid protecting group (e.g., methyl); and R^(2p) is aprotected R² group where applicable.

An exemplary embodiment of the preparative method in Scheme 1 is shownin Scheme 1a, where Ar is an optionally substituted aryl group.

Compounds of the formula (III-2) can be prepared according to Scheme 2,wherein R¹, R⁸ and Y are as defined for formula (III-2), or anyvariation thereof detailed herein; P² is an amine protecting group(e.g., Boc); P⁰ is a carboxylic acid protecting group (e.g., methyl); Xis a leaving group (e.g., alkoxy, alkylthio, or halogen); m is 1, 2, 3,4 or 5; and q is 0, 1, 2 or 3.

An exemplary embodiment of the preparative method in Scheme 2 is shownin Scheme 2a, where Ar is an optionally substituted aryl group, X is aleaving group (e.g., alkoxy, alkylthio, or halogen); and R is anoptional substituent (e.g., any of the R⁸ groups detailed herein).

Compounds of the formula (II-1) can be prepared according to Scheme 3,wherein R¹, R³ and L¹ are as defined for formula (II-1), or anyvariation thereof detailed herein; P³ is an amine protecting group(e.g., Boc); and P⁰ is a carboxylic acid protecting group (e.g.,tert-butyl).

An exemplary embodiment of the preparative method in Scheme 3 is shownin Scheme 3a, where Ar is an optionally substituted aryl group, and L isa linker moiety (e.g., any of the L¹ groups detailed herein).

Compounds of the formula (IV) can be prepared according to Scheme 4,wherein R¹ and R² are as defined for formula (IV), or any variationthereof detailed herein; P⁰ is a carboxylic acid protecting group (e.g.,methyl); p is 2, 3, 4, 5, 6 or 7; and R^(2p) is a protected R² groupwhere applicable.

An exemplary embodiment of the preparative method in Scheme 4 is shownin Scheme 4a, where Ar is an optionally substituted aryl group.

Compounds of the formula (IV-2) can be prepared according to Scheme 5,wherein R¹, R⁸ and Y are as defined for formula (IV-2), or any variationthereof detailed herein; X is a leaving group (e.g., alkoxy, alkylthio,or halogen); P⁰ is a carboxylic acid protecting group (e.g., methyl); pis 1, 2, 3, 4 or 5; and q is 0, 1, 2 or 3.

An exemplary embodiment of the preparative method in Scheme 5 is shownin Scheme 5a, where Ar is an optionally substituted aryl group, X is aleaving group (e.g., alkoxy, alkylthio, or halogen); and R is anoptional substituent (e.g., any of the R⁸ groups detailed herein).

It is understood that the schemes above may be modified to arrive atvarious compounds of the invention by selection of appropriate reagentsand starting materials. For a general description of protecting groupsand their use, see P. G. M. Wuts and T. W. Greene, Greene's ProtectiveGroups in Organic Synthesis 40 edition, Wiley-Interscience, New York,2006.

Pharmaceutical Compositions and Formulations

Pharmaceutical compositions of any of the compounds detailed herein areembraced by this invention. Thus, the invention includes pharmaceuticalcompositions comprising a compound of the invention or apharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable carrier or excipient. In one aspect, the pharmaceuticallyacceptable salt is an acid addition salt, such as a salt formed with aninorganic or organic acid. Pharmaceutical compositions according to theinvention may take a form suitable for oral, buccal, parenteral, nasal,topical or rectal administration or a form suitable for administrationby inhalation.

A compound as detailed herein may in one aspect be in a purified formand compositions comprising a compound in purified forms are detailedherein. Compositions comprising a compound as detailed herein or a saltthereof are provided, such as compositions of substantially purecompounds. In some embodiments, a composition containing a compound asdetailed herein or a salt thereof is in substantially pure form. In onevariation, “substantially pure” intends a composition that contains nomore than 35% impurity, wherein the impurity denotes a compound otherthan the compound comprising the majority of the composition or a saltthereof. For example, a composition of a substantially pure compoundselected from a compound of Table 1 or Table 2 intends a compositionthat contains no more than 35% impurity, wherein the impurity denotes acompound other than the compound or a salt thereof. In one variation, acomposition of substantially pure compound or a salt thereof is providedwherein the composition contains no more than 25% impurity. In anothervariation, a composition of substantially pure compound or a saltthereof is provided wherein the composition contains or no more than 20%impurity. In still another variation, a composition of substantiallypure compound or a salt thereof is provided wherein the compositioncontains or no more than 10% impurity. In a further variation, acomposition of substantially pure compound or a salt thereof is providedwherein the composition contains or no more than 5% impurity. In anothervariation, a composition of substantially pure compound or a saltthereof is provided wherein the composition contains or no more than 3%impurity. In still another variation, a composition of substantiallypure compound or a salt thereof is provided wherein the compositioncontains or no more than 1% impurity. In a further variation, acomposition of substantially pure compound or a salt thereof is providedwherein the composition contains or no more than 0.5% impurity. In yetother variations, a composition of substantially pure compound meansthat the composition contains no more than 15% or preferably no morethan 10% or more preferably no more than 5% or even more preferably nomore than 3% and most preferably no more than 1% impurity, whichimpurity may be the compound in a different stereochemical form. Forinstance, a composition of substantially pure (S) compound means thatthe composition contains no more than 15% or no more than 10% or no morethan 5% or no more than 3% or no more than 1% of the (R) form of thecompound.

In one variation, the compounds herein are synthetic compounds preparedfor administration to an individual such as a human. In anothervariation, compositions are provided containing a compound insubstantially pure form. In another variation, the invention embracespharmaceutical compositions comprising a compound detailed herein and apharmaceutically acceptable carrier or excipient. In another variation,methods of administering a compound are provided. The purified forms,pharmaceutical compositions and methods of administering the compoundsare suitable for any compound or form thereof detailed herein.

The compound may be formulated for any available delivery route,including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal orrectal), parenteral (e.g., intramuscular, subcutaneous or intravenous),topical or transdermal delivery form. A compound may be formulated withsuitable carriers to provide delivery forms that include, but are notlimited to, tablets, caplets, capsules (such as hard gelatin capsules orsoft elastic gelatin capsules), cachets, troches, lozenges, gums,dispersions, suppositories, ointments, cataplasms (poultices), pastes,powders, dressings, creams, solutions, patches, aerosols (e.g., nasalspray or inhalers), gels, suspensions (e.g., aqueous or non-aqueousliquid suspensions, oil-in-water emulsions or water-in-oil liquidemulsions), solutions and elixirs.

One or several compounds described herein can be used in the preparationof a formulation, such as a pharmaceutical formulation, by combining thecompound or compounds as an active ingredient with a pharmaceuticallyacceptable carrier, such as those mentioned above. Depending on thetherapeutic form of the system (e.g., transdermal patch vs. oraltablet), the carrier may be in various forms. In addition,pharmaceutical formulations may contain preservatives, solubilizers,stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters,and salts for the adjustment of osmotic pressure, buffers, coatingagents or antioxidants. Formulations comprising the compound may alsocontain other substances which have valuable therapeutic properties.Pharmaceutical formulations may be prepared by known pharmaceuticalmethods. Suitable formulations can be found, e.g., in Remington: TheScience and Practice of Pharmacy, Lippincott Williams & Wilkins, 21^(st)ed. (2005), which is incorporated herein by reference.

Compounds as described herein may be administered to individuals (e.g.,a human) in a form of generally accepted oral compositions, such astablets, coated tablets, and gel capsules in a hard or in soft shell,emulsions or suspensions. Examples of carriers, which may be used forthe preparation of such compositions, are lactose, corn starch or itsderivatives, talc, stearate or its salts, etc. Acceptable carriers forgel capsules with soft shell are, for instance, plant oils, wax, fats,semisolid and liquid poly-ols, and so on. In addition, pharmaceuticalformulations may contain preservatives, solubilizers, stabilizers,re-wetting agents, emulgators, sweeteners, dyes, adjusters, and saltsfor the adjustment of osmotic pressure, buffers, coating agents orantioxidants.

Any of the compounds described herein can be formulated in a tablet inany dosage form described, for example, a compound as described hereinor a pharmaceutically acceptable salt thereof can be formulated as a 10mg tablet.

Compositions comprising a compound provided herein are also described.In one variation, the composition comprises a compound and apharmaceutically acceptable carrier or excipient. In another variation,a composition of substantially pure compound is provided.

Methods of Use

Compounds and compositions of the invention, such as a pharmaceuticalcomposition containing a compound of any formula provided herein or asalt thereof and a pharmaceutically acceptable carrier or excipient, maybe used in methods of administration and treatment as provided herein.The compounds and compositions may also be used in in vitro methods,such as in vitro methods of administering a compound or composition tocells for screening purposes and/or for conducting quality controlassays.

In one aspect, provided is a method of treating a fibrotic disease in anindividual in need thereof comprising administering to the individual atherapeutically effective amount of a compound of formula (I), or anyvariation thereof, e.g., a compound of formula (I-A), (I-B), (II),(II-1), (III), (III-1), (III-2), (IV), (IV-1) or (IV-2), a compoundselected from Compound Nos. 1-86 in Table 1, a compound selected fromCompound Nos. 87-126 in Table 2, or a pharmaceutically acceptable saltthereof. In one aspect, the individual is a human. The individual, suchas human, may be in need of treatment, such as a human who has or issuspected of having a fibrotic disease. In one aspect of the methodsdetailed herein, the methods described exclude use of a compound ofTable 1x. In another aspect, the methods described herein include theuse of a compound of Table 1X.

In another aspect, provided is a method of delaying the onset and/ordevelopment of a fibrotic disease in an individual (such as a human) whois at risk for developing a fibrotic disease. It is appreciated thatdelayed development may encompass prevention in the event the individualdoes not develop the fibrotic disease. An individual at risk ofdeveloping a fibrotic disease in one aspect has or is suspected ofhaving one or more risk factors for developing a fibrotic disease. Riskfactors for fibrotic disease may include an individual's age (e.g.,middle-age or older adults), the presence of inflammation, having one ormore genetic component associated with development of a fibroticdisease, medical history such as treatment with a drug or procedurebelieved to be associated with an enhanced susceptibility to fibrosis(e.g., radiology) or a medical condition believed to be associated withfibrosis, a history of smoking, the presence of occupational and/orenvironmental factors such as exposure to pollutants associated withdevelopment of a fibrotic disease.

In some embodiments, the fibrotic disease is fibrosis of a tissue suchas the lung (pulmonary fibrosis), the liver, the skin, the heart(cardiac fibrosis), the kidney (renal fibrosis), or the gastrointestinaltract (gastrointestinal fibrosis).

In some embodiments, the fibrotic disease is a pulmonary fibrosis, e.g.,idiopathic pulmonary fibrosis (IPF).

In some embodiments, the fibrotic disease is a liver fibrosis, e.g.,infectious liver fibrosis (from pathogens such as HCV, HBV or parasitessuch as schistosomiasis), NASH, alcoholic steatosis induced liverfibrosis, and cirrhosis.

In another aspect, provided is a method of treating liver fibrosis in anindividual, comprising administering to the individual a therapeuticallyeffective amount of a compound of formula (I), or any variation thereof,e.g., a compound of formula (I-A), (I-B), (II), (II-1), (III), (III-1),(III-2), (IV), (IV-1) or (IV-2), a compound selected from Compound Nos.1-86 in Table 1, a compound selected from Compound Nos. 87-126 in Table2, or a pharmaceutically acceptable salt thereof. In one aspect, theindividual is a human. The individual, such as the human, may be in needof treatment, such as a human who has or is suspected of having liverfibrosis. In some embodiments, the liver fibrosis is a result of orassociated with nonalcoholic fatty liver disease (NAFLD), nonalcoholicsteatohepatitis (NASH), alcoholic steatosis, or infection (such as viralhepatitis, which may be caused by HCV or HBV, or parasitic hepatitis,which may be caused by schistosomiasis). In one aspect of the methodsdetailed herein, the methods described exclude use of a compound ofTable 1x. In another aspect, the methods described herein include theuse of a compound of Table 1X.

In another aspect, provided is a compound of formula (I), or anyvariation thereof, e.g., a compound of formula (I-A), (I-B), (II),(II-1), (III), (III-1), (III-2), (IV), (IV-1) or (IV-2), a compoundselected from Compound Nos. 1-86 in Table 1, a compound selected fromCompound Nos. 87-126 in Table 2, or a pharmaceutically acceptable saltthereof, for use in the treatment of liver fibrosis.

Also provided is use of a compound of formula (I), or any variationthereof, e.g., a compound of formula (I-A), (I-B), (II), (II-1), (III),(III-1), (III-2), (IV), (IV-1) or (IV-2), a compound selected fromCompound Nos. 1-86 in Table 1, a compound selected from Compound Nos.87-126 in Table 2, or a pharmaceutically acceptable salt thereof, in themanufacture of a medicament for the treatment of liver fibrosis.

In another aspect, provided is a method of delaying the onset and/ordevelopment of liver fibrosis in an individual (such as a human) who isat risk for developing liver fibrosis. It is appreciated that delayeddevelopment may encompass prevention in the event the individual doesnot develop liver fibrosis. An individual at risk of developing afibrotic disease in one aspect has or is suspected of having one or morerisk factors for developing liver fibrosis. Risk factors for liverfibrosis may include an individual's age (e.g., middle-age or olderadults), the presence of inflammation in the liver, having one or moregenetic component associated with development of liver fibrosis, medicalhistory such as treatment with a drug or procedure believed to beassociated with an enhanced susceptibility to liver fibrosis or amedical condition believed to be associated with liver fibrosis (such asnonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis(NASH), alcoholism, alcoholic steatosis, or liver infection (such asviral hepatitis, which may be caused by HCV or HBV, or parasitichepatitis, which may be caused by schistosomiasis)), a history ofsmoking, the presence of occupational and/or environmental factors suchas exposure to pollutants associated with development of liver fibrosis.

In some embodiments, the fibrotic disease is biliary tract fibrosis.

In some embodiments, the fibrotic disease is kidney fibrosis, e.g.,diabetic nephrosclerosis, hypertensive nephrosclerosis, focal segmentalglomerulosclerosis (“FSGS”), and acute kidney injury from contrastinduced nephropathy.

In some embodiments, the fibrotic disease is systemic and localsclerosis or scleroderma, keloids and hypertrophic scars, or postsurgical adhesions.

In some embodiments, the fibrotic disease is atherosclerosis orrestenosis.

In some embodiments, the fibrotic disease is a gastrointestinalfibrosis, e.g., Crohn's disease.

In some embodiments, the fibrotic disease is cardiac fibrosis, e.g.,post myocardial infarction induced fibrosis and inheritedcardiomyopathy.

In one aspect, provided is a compound of formula (I), or any variationthereof, e.g., a compound of formula (I-A), (I-B), (II), (II-1), (III),(III-1), (III-2), (IV), (IV-1) or (IV-2), a compound selected fromCompound Nos. 1-86 in Table 1, a compound selected from Compound Nos.87-126 in Table 2, or a pharmaceutically acceptable salt thereof, foruse in the treatment of a fibrotic disease.

Also provided is use of a compound of formula (I), or any variationthereof, e.g., a compound of formula (I-A), (I-B), (II), (II-1), (III),(III-1), (III-2), (IV), (IV-1) or (IV-2), a compound selected fromCompound Nos. 1-86 in Table 1, a compound selected from Compound Nos.87-126 in Table 2, or a pharmaceutically acceptable salt thereof, in themanufacture of a medicament for the treatment of a fibrotic disease.

In another aspect, provided is a method of inhibiting αvβ1 integrin inan individual comprising administering a compound of formula (I), or anyvariation thereof, e.g., a compound of formula (I-A), (I-B), (II),(II-1), (III), (III-1), (III-2), (IV), (IV-1) or (IV-2), a compoundselected from Compound Nos. 1-86 in Table 1, a compound selected fromCompound Nos. 87-126 in Table 2, or a pharmaceutically acceptable saltthereof.

Also provided is a method of inhibiting TGFβ activation in a cellcomprising administering to the cell a compound of formula (I), or anyvariation thereof, e.g., a compound of formula (I-A), (I-B), (II),(II-1), (III), (III-1), (III-2), (IV), (IV-1) or (IV-2), a compoundselected from Compound Nos. 1-86 in Table 1, a compound selected fromCompound Nos. 87-126 in Table 2, or a pharmaceutically acceptable saltthereof.

In any of the described methods, in one aspect the individual is ahuman, such as a human in need of the method. The individual may be ahuman who has been diagnosed with or is suspected of having a fibroticdisease. The individual may be a human who does not have detectabledisease but who has one or more risk factors for developing a fibroticdisease.

Kits

The invention further provides kits for carrying out the methods of theinvention, which comprises one or more compounds described herein or apharmacological composition comprising a compound described herein. Thekits may employ any of the compounds disclosed herein. In one variation,the kit employs a compound described herein or a pharmaceuticallyacceptable salt thereof. The kits may be used for any one or more of theuses described herein, and, accordingly, may contain instructions foruse in the treatment of a fibrotic disease. In some embodiments, the kitcontains instructions for use in the treatment of liver fibrosis.

Kits generally comprise suitable packaging. The kits may comprise one ormore containers comprising any compound described herein. Each component(if there is more than one component) can be packaged in separatecontainers or some components can be combined in one container wherecross-reactivity and shelf life permit. One or more components of a kitmay be sterile and/or may be contained within sterile packaging.

The kits may be in unit dosage forms, bulk packages (e.g., multi-dosepackages) or sub-unit doses. For example, kits may be provided thatcontain sufficient dosages of a compound as disclosed herein (e.g., atherapeutically effective amount) and/or a second pharmaceuticallyactive compound useful for a disease detailed herein (e.g., fibrosis) toprovide effective treatment of an individual for an extended period,such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kitsmay also include multiple unit doses of the compounds and instructionsfor use and be packaged in quantities sufficient for storage and use inpharmacies (e.g., hospital pharmacies and compounding pharmacies).

The kits may optionally include a set of instructions, generally writteninstructions, although electronic storage media (e.g., magnetic disketteor optical disk) containing instructions are also acceptable, relatingto the use of component(s) of the methods of the present invention. Theinstructions included with the kit generally include information as tothe components and their administration to an individual.

EXEMPLARY EMBODIMENTS

The invention is further described by the following embodiments. Thefeatures of each of the embodiments are combinable with any of the otherembodiments where appropriate and practical.

Embodiment 1. A compound of formula (I):

or a salt thereof, wherein:

-   -   R¹ is C₆-C₁₄ aryl or 5- to 10-membered heteroaryl, wherein the        C₆-C₁₄ aryl and 5- to 10-membered heteroaryl of R¹ are        independently optionally substituted by R¹⁰;    -   R² is 5- to 10-membered heteroaryl containing at least 2 ring        nitrogen atoms, 3- to 12-membered heterocyclyl containing at        least 2 ring nitrogen atoms, or —NH—R³, wherein the 5- to        10-membered heteroaryl and 3- to 12-membered heterocyclyl of R²        are independently optionally substituted by R¹⁰;    -   R³ is 5- to 10-membered heteroaryl containing at least 1 ring        nitrogen atom, or 3- to 12-membered heterocyclyl containing at        least 1 ring nitrogen atom, wherein the 5- to 10-membered        heteroaryl and 3- to 12-membered heterocyclyl of R³ are        independently optionally substituted by R¹⁰;    -   -A-L- is -A¹-L¹-, -A²-L²-, or A³;    -   A¹ is C₃-C₈ cycloalkylene, C₃-C₈ cycloalkenylene, C₆-C₁₄        arylene, 5- to 10-membered heteroarylene or 3- to 12-membered        heterocyclylene, wherein the C₃-C₈ cycloalkylene, C₃-C₈        cycloalkenylene, C₆-C₁₄ arylene, 5- to 10-membered heteroarylene        and 3- to 12-membered heterocyclylene of A¹ are independently        optionally substituted by R¹⁰;    -   A² is C₃-C₈ alkylene or C₃-C₈ alkenylene, wherein the C₃-C₈        alkylene and C₃-C₈ alkenylene of A² are independently optionally        substituted by R⁹;    -   A³ is C₅-C₁₀ alkylene or C₅-C₁₀ alkenylene, wherein the C₅-C₁₀        alkylene and C₅-C₁₀ alkenylene of A³ are independently        optionally substituted by R⁹;    -   L¹        is —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Y¹—X¹—, —O—Z—Y¹—, —O—Z—Y¹—X¹—,        —O—Z—X¹—Y¹—, —O—Z—X¹—Y¹—X¹—, —Z—O—Z—, —X¹—Z—O—Z—, —Z—O—Z—X¹—,        —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, —Z—O—Y¹—X¹—, —X¹—Z—O—Y¹—,        —X¹—Z—O—Y¹—X¹—, —N(R⁴)—Z—, —N(R⁴)—Z—X¹—, X², —X²—Y¹—, Y², or        —Y²—X²—;    -   L² is C₃-C₆ cycloalkylene optionally substituted by R¹⁰;    -   each X¹ is independently C₁-C₆ alkylene or C₂-C₆ alkenylene,        wherein the C₁-C₆ alkylene and C₂-C₆ alkenylene of X¹ are        independently optionally substituted by R¹⁰;    -   each X² is independently C₁-C₆ alkylene or C₂-C₆ alkenylene,        wherein the C₁-C₆ alkylene and C₂-C₆ alkenylene of X² are        independently optionally substituted by R⁹;    -   each Y¹ is independently C₃-C₆ cycloalkylene optionally        substituted by R¹⁰;    -   each Y² is independently saturated 3- to 4-membered        heterocyclylene optionally substituted by R¹⁰;    -   each Z is independently —CR^(5a)R^(5b)—;    -   each R⁴, R^(5a) and R^(5b) is independently H or C₁-C₆ alkyl;    -   each R⁹ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, halogen, —CN, —OR¹¹, —SR¹¹, —NR¹²R¹¹, —NO₂,        —C═NH(OR¹¹), —C(O)R¹¹, —OC(O)R¹¹, —C(O)OR¹¹, —C(O)NR¹²R¹³,        —NR¹¹C(O)R¹², —NR¹¹C(O)OR¹², —NR¹¹C(O)NR¹²R¹³, —S(O)R¹¹,        —S(O)₂R¹¹, —NR¹¹ S(O)R¹², —NR¹¹S(O)₂R¹², —S(O)NR¹²R¹³,        —S(O)₂NR¹²R¹³, —P(O)(OR¹²) (OR¹³), C₃-C₈ cycloalkyl, 3- to        12-membered heterocyclyl, 5- to 10-membered heteroaryl or C₆-C₁₄        aryl, wherein each R⁹ is independently optionally substituted by        halogen,        oxo, —OR¹⁴, —NR¹⁴R¹⁵, —C(O)R¹⁴, —CN, —S(O)R¹⁴, —S(O)₂R¹⁴,        —P(O)(OR¹⁴)(OR¹⁵), C₃-C₈ cycloalkyl, 3- to 12-membered        heterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄ aryl, or        C₁-C₆ alkyl optionally substituted by oxo, —OH or halogen;    -   each R¹⁰ is independently oxo or R⁹.    -   R¹¹ is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄ aryl, 5- to 6-membered        heteroaryl or 3- to 6-membered heterocyclyl, wherein the C₁-C₆        alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄        aryl, 5- to 6-membered heteroaryl and 3- to 6-membered        heterocyclyl are independently optionally substituted by        halogen, oxo, —CN, —OR¹⁶, —NR¹⁶R¹⁷, —P(O)(OR¹⁶)(OR¹⁷), or C₁-C₆        alkyl optionally substituted by halogen, —OH or oxo;    -   R¹² and R¹³ are each independently hydrogen, C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄ aryl, 5- to        6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein        the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl,        C₆-C₁₄ aryl, 5- to 6-membered heteroaryl and 3- to 6-membered        heterocyclyl are independently optionally substituted by        halogen, oxo, —CN, —OR¹⁶, —NR¹⁶R¹⁷ or C₁-C₆ alkyl optionally        substituted by halogen, —OH or oxo;    -   or R¹² and R¹³ are taken together with the atom to which they        attached to form a 3- to 6-membered heterocyclyl optionally        substituted by halogen, oxo, —OR¹⁶, —NR¹⁶R¹⁷ or C₁-C₆ alkyl        optionally substituted by halogen, oxo or —OH;    -   R¹⁴ and R¹⁵ are each independently hydrogen, C₁-C₆ alkyl        optionally substituted by halogen or oxo, C₂-C₆ alkenyl        optionally substituted by halogen or oxo, or C₂-C₆ alkynyl        optionally substituted by halogen or oxo;    -   or R¹⁴ and R¹⁵ are taken together with the atom to which they        attached to form a 3- to 6-membered heterocyclyl optionally        substituted by halogen, oxo or C₁-C₆ alkyl optionally        substituted by halogen or oxo; and    -   R¹⁶ and R¹⁷ are each independently hydrogen, C₁-C₆ alkyl        optionally substituted by halogen or oxo, C₂-C₆ alkenyl        optionally substituted by halogen or oxo, or C₂-C₆ alkynyl        optionally substituted by halogen or oxo;    -   or R¹⁶ and R¹⁷ are taken together with the atom to which they        attached to form a 3-6 membered heterocyclyl optionally        substituted by halogen, oxo or C₁-C₆ alkyl optionally        substituted by oxo or halogen;    -   provided that the compound is other than a compound in Table 1X        and salts thereof.

Embodiment 2. The compound of embodiment 1, or a salt thereof, whereinR¹ is a fused bicyclic C₉-C₁₄ aryl optionally substituted by R¹⁰ or afused bicyclic 7- to 10-membered heteroaryl optionally substituted byR¹⁰.

Embodiment 3. The compound of embodiment 1 or 2, or a salt thereof,wherein R¹ is a fused bicyclic 7- to 10-membered heteroaryl optionallysubstituted by R¹⁰.

Embodiment 4. The compound of embodiment 3, or a salt thereof, whereinR¹ is indazolyl optionally substituted by R¹⁰, benzimidazolyl optionallysubstituted by R¹⁰, or benzoxazolyl optionally substituted by R¹⁰.

Embodiment 5. The compound of embodiment 1, or a salt thereof, whereinR¹ is phenyl optionally substituted by R¹⁰.

Embodiment 6. The compound of embodiment 1, or a salt thereof, whereinR¹ is a monocyclic 5- or 6-membered heteroaryl optionally substituted byR¹⁰.

Embodiment 7. The compound of any one of embodiments 1 to 6, or a saltthereof, wherein the -A-L-moiety is -A¹-L¹-.

Embodiment 8. The compound of embodiment 7, or a salt thereof, whereinA¹ is C₆-C₁₄ arylene optionally substituted by R¹⁰.

Embodiment 9. The compound of embodiment 7, or a salt thereof, whereinA¹ is C₃-C₈ cycloalkylene optionally substituted by R¹⁰.

Embodiment 10. The compound of embodiment 7, or a salt thereof, whereinA¹ is 5- to 10-membered heteroarylene optionally substituted by R¹⁰.

Embodiment 11. The compound of embodiment 7, or a salt thereof, whereinA¹ is 3- to 12-membered heterocyclylene optionally substituted by R¹⁰.

Embodiment 12. The compound of embodiment 7, or a salt thereof, whereinA¹ is selected from the group consisting of 1,4-phenylene,1,3-phenylene, 1,1-cyclopropylene, 1,2-cyclopropylene,1,3-cyclobutylene, 1,4-cyclohexylene, 1,3-azetidinylene,1,3-pyrrolidinylene, and 2,5-benzo[d]oxazolylene.

Embodiment 13. The compound of any one of embodiments 7 to 12, or a saltthereof, wherein L¹

is —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Z—Y¹—, —O—Z—X¹—Y¹—, —Z—O—Z—, —X¹—Z—O—Z—,—Z—O—Z—X¹—, —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, or —X¹—Z—O—Y¹—.

Embodiment 14. The compound of embodiment 13, or a salt thereof, whereinZ is —CR^(5a)R^(5b)— where each of R^(5a) and R^(5b) is H.

Embodiment 15. The compound of embodiment 13, or a salt thereof, whereinL¹ is selected from the group consisting

of —O—(CH₂)₃—, —O—(CH₂)₄—, —CH₂—O—(CH₂)₃—, —CH₂—O—(CH₂)₂—,—CH(CH₃)—O—(CH₂)₂—, —CH₂—O—(C H₂)₃—,

wherein the wavy lines denote attachment points to the parent molecule.

Embodiment 16. The compound of any one of embodiments 7 to 12, or a saltthereof, wherein L¹ is —N(R⁴)—Z— or —N(R⁴)—Z—X¹—.

Embodiment 17. The compound of embodiment 16, or a salt thereof, whereinR⁴ is H and Z is —CR^(5a)R^(5b)— where each of R^(5a) and R^(5b) is H.

Embodiment 18. The compound of embodiment 17, or a salt thereof, whereinL¹

is —NH—C(CH₃)₂—(CH₂)₂—.

Embodiment 19. The compound of any one of embodiments 7 to 12, or a saltthereof, wherein L¹ is X² or —X²—Y¹—.

Embodiment 20. The compound of embodiment 19, or a salt thereof, whereinL¹ is selected from the group consisting of —(CH₂)₂—, —(CH₂)₄—,—(CH₂)₅—, —CF₂—(CH₂)₃— and

wherein the wavy lines denote attachment points to the parent molecule.

Embodiment 21. The compound of any one of embodiments 7 to 12, or a saltthereof, wherein L¹ is Y², or —Y²—X²—.

Embodiment 22. The compound of embodiment 21, or a salt thereof, whereinY² is saturated 4-membered heterocyclylene optionally substituted byR¹⁰.

Embodiment 23. The compound of embodiment 21, or a salt thereof, whereinY² is 1,3-azetidinylene.

Embodiment 24. The compound of embodiment 21, or a salt thereof, whereinL¹ is selected from the group consisting of

wherein the wavy lines denote attachment points to the parent molecule.

Embodiment 25. The compound of any one of embodiments 1 to 6, or a saltthereof, wherein the -A-L- moiety is -A²-L²- or A³.

Embodiment 26. The compound of embodiment 25, or a salt thereof, whereinA² is C₃-C₈ alkylene optionally substituted by R⁹.

Embodiment 27. The compound of embodiment 25, or a salt thereof, whereinA³ is C₅-C₁₀ alkenylene optionally substituted by R⁹.

Embodiment 28. The compound of embodiment 25, or a salt thereof, whereinthe -A-L-moiety is selected from the group consisting of —CH₂(CH₂)₅CH₂—,—CH₂(CH₂)₄CH₂—, —CH═CH—(CH₂)₃CH₂—, and

wherein the wavy lines denote attachment points to the parent molecule.

Embodiment 29. The compound of any one of embodiments 1 to 28, or a saltthereof, wherein R² is 5- to 10-membered heteroaryl containing at least2 ring nitrogen atoms optionally substituted by R¹⁰, or 3- to12-membered heterocyclyl containing at least 2 ring nitrogen atomsoptionally substituted by R¹⁰.

Embodiment 30. The compound of embodiment 29, or a salt thereof, whereinR² is selected from the group consisting of5,6,7,8-tetrahydro-naphthyridinyl,1,2,3,4-tetrahydro-1,8-naphthyridinyl,3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, and2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl.

Embodiment 31. The compound of any one of embodiments 1 to 28, or a saltthereof, wherein R² is —NH—R³.

Embodiment 32. The compound of embodiment 31, or a salt thereof, whereinR³ is 5- to 10-membered heteroaryl containing at least 1 ring nitrogenatom optionally substituted by R¹⁰.

Embodiment 33. The compound of embodiment 32, or a salt thereof, whereinR³ is selected from the group consisting of 4,5-dihydro-1H-imidazolyl,5,6-dihydro-4H-1,3-oxazinyl, 4,5-dihydrothiazolyl,3,4,5,6-tetrahydropyrazinyl, 5,6-dihydro-4H-1,3-thiazinyl.

Embodiment 34. The compound of embodiment 31, or a salt thereof, whereinR³ is pyridinyl optionally substituted by R¹⁰.

Embodiment 35. The compound of embodiment 34, or a salt thereof, whereinR³ is selected from the group consisting of 4,5-dihydro-1H-imidazolyl,5,6-dihydro-4H-1,3-oxazinyl, 4,5-dihydrothiazolyl,3,4,5,6-tetrahydropyrazinyl, 5,6-dihydro-4H-1,3-thiazinyl.

Embodiment 36. The compound of embodiment 1, wherein the compound isselected from Compound Nos. 1-86 in Table 1, or a salt thereof.

Embodiment 37. A pharmaceutical composition comprising a compound of anyone of embodiments 1 to 36, or a salt thereof, and a pharmaceuticallyacceptable carrier or excipient.

Embodiment 38. A method of treating a fibrotic disease in an individualin need thereof comprising administering to the individual atherapeutically effective amount of a compound of any one of embodiments1 to 36 or a pharmaceutically acceptable salt thereof.

Embodiment 39. The method of embodiment 38, wherein the fibrotic diseaseis pulmonary fibrosis, liver fibrosis, skin fibrosis, cardiac fibrosis,kidney fibrosis, or gastrointestinal fibrosis.

Embodiment 40. A kit comprising a compound of any one of embodiments 1to 36, or a pharmaceutically acceptable salt thereof.

Embodiment 41. The kit of embodiment 40, further comprising instructionsfor the treatment of a fibrotic disease.

Embodiment 42. A method of inhibiting αvβ1 integrin in an individualcomprising administering a compound of any one of embodiments 1 to 36 ora pharmaceutically acceptable salt thereof.

Embodiment 43. A method of inhibiting TGFβ activation in a cellcomprising administering to the cell a compound of any one ofembodiments 1 to 36 or a pharmaceutically acceptable salt thereof.

Embodiment 44. Use of a compound of any one of embodiments 1 to 36 or apharmaceutically acceptable salt thereof in the manufacture of amedicament for the treatment of a fibrotic disease.

SYNTHETIC EXAMPLES

The chemical reactions in the Synthetic Examples described can bereadily adapted to prepare a number of other compounds of the invention,and alternative methods for preparing the compounds of this inventionare deemed to be within the scope of this invention. For example, thesynthesis of non-exemplified compounds according to the invention can besuccessfully performed by modifications apparent to those skilled in theart, e.g., by appropriately protecting interfering groups, by utilizingother suitable reagents known in the art other than those described, orby making routine modifications of reaction conditions. Alternatively,other reactions disclosed herein or known in the art will be recognizedas having applicability for preparing other compounds of the invention.

Example 1 Synthesis of(S)-2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Compound 1a-int: To a mixture of 2-aminonicotinaldehyde (50 g, 409.4mmol) in EtOH (600 mL) was added ethyl 4-oxopentanoate (59.02 g, 409.4mmol, 58.44 mL) and L-proline (23.57 g, 204.7 mmol). The reaction wasrefluxed at 80° C. for 12 hrs. TLC (PE:EtOAc=1:1, R_(f)=0.5) showed thereaction was complete. The reaction mixture was concentrated to give aresidue. The residue was purified by column chromatography (SiO₂,PE:EtOAc=3:1 to 1:1) to obtain a pure product compound 1a-int. LCMS(ESI+): m/z=231.0 (M+H)⁺, RT=0.72 min.

Compound 1b-int: To a solution of compound 1a-int (39 g, 169.37 mmol) inMeOH (500 mL) was added Pd/C (12 g) under N₂. The suspension wasdegassed under vacuum and purged with H₂ several times. The mixture wasstirred under H₂ (50 psi) at 50° C. for 6 hrs. TLC (PE:EtOAc=10:1,R_(f)=0.6) indicated the compound 1a-int was consumed completely. Thecatalyst was removed by filtration and washed with MeOH (500 mL) 2times. The mixture concentrated under reduced pressure to give compound1b-int, which was used directly in the next step without any furtherpurification.

Compound 1c-int: Compound 1b-int (36.00 g, 153.66 mmol) was added to theBoc₂O (300 mL) at 25° C. The reaction mixture was allowed to stir at 50°C. for 12 hrs. LCMS indicated the desired product and the reaction wascomplete. The crude product was purified by column chromatography (SiO₂,PE:EtOAc=10:1 to 1:1) to give a pure compound 1c-int. LCMS (ESI+):m/z=335.2 (M+H)⁺, RT=0.64 min.

Compound 1d-int: To a solution of compound 1c-int (20 g, 59.81 mmol) inTHF (200 mL) was added LiBH₄ (2.61 g, 119.62 mmol) at 0° C. The reactionwas stirred at 30° C. for 30 min and at 40° C. for 5 hrs. TLC(PE:EtOAc=10:1, R_(f)=0.5) indicated the compound 1c-int was consumedcompletely. The desired product was detected by LCMS. The mixture waspoured into saturated NH₄Cl (500 mL). The product was extracted withEtOAc (500 mL). The organic layer was washed with brine (200 mL), driedby NaSO₄ and concentrated in vacuo. The residue was purified by columnchromatography (SiO₂, PE:EtOAc=10:1 to 1:1) to give compound 1d-int.LCMS (ESI+): m/z=335.2 (M+H)⁺, RT=0.695 min; ¹H NMR (400 MHz,CHLOROFORM-d): 6 ppm 1.29 (t, J=7.02 Hz, 1H) 1.56 (s, 8H) 1.54-1.57 (m,1H) 1.92-1.99 (m, 4H) 2.75 (t, J=6.58 Hz, 2H) 2.92 (t, J=6.58 Hz, 2H)3.66-3.74 (m, 2H) 3.75-3.82 (m, 2H) 4.19-4.33 (m, 1H) 4.25 (br s, 1H)6.86 (d, J=7.45 Hz, 1H) 7.34 (d, J=7.45 Hz, 1H).

Compound 1e-int: To a solution of 1d-int (3 g, 10.26 mmol) and methyl(2S)-2-(benzyloxycarbonyl amino)-3-(4-hydroxyphenyl)propanoate (4.06 g,12.31 mmol) in dry THF (10 mL) was added ADDP (6.47 g, 25.65 mmol) at 0°C. under N₂. Bu₃P (5.19 g, 25.65 mmol, 6.33 mL) was added drop-wised tothe reaction mixture at 0° C. After the addition was complete, thereaction mixture was allowed to warm to 20° C. with stirring over 2 hrthen maintained at 40° C. over 12 hr. TLC (PE:EtOAc=2:1, R_(f)=0.2)indicated 1d-int (3 g, 10.26 mmol) remained, but some new spots weredetected. LCMS indicated that 1e-int was present. The mixture wasconcentrated to give the crude product. The crude product was purifiedby column chromatography (SiO₂, PE:EtOAc=10:1 to 1:1) to obtain compound1e-int. LCMS (ESI+): m/z=604.3 (M+H)⁺; RT: 2.355 min.

Compound 1f-int: To a solution of compound 1e-int (3.00 g, 4.97 mmol) inMeOH (30 mL) was added Pd/C (0.5 g). The suspension was degassed undervacuum and purged with H₂ several times. The mixture was stirred underH₂ (15 psi) at 30° C. for 3 hrs. TLC (PE:EtOAc=1:1, R_(f)=0.3) indicatedcompound 1e-int was consumed completely. LCMS indicated the desiredproduct was present. The product was filtered and concentrated underreduced pressure. The crude product was purified by columnchromatography (SiO₂, PE:EtOAc=1:1 to 10:1) to give compound 1f-int.LCMS (ESI+): m/z=470.2 (M+H)⁺; RT=0.63 min.

Compound 1g-int: A solution of compound 1f-int (200 mg, 425.92 umol),benzoic acid (52.01 mg, 425.92 umol), EDCI (106.14 mg, 553.7 umol), HOBt(74.82 mg, 553.7 umol) and DIEA (82.57 mg, 638.88 umol) in DMF (2 mL)was stirred at 25° C. for 10 hrs. LCMS showed that 1g-int was present.The reaction was poured into water (10 mL) and extracted with ethylacetate (15 mL×3). The organic layers were combined, washed with brine(20 mL), dried over sodium sulfate and evaporated under reducedpressure. The crude product was purified by prep-TLC (PE:EtOAc=5:1,R_(f)=0.5) to give compound 1g-int. LCMS (ESI+): m/z 574.3 (M+H)+, RT:0.95 min.

Compound 1h-int: A solution of compound 1g-int (90 mg, 156.88 umol) inHCl/EtOAc (10 mL) was stirred at 25° C. for 12 hrs. LCMS showed that thedesired product was present. The solvent was removed in vacuo to givecompound 1h-int. The crude product was used directly in the next step.LCMS (ESI+): m/z 474.2 (M+H)⁺, RT: 0.84 min.

Example 1: To a solution of compound 1h-int (100 mg, 196.07 umol) in THF(3 mL) and H₂O (3 mL) was added LiOH·H₂O (41.14 mg, 980.35 umol) at 25°C. The mixture was stirred at 25° C. for 12 hrs. LCMS showed that thedesired product was present. The reaction mixture was adjusted to pH 6with 10% citric acid and the solvent was removed. The crude product waspurified by prep-HPLC to give Example 1.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: ACN (gradient of B 15% at T=0 to45% at T=10 min); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄) δ=7.71-7.75 (m, 2H) 7.49-7.55 (m, 2H)7.40-7.46 (m, 2H) 7.19 (d, J=8.60 Hz, 2H) 6.78 (d, J=8.60 Hz, 2H) 6.60(d, J=7.28 Hz, 1H) 4.80 (dd, J=9.48, 4.85 Hz, 1H) 4.00 (t, J=5.73 Hz,2H) 3.45-3.51 (m, 2H) 3.24-3.30 (m, 2H) 3.03 (dd, J=13.89, 9.70 Hz, 1H)2.87 (t, J=7.50 Hz, 2H) 2.79 (t, J=6.28 Hz, 2H) 2.09-2.17 (m, 2H) 1.94(quin, J=5.95 Hz, 2H); LCMS (ESI+): m/z 460. (M+H)⁺, RT: 2.2 min; HPLCpurity: 99.6%, RT: 5 min; Chiral SFC purity: 97.5%, e.e. value: 95.0%,RT: 3.0 min.

Example 2 Synthesis of(S)-2-(1-methyl-1H-benzo[d]imidazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 2 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by1-methyl-1H-benzo[d]imidazole-6-carboxylic acid in the reaction withintermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: ACN (gradient: % B at T=0: 20; atT=12 min: 50%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 8.95 (s, 1H) 8.20 (s, 1H) 7.88-7.90(d, J=8.80 Hz, 1H) 7.79-7.81 (d, J=8.80 Hz, 1H) 7.51-7.53 (d, J=7.20 Hz,2H) 7.20-7.22 (d, J=8.40 Hz, 2H) 6.78-6.80 (d, J=8.40 Hz, 2H) 6.58-6.607.20-7.22 (d, J=8.40 Hz, 1H) 4.80 (m, 1H) 4.07 (s, 3H) 3.98-4.01 (t,J=5.73 Hz, 2H) 3.46-3.49 (t, J=5.51 Hz, 2H) 3.31 (m, 1H) 3.04-3.10 (m,1H) 2.77-2.88 (m, 4H) 2.10-2.14 (m, 2H) 1.91-1.94 (m, 2H); LCMS (ESI+):m/z 513.6 (M+H)⁺, RT: 1.83 min; HPLC purity: 99.1%, RT: 2.95 min; ChiralSFC purity: 95.3%, e.e. value: 90.58%, RT: 2.5 min.

Example 3 Synthesis of(S)-2-(5-(difluoromethyl)pyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 3 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by5-(difluoromethyl)pyrazine-2-carboxylic acid in the reaction withintermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: ACN (gradient: % B at T=0: 23; atT=10 min: 53); Column: Luna C18 100*30 5u; Flow rate: 25 mL/min; Monitorwavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 1.95 (br s, 2H) 2.08-2.17 (m, 2H)2.81 (br s, 2H) 2.87 (br t, J=7.89 Hz, 2H) 3.14 (dd, J=14.03, 7.89 Hz,1H) 3.26-3.30 (m, 1H) 3.28 (br s, 1H) 3.49 (br s, 2H) 3.98 (br d, J=5.26Hz, 2H) 6.56-6.64 (m, 1H) 6.73-6.78 (m, 2H) 6.89-6.95 (m, 1H) 6.92 (d,J=2.19 Hz, 1H) 7.06 (s, 1H) 7.04-7.07 (m, 1H) 7.10-7.17 (m, 2H) 7.54 (brs, 1H) 8.88-9.01 (m, 1H) 8.95 (br s, 1H) 9.21-9.29 (m, 1H) 9.25 (s, 1H);LCMS (ESI+): m/z=512.1 (M+H)⁺, RT: 2.6 min.

Example 4 Synthesis of(S)-2-(6-phenylpyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 4 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by6-phenylpyrazine-2-carboxylic acid in the reaction with intermediate1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: 10 mM NH₄HCO₃ in H₂O; B: AcN (gradient: % B at T=0: 30;at T=12 min: 60); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, DMSO-d₆): δ ppm 9.41 (s, 1H), 9.05 (s, 1H), 8.19 (br d,J=7.50 Hz, 2H), 7.54 (br d, J=6.39 Hz, 3H), 7.13 (br d, J=8.16 Hz, 1H),7.10-7.16 (m, 1H), 7.06 (br d, J=7.28 Hz, 1H), 6.72 (br d, J=8.38 Hz,2H), 6.26 (d, J=7.06 Hz, 1H), 4.61 (br t, J=5.95 Hz, 1H), 3.80 (br t,J=6.06 Hz, 2H), 3.22 (br t, J=5.18 Hz, 2H), 3.16 (br d, J=5.95 Hz, 2H),2.56 (br d, J=5.95 Hz, 4H), 1.86-1.95 (m, 2H), 1.72 (br d, J=4.85 Hz,2H); LCMS (ESI+): m/z 538.1. (M+H)⁺, RT: 2.4 min; HPLC purity: 97.8%,RT=5.1 min; Chiral SFC purity: 100%, ee value: 100%, RT=2.8 min.

Example 5 Synthesis of(S)-2-(2,6-dichloro-4-cyanobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 5 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by2,6-dichloro-4-cyanobenzoic acid in the reaction with intermediate1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 20%; atT=11.5 min: 50%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.83 (s, 2H), 7.56 (d, J=7.50 Hz,1H), 7.19 (d, J=8.60 Hz, 2H), 6.73-6.84 (m, 2H), 6.62 (d, J=7.50 Hz,1H), 4.88-4.93 (m, 1H), 4.00 (t, J=5.84 Hz, 2H), 3.42-3.53 (m, 2H), 3.22(dd, J=14.22, 5.18 Hz, 1H), 2.83-2.96 (m, 3H), 2.80 (t, J=6.28 Hz, 2H),2.07-2.22 (m, 2H), 1.93 (dt, J=12.02, 5.90 Hz, 2H); LCMS (ESI+):m/z=553.0 (M+H)⁺; RT: 2.3 min; HPLC purity: 100%, RT: 4.9 min; ChiralSFC purity: 100%, e.e. value: 100%, RT: 3.0 min.

Example 6 Synthesis of(S)-2-(2-fluoro-6-(trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 6 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by2-fluoro-6-(trifluoromethyl)benzoic acid in the reaction withintermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 21%; atT=10 min: 51%); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.62-7.63 (m, 1H), 7.54-7.56 (d,J=7.2 Hz, 2H), 7.42-7.46 (m, 2H), 7.17-7.19 (d, J=8.4 Hz, 2H), 6.78-6.80(d, J=8.4 Hz, 2H), 6.61-6.63 (d, J=7.6 Hz, 1H), 4.82 (m, 1H), 4.01-4.03(t, 2H), 3.47-3.50 (t, 2H), 3.15 (dd, 1H), 2.87-2.98 (m, 3H), 2.79-2.82(t, 2H), 2.15 (m, 2H), 1.93-1.96 (m, 2H); LCMS (ESI+): m/z=546.1 (M+H)⁺,RT: 2.3 min; HPLC purity=99.6% RT: 4.9 min; Chiral SFC purity: 94.5%, eevalue: 89.0%, RT: 6.3 min.

Example 7 Synthesis of(S)-2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 7 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by 2,6-difluorobenzoicacid in the reaction with intermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 20%; atT=11.5 min: 45%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.60 (d, J=7.50 Hz, 1H), 7.46-7.55(m, 1H), 2.85 (t, J=6.17 Hz, 2H), 7.23 (d, J=8.60 Hz, 2H), 7.05 (t,J=8.05 Hz, 2H), 6.84 (d, J=8.60 Hz, 2H), 6.67 (d, J=7.28 Hz, 1H),4.78-4.83 (m, 1H), 4.08 (t, J=5.84 Hz, 2H), 3.51-3.56 (m, 2H), 3.26 (dd,J=14.00, 5.18 Hz, 1H), 3.00 (dd, J=14.00, 8.93 Hz, 1H), 2.94 (t, J=7.50Hz, 2H), 2.15-2.24 (m, 2H), 1.99 (quin, J=5.95 Hz, 2H); LCMS (ESI+):m/z=496.1 (M+H)⁺, RT=2.2 min; HPLC purity: 99.1%, RT: 4.5 min; ChiralSFC purity: 100%, e.e. value: 100%, RT: 3.0 min.

Example 8 Synthesis of(S)-2-(2-methylpyrimidine-4-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 8 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by2-methylpyrimidine-4-carboxylic acid in the reaction with intermediate1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 17%; atT=11.5 min: 47%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ 8.86 (d, J=5.0 Hz, 1H) 7.81 (d, J=5.0Hz, 1H) 7.53 (d, J=7.2 Hz, 1H) 7.06-7.15 (m, 2H) 6.71-6.79 (m, 2H) 6.59(d, J=7.2 Hz, 1H) 4.77-4.81 (m, 1H) 3.97 (t, J=5.8 Hz, 2H) 3.42-3.50 (m,2H) 3.22-3.27 (m, 1H) 3.08-3.16 (m, 1H) 2.82-2.89 (m, 2H) 2.78 (t, J=6.1Hz, 2H) 2.72 (s, 3H) 2.05-2.16 (m, 2H) 1.86-1.96 ppm (m, 2H); LCMS(ESI+): m/z=575.5 (M+H)⁺, RT=2.1 min; HPLC purity=100%, RT: 4.3 min;Chiral SFC purity: 95.7%, ee value: 91.2%, RT: 3.8 min.

Example 9 Synthesis of(S)-2-(1-methyl-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 9 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by1-methyl-1H-benzo[d]imidazole-5-carboxylic acid in the reaction withintermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 15%; atT=12 min: 45%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ 9.09 (s, 1H), 8.19 (d, J=0.88 Hz, 1H),7.94-7.98 (m, 1H), 7.84-7.89 (m, 1H), 7.52 (d, J=7.28 Hz, 1H), 7.21 (d,J=8.60 Hz, 2H), 6.79 (d, J=8.60 Hz, 2H), 6.59 (d, J=7.28 Hz, 1H),4.82-4.85 (m, 1H), 4.09 (s, 3H), 3.99 (t, J=5.84 Hz, 2H), 3.44-3.50 (m,2H), 3.27-3.30 (m, 1H), 3.08 (br d, J=9.70 Hz, 1H), 2.86 (d, J=7.72 Hz,2H), 2.76-2.82 (m, 2H), 2.08-2.17 (m, 2H), 1.87-1.97 ppm (m, 2H); LCMS(ESI+): m/z=514.2 (M+H)⁺, RT=1.8 min; HPLC: RT=3.1 min, purity: 100%;Chiral SFC purity: 100%, ee value: 100%, RT=3.3 min.

Examples 10-12 Synthesis of(S)-2-(benzo[d]oxazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid (Example 10)

(S)-2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid (Example 11)

(S)-2-(3-formamido-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid (Example 12)

Examples 10, 11 and 12 were prepared by the same procedure used toprepare Example 1 with the exception that benzoic acid was replaced bybenzo[d]oxazole-5-carboxylic acid in the reaction with intermediate1f-int. Subsequent treatment with LiOH as in Example 1 resulted in theformation of Examples 10, 11 and 12 as a separable mixture.

HPLC purification condition: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 40%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

Example 10: ¹H NMR (400 MHz, DMSO-d₆): δ ppm 8.81 (s, 1H), 8.75 (br d,J=8.16 Hz, 1H), 8.24 (s, 1H), 7.86-7.92 (m, 1H), 7.79-7.84 (m, 1H), 7.20(d, J=8.60 Hz, 2H), 6.98 (d, J=7.06 Hz, 1H), 6.78 (d, J=8.60 Hz, 2H),6.32 (br s, 1H), 6.22 (d, J=7.28 Hz, 1H), 4.50-4.60 (m, 1H), 3.86 (br t,J=6.39 Hz, 2H), 3.19 (br s, 2H), 3.09 (br d, J=4.19 Hz, 1H), 3.00 (br d,J=10.80 Hz, 1H), 2.51-2.60 (m, 4H), 1.89-1.99 (m, 2H), 1.70 (quin,J=5.73 Hz, 2H); LCMS (ESI+): m/z=501.1 (M+H)⁺, RT: 2.1 min; HPLC purity:99.5%, RT: 2.3 min; Chiral SFC purity: 100%, ee value: 100%, RT=2.6 min.

Example 11: ¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.59 (d, J=1.98 Hz,1H), 7.48-7.57 (m, 2H), 7.15 (d, J=8.60 Hz, 2H), 6.93 (d, J=8.60 Hz,1H), 6.76 (d, J=8.60 Hz, 2H), 6.58 (d, J=7.28 Hz, 1H), 4.74 (dd, J=9.26,5.07 Hz, 1H), 3.98 (t, J=5.84 Hz, 2H), 3.42-3.49 (m, 2H), 3.23 (dd,J=14.11, 5.07 Hz, 1H), 3.01 (dd, J=14.00, 9.37 Hz, 1H), 2.85 (t, J=7.50Hz, 2H), 2.77 (t, J=6.28 Hz, 2H), 2.07-2.16 (m, 2H), 1.92 (quin, J=5.95Hz, 1H), 1.87-1.96 (m, 1H); LCMS (ESI+): m/z=491.1 (M+H)⁺, RT: 2.1 min;HPLC purity: 100%, RT: 3.0 min; Chiral SFC purity: 100%, e.e. value:100%, RT=2.5 min.

Example 12: ¹H NMR (400 MHz, DMSO-d₆): δ ppm 9.59 (s, 1H), 8.44 (d,J=2.20 Hz, 1H), 8.24-8.29 (m, 2H), 7.39 (dd, J=8.38, 2.21 Hz, 1H), 7.15(d, J=8.60 Hz, 2H), 6.98 (d, J=7.28 Hz, 1H), 6.84 (d, J=8.38 Hz, 1H),6.76 (d, J=8.82 Hz, 2H), 6.34 (br s, 1H), 6.22 (d, J=7.28 Hz, 1H),4.41-4.50 (m, 1H), 3.86 (t, J=6.28 Hz, 2H), 3.19 (br s, 2H), 3.04 (brdd, J=13.78, 4.52 Hz, 1H), 2.95 (br dd, J=13.78, 9.81 Hz, 1H), 2.49-2.57(m, 4H), 1.89-1.97 (m, 2H), 1.66-1.74 (m, 2H); LCMS (ESI+): m/z=519.1(M+H)⁺, RT: 1.9 min; HPLC purity: 92.7%, RT: 3.8 min; Chiral SFC purity:100%, e.e. value: 100%, RT=3.5 min.

Example 13 Synthesis of(S)-2-(isonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 13 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by isonicotinic acidin the reaction with intermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 40%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 8.76 (br d, J=3.97 Hz, 2H), 7.85(d, J=6.17 Hz, 2H), 7.54 (d, J=7.50 Hz, 1H), 7.19 (d, J=8.60 Hz, 2H),6.80 (d, J=8.60 Hz, 2H), 6.60 (d, J=7.28 Hz, 1H), 4.81-4.84 (m, 1H),4.00 (t, J=5.84 Hz, 1H), 3.94-4.07 (m, 1H), 3.43-3.55 (m, 2H), 3.33-3.37(m, 1H), 3.27-3.30 (m, 1H), 3.32-3.37 (m, 1H), 3.02 (dd, J=14.11, 9.92Hz, 1H), 2.87 (t, J=7.61 Hz, 2H), 2.80 (t, J=6.17 Hz, 1H), 2.76-2.83 (m,1H), 2.06-2.21 (m, 2H), 1.94 (quin, J=5.95 Hz, 2H); HPLC purity: 98.2%,RT: 3.3 min; LCMS (ESI+): m/z=460.1 (M+H)⁺, RT=1.8 min; Chiral SFCpurity: 99.7%, ee value: 99.3%, RT=3.4 min.

Example 14 Synthesis of(S)-2-(nicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 14 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by nicotinic acid inthe reaction with intermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 40%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, DMSO-d₆): δ ppm 8.93 (s, 1H), 8.88-8.90 (d, J=8.00 Hz,1H), 8.69-8.70 (d, J=4.00 Hz, 1H), 7.47-7.50 (m, 1H), 7.19-7.21 (d,J=8.40 Hz, 2H), 7.00-7.02 (d, J=7.60 Hz, 1H), 6.80-6.82 (d, J=8.40 Hz,2H), 6.39 (s, 1H), 6.24-6.26 (d, J=7.20 Hz, 1H), 4.53-4.59 (m, 1H),3.87-3.90 (m, 2H), 3.22 (m, 1H), 3.10-3.13 (m, 1H), 2.93-2.99 (m, 1H),2.55-2.60 (m, 4H), 1.95-1.99 (m, 2H), 1.72-1.74 (m, 2H); HPLC purity:99.7%, RT: 3.3 min; LCMS (ESI+): m/z=461.1 (M+H)⁺, RT=1.9 min; ChiralSFC purity: 98.0%, ee value: 96.0%, RT=3.0 min.

Example 15 Synthesis of(S)-2-(3,5-dichloroisonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 15 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by3,5-dichloroisonicotinic acid in the reaction with intermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 40%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, DMSO-d₆): δ ppm 9.19 (d, J=8.38 Hz, 1H), 8.60 (s, 2H),7.14 (d, J=8.60 Hz, 2H), 7.00 (d, J=7.28 Hz, 1H), 6.79 (d, J=8.60 Hz,2H), 6.33 (br s, 1H), 6.24 (d, J=7.28 Hz, 1H), 4.61 (td, J=8.88, 4.96Hz, 1H), 3.89 (t, J=6.39 Hz, 2H), 3.20 (br s, 2H), 3.04 (dd, J=14.00,4.96 Hz, 1H), 2.82 (dd, J=14.00, 9.37 Hz, 1H), 2.51-2.60 (m, 4H),1.91-2.01 (m, 2H), 1.67-1.76 (m, 2H); LCMS (ESI+): m/z=529.2 (M+H)⁺, RT:2.4 min; HPLC purity: 97.8%, RT: 4.4 min; Chiral SFC purity: 100%, eevalue: 100%, RT=2.5. min.

Example 16 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Example 16 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by 2,6-dichlorobenzoicacid in the reaction with intermediate 1f-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: 10 mM NH₄HCO₃ in H₂O; B: AcN (gradient % B at T=0: 25%;at T=12 min: 45%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 1.93-1.89 (m, 2H) 2.12-2.09 (m, 2H)2.86-2.76 (m, 4H) 2.96-2.87 (m, 1H) 3.21-3.16 (m, 1H) 3.46 (t, J=6.0 Hz,2H) 3.97 (d, J=5.6 Hz, 2H) 4.86-4.85 (m, 1H) 6.60 (d, J=8.0 Hz, 1H) 6.74(d, J=8.4 Hz, 2H) 7.20 (d, J=8.4 Hz, 2H) 7.35-7.30 (m, 3H) 7.52 (d,J=6.4 Hz, 1H); LCMS (ESI+): m/z=528.1 (M+H)⁺, RT: 2.25 min; HPLC purity:100%, RT: 4.7 min; Chiral SFC purity: 100%, ee value: 100%, RT: 2.7 min.

Example 17 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 17a: 51e (150 mg, 0.34 mmol) and 53c (54 mg, 0.34 mmol) in EtOH(5 mL) were heated at reflux for 3 hrs. LCMS showed desired product wasformed, TLC (Ethyl acetate:Methanol=10:1, R_(f)=0.22) showed new aproduct spot. The mixture was concentrated and the residue was purifiedby prep-TLC (EtOAc:MeOH=10:1) to give 17a.

Example 17: 17a (95 mg, 0.17 mmol) and LiOH·H₂O (14.5 mg, 0.35 mmol) inTHF (5 mL)/H₂O (1 mL) were stirred at 20° C. for 2 hrs. LCMS showedExample 17 was present. The mixture was concentrated and the residue waspurified by prep-HPLC to give Example 17.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 45%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.49-7.61 (m, 3H), 7.42 (d, J=8.6Hz, 2H), 6.99-7.08 (m, 2H), 5.09 (br s, 1H), 4.16-4.24 (m, 2H), 3.88 (s,3H), 3.56-3.67 (m, 2H), 3.50 (dt, J=3.31, 1.65 Hz, 4H), 3.41 (dd,J=14.11, 5.29 Hz, 1H), 3.15 (dd, J=14.11, 9.26 Hz, 1H), 1.99-2.09 (m,4H); LCMS (ESI+): m/z=535.0 (M+H)⁺, RT: 2.3 min; HPLC purity: 97.3%, RT:7.6 min; Chiral SFC purity: 100%, ee value: 100%, RT: 3.0 min.

Example 18 Synthesis of2-(2,6-dichlorobenzamido)-3-(4-(3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propoxy)phenyl)propanoicacid

Compound 18a-int: To a solution of 2,6-dichlorobenzoic acid (2.29 g, 12mmol) in DMF (60 mL) was added EDCI (2.3 g, 12 mmol), HOBt (1.62 g, 12mmol) and TEA (2.02 g, 20 mmol, 2.77 mL) at 5-10° C. The mixture wasstirred at 5-10° C. for 1 hr, then methyl(2S)-2-amino-3-(4-nitrophenyl)propanoate (3.6 g, 16.06 mmol) in DMF (20mL) was added and stirred at 10-20° C. for 2 hrs. TLC (PE:EtOAc=1:1,R_(f)=0.5) indicated the reaction was completed. The mixture was pouredinto water (100 mL), extracted with EtOAc (200 mL×2). The combinedorganic layers were washed with 1N HCl (100 mL), H₂O (100 mL), sat.NaHCO₃ (100 mL), brine (50 mL), dried over Na₂SO₄ then concentrated togive a crude product, which was crystallized from PE:DCM=10:1 to afford18a-int; ¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.28-7.34 (m, 3H), 7.08(d, J=8.53 Hz, 2H), 6.72-6.77 (m, 2H), 6.28 (d, J=7.78 Hz, 1H), 5.15(dt, J=8.00, 5.60 Hz, 1H), 4.82 (s, 1H), 3.75-3.78 (m, 3H), 3.21 (d,J=5.65 Hz, 2H).

Compound 18b-int: To a solution of (2-chloropyridin-3-yl)methanol (50 g,348 mmol) in dry DCM (500 mL) was added PBr₃ (94.3 g, 348 mmol) at 20°C. The reaction mixture was stirred at 20° C. for 2 hr. LCMS indicated18b-int was detected. Water (50 mL) was added slowly at 0° C. Thensaturated aqueous K₂CO₃ was added to pH 7. The organic layer wasseparated and water phase was extracted with DCM (200 mL). The organiclayer was concentrated to give crude product which was purified bysilica gel column chromatography (PE:EtOAc=20:1˜5:1) to give 18b-int; ¹HNMR (400 MHz, METHANOL-d₄): δ ppm 7.81 (s, 2H), 7.56 (d, J=7.50 Hz, 1H),7.19 (d, J=8.60 Hz, 2H), 6.73-6.84 (m, 2H), 6.62 (d, J=7.50 Hz, 1H),4.88-4.93 (m, 1H), 4.00 (t, J=5.84 Hz, 2H), 3.42-3.53 (m, 2H), 3.22 (dd,J=14.22, 5.18 Hz, 1H), 2.83-2.96 (m, 3H), 2.80 (t, J=6.28 Hz, 2H),2.07-2.22 (m, 2H), 1.93 (dt, J=12.02, 5.90 Hz, 2H).

Compound 18c-int: To a solution of tetrahydropyran-2-one (26.67 g,266.38 mmol, 24.03 mL) in THF (50 mL) was added LDA (2 M, 146.51 mL,1.10 eq) at −75° C. drop-wise. After the addition was complete, thereaction mixture was stirred at −75° C. for 0.5 hr. Compound 18b-int(55.00 g, 266.38 mmol) was added to the reaction mixture. The reactionmixture was warmed to −30° C. over 3 hr. The reaction mixture was pouredinto saturated NH₄Cl (50 mL) then the organic layer was separated andconcentrated. The crude product was purified by silica gel column(PE:EA=10:1 to 3:1) to give 18c-int.

Compound 18d-int: To 18c-int (22 g, 97.49 mmol) in THF (100 mL) andwater (100 mL) was added LiOH·H₂O (12.27 g, 292.47 mmol). The reactionmixture was stirred at 20° C. for 2 hrs. LCMS showed a peak with desiredMS was detected. THF was evaporated and to the mixture was added citricacid until the pH 5 was attained. The product was extracted with EtOAc(300 mL×3). The combined organic layer was dried over Na₂SO₄ andconcentrated to give 2-[(2-chloro-3-pyridyl)methyl]-5-hydroxy-pentanoicacid (23.00 g, crude) as an oil. The product was used in the next stepwithout purification. A solution of2-[(2-chloro-3-pyridyl)methyl]-5-hydroxy-pentanoic acid (23.00 g, 94.38mmol) in DMF (150 mL) was added imidazole (12.85 g, 188.76 mmol) andTBDMSCl (21.34 g, 141.57 mmol, 17.35 mL). The reaction mixture wasstirred at 40° C. for 16 hrs. LCMS indicated that the reaction wascomplete. Water (500 mL) was added and the product was extracted withEtOAc (500 mL×2). The combined organic layer was concentrated and thecrude product was purified by silica gel column (PE:EtOAc=10:1 to 1:2)to give compound 18d-int; LCMS (ESI+): m/z=357.9 (M+H)⁺, RT=1.5 min.

Compound 18e-int: To a solution of compound 18d-int (15 g, 41.91 mmol)in toluene (100 mL) was added DPPA (13.84 g, 50.29 mmol, 10.90 mL), TEA(12.72 g, 125.73 mmol, 17.42 mL) and BnOH (13.6 g 125.73 mmol 13.08 mL)at 20° C. Then the reaction mixture was stirred at 80° C. for 2 hr. LCMSindicated the starting material was consumed completely. The reactionmixture was concentrated and the crude product was purified by silicagel column (PE:EtOAc=20:1 to 4:1) to give compound 18e-int; LCMS (ESI+):m/z=463.0 (M+H)⁺, RT=1.7 min.

Compound 18f-int: To compound 18e-int (1 g, 2.16 mmol) in THF (20 mL)was added NaH (259.13 mg, 6.48 mmol, 60% purity). The reaction mixturewas stirred at 100° C. under microwave conditions for 1 hr. LCMS showedthe desired product was present and the reactant was consumed. Thesolvent was evaporated under reduced pressure and the product waspurified by silica gel column (PE:EtOAc=10:1 to 1:1) to give 18f-int;LCMS (ESI+): m/z=293.1 (M+H)⁺, RT=1.1 min.

Compound 18g-int: Compound 18f-int (1.2 g, 4.1 mmol) in THF (10 mL) wasadded to TBAF (1M, 8.2 mL) and the reaction mixture was stirred at 20°C. for 16 hrs. LCMS and TLC (DCM:MeOH=10:1, R_(f)=0.3) indicated thereaction was complete. The solvent was evaporated and the product waspurified by silica gel column (DCM:MeOH=1:0 to 10:1) to give3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propan-1-ol (530 mg, 2.97mmol, 72.53% yield) as a yellow oil. 500 mg (2.81 mmol) of this materialwas dissolved in THF and Boc₂O (4.91 g, 22.48 mmol, 5.16 mL), then thereaction mixture was stirred at 50° C. for 5 hrs. LCMS and TLC(PE:EtOAc=1:1) showed the reaction was complete. The crude product waspurified by silica gel column (PE:EtOAc=1:0 to 1:1) to give 18g-int;LCMS (ESI+): m/z=279.0 (M+H)⁺, RT=0.9 min.

Compound 18h-int: To Compound 18g-int (110 mg, 395.19 umol) in DCM (2mL) was added MsCl (54.32 mg, 474.23 umol, 36.70 uL) and TEA (79.98 mg,790.38 umol, 109.56 uL). The reaction mixture was stirred at 20° C. for1 hr. TLC (PE:EtOAc=1:1, R_(f)=0.6) indicated the reaction was complete.Water (1 mL) was added and the organic layer was separated. The solventwas evaporated under reduced pressure to give compound 18h, which wasused in the next step without further purification.

Compound 18i-int: To a mixture of 18h-int (120 mg, 336.66 umol) andmethyl (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-(4-hydroxyphenyl)propanoate(123.96 mg, 336.66 umol) in DMF (2 mL) was added K₂CO₃ (139.59 mg, 1.01mmol). The reaction mixture was stirred at 110° C. for 16 hrs. LCMSshowed the reaction mixture was complete. The solvent was evaporated andthe crude product was purified by prep-TLC (PE:EA=1:1, R_(f)=0.7) togive compound 18i-int; LCMS (ESI+): m/z=628.1 (M+H)⁺, RT=1.4 min.

Example 18: A solution of 18i-int (50.00 mg, 79.55 umol) in MeCN (1 mL)and H₂O (1 mL) was added to AcOH (9.55 mg, 159.10 umol, 9.1 uL) and HCl(10N, 159.1 uL). The reaction mixture was stirred at 70° C. for 16 hrs.LCMS showed the reaction was completed, then the solvent was removed byevaporation under reduced pressure. The crude product was purified byprep-HPLC to give Example 18.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 20%; atT=12 min: 50%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.58-7.59 (m, 1H), 7.34-7.35 (m,1H), 7.33-7.34 (m, 3H), 7.23 (d, J=8.40 Hz, 2H), 6.84 (d, J=8.80 Hz,2H), 6.70 (t, J=6.80 Hz, 1H), 4.30-4.35 (m, 1H), 4.02 (t, J=5.60 Hz,2H), 3.29-3.39 (m, 1H), 3.19-3.20 (m, 1H), 2.94-2.97 (m, 2H), 1.83-1.91(M, 4H); LCMS (ESI+): m/z=514.0 (M+H)⁺, RT=2.2 min; HPLC purity: 99.0%,RT: 2.3 min. Chiral SFC showed an equal mixture of all fourdiastereomers.

Example 19 Synthesis of(S)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid

Compound 19a-int: A solution of 6-oxoheptanoic acid (25 g, 173.41 mmol)in HCl/MeOH (250 mL) was stirred at 80° C. for 10 hr. LCMS showed thatthe product was present. The solvent was removed and the residue wasdissolved in ethyl acetate (200 mL). Then the organic layer was washedwith saturated NaHCO₃ (150 mL), brine (150 mL) then concentrated to give19a-int; LCMS (ESI+): m/z=159.1 (M+H)⁺, RT=0.51 min.

Compound 19b-int: 19a-int (21 g, 132.75 mmol),2-aminopyridine-3-carbaldehyde (17.83 g, 146.03 mmol) and L-proline(7.64 g, 66.38 mmol) in EtOH (200 mL) were stirred at 80° C. for 10 hrs.LCMS showed that the 19b-int was formed. The solvent was removed and thecrude product was purified by chromatography on silica gel(PE:EtOAc=10:1 to 1:1, R_(f)=0.3) to give 19b-int; LCMS (ESI+):m/z=245.0 (M+H)⁺, RT=0.75 min.

Compound 19c-int: To 19b-int (8.6 g, 35.20 mmol) in MeOH (100 mL) wasadded Pd/C (1 g) at 0° C. The mixture was degassed with N₂ thensaturated with H₂; the reaction was stirred at 0-20° C. under H₂ (50psi) for 12 hrs. TLC (PE:EtOAc=2:1, R_(f)=0.25) showed the reaction wascomplete. The catalyst was removed by filtration and the filtrate wasconcentrated to give 19c-int.

Compound 19d-int: A solution of compound 19c-int (8 g, 32.22 mmol) inBoc₂O (56.26 g, 257.76 mmol, 59.22 mL) was stirred at 40-60° C. for 12hrs. TLC (PE:EtOAc=2:1, R_(f)=0.5) indicated the reaction was complete.The reaction mixture was applied to silica gel and purified by silicagel chromatography (PE:EtOAc=10:1 to 1:1, R_(f)=0.3) to give 19d-int.

Compound 19e-int: To 19d-int in dioxane (100 mL)/H₂O (5 mL) was addedLiOH. H₂O (2.53 g, 60.27 mmol); the mixture was stirred at 20° C. for 12hrs. TLC (PE:EtOAc=1:1, R_(f)=0.15) indicated the reaction was complete.The mixture was concentrated and the residue was poured into H₂O (100mL) and DCM (200 mL), then adjusted to pH 6 with 1N HCl; the organiclayer was separated and the aqueous layer was extracted with DCM (200mL). The combined organics were dried over Na₂SO₄, then concentrated togive 19e-int.

Compound 19f-int: To a solution of 19e-int (10 g, 29.9 mmol) in DCM (100mL) was added EDCI (6.88 g, 35.88 mmol), HOBt (4.85 g, 35.88 mmol) andTEA (6.05 g, 59.81 mmol, 8.29 mL) at 20° C. The mixture was stirred at10-20° C. for 0.5 hrs; N-methoxymethanamine hydrochloride (3.5 g, 35.88mmol) was added and the mixture stirred at 10-20° C. for 2.5 hrs. TLC(PE:EtOAc=1:1, R_(f)=0.5) indicated the reaction was complete by the endof this period. The mixture was poured into H₂O (100 mL), extracted withDCM (100 mL×2) and the combined organics were dried over Na₂SO₄,concentrated in vacuo. The residue was purified by silica gelchromatography (PE:EtOAc=5:1 to 2:1) to give 19f-int; LCMS (ESI+):m/z=378.1 (M+H)+, RT=0.33 min.

Compound 19g-int: To 19f-int (7.5 g) in THF (120 mL) was added dropwiseDIBALH (1M THF solution, 29.8 mL) at −78° C. The mixture was stirred at−78° C. for 3 hrs. TLC (PE:EtOAc=2:1, R_(f)=0.5) indicated the reactionwas complete. The mixture was poured into ice water (100 mL) andextracted with EtOAc (100 mL×2). The combined organics were dried overNa₂SO₄ then the solvent removed to give 19g-int.

Compound 19h-int: To a mixture of methyl(triphenyl)phosphonium bromide(13.46 g, 37.68 mmol) in THF (100 mL) was added t-BuOK (1 M solution inTHF, 37.68 mL, 37.68 mmol) at 0° C. The mixture was stirred at 20° C.for 1 hr then 19g-int (6 g, 18.84 mmol, 1.00 eq) was added. This mixturewas stirred at 20° C. for 2 hrs, after this time TLC (PE:EtOAc=2:1,R_(f)=0.43) indicated that reaction was complete. The mixture wasquenched with aq. NH₄Cl (1M, 40 mL), extracted with EtOAc (100 mL×2),dried over Na₂SO₄ then concentrated. The residue was purified by silicagel chromatography (PE:EtOAc=10:1) to give 19h-int; LCMS (ESI+):m/z=317.3 (M+H)+, RT=0.79 min.

Compound 19i-int: To a mixture of compound 19l-int (2 g, 6.62 mmol) andcompound 19h-int (2.09 g, 6.62 mmol) in DCM (200 mL) was added Grubbs IIcatalyst (561.95 mg, 662 umol). The mixture was purged with N₂ (3×) thenstirred at 40° C. for 24 hrs, after this time TLC (PE:EtOAc=2:1,R_(f)=0.50) indicated the reaction was complete. The mixture wasconcentrated and the residue was purified by silica gel chromatography(PE:EtOAc=5:1) to give 19i-int; LCMS (ESI+): m/z=590.4 (M+H)⁺, RT=0.81min.

Compound 19j-int: To 19i-int (390 mg, 660.41 umol) in EtOAc (50 mL) wasadded Pd/C (50 mg, 660.41 umol). The mixture was purged with N₂ (3×)then stirred at 20-30° C. for 4 hrs under an atmosphere of H₂ gas. Afterthis time LCMS indicated the most of 19i-int was consumed so mixture wasfiltered to remove the catalyst. The filtrate was concentrated in vacuumto give 19j-int; LCMS (ESI+): m/z=592.4 (M+H)+, RT=0.78 min.

Compound 19k-int: Compound 19j-int (370 mg, 624.42 umol) in TFA/DCM (5mL) was stirred at 25° C. for 10 hrs; after this time LCMS showed thatthe reaction was complete. The solvent was removed to give 19k-int; LCMS(ESI+): m/z=492.2 (M+H)⁺, RT=0.92 min.

Compound 19l-int: Methyl (2S)-2-aminopent-4-enoate (45 g, 348.41 mmol)in DCM (500 mL) was added dropwise to TEA (88.14 g, 871.03 mmol, 120.74mL) and 2,6-dichlorobenzoyl chloride (21 g, 100.26 mmol, 14.38 mL) inDCM at 20° C. The mixture was stirred at 20-40° C. for 12 hrs and waspoured into H₂O (500 mL). The organic layer was separated and washedwith 1N HCl (200 mL), sat. NaHCO₃ (200 mL), brine (200 mL) and driedover Na₂SO₄. The solvent was removed by evaporation under reducedpressure and dried in vacuo to give 19l-int.

Example 19: A solution of 19k-int (300 mg, 0.61 mmol) and LiOH·H₂O(51.13 mg, 1.22 mmol) in THF (5 mL)/H₂O (5 mL) was stirred at 25° C. for10 hrs. LCMS showed that Example 19 was present and the reactioncomplete. The solvent was removed and the crude product was purified byprep-HPLC to give Example 19.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 15%; atT=10 min: 45%); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.59 (d, J=7.28 Hz, 1H), 7.36-7.45(m, 3H), 6.63 (d, J=7.28 Hz, 1H), 4.63 (dd, J=9.48, 4.63 Hz, 1H),3.47-3.52 (m, 2H), 2.81 (t, J=6.17 Hz, 2H), 2.70 (t, J=7.83 Hz, 2H),1.90-2.00 (m, 3H), 1.66-1.84 (m, 3H), 1.52 (br d, J=4.85 Hz, 2H), 1.40(br s, 6H); LCMS (ESI+): m/z=478.0 (M+H)⁺, RT=2.3 min; HPLC: RT=5.0 min,purity: 92.9%; Chiral SFC purity: 100%, e. e. value: 100%, RT=3.3 min.

Example 20 Synthesis of(S,E)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)non-4-enoicacid

Compound 20a-int: To compound 19i-int (200 mg, 338.67 umol) in DCM (40mL) was added TFA (5 mL); the mixture was stirred at 20° C. for 4 hrs.After this time LCMS indicated the reaction was complete. The mixturewas concentrated and the residue was poured into H₂O (10 mL) and sat.NaHCO₃ (20 mL) then extracted with DCM (50 mL×2). The combined organicswere dried over Na₂SO₄ and concentrated to give compound 20a. Thismaterial was used in next step without further purification; LCMS(ESI+): m/z=490.3 (M+H)⁺, RT=0.77 min.

Example 20: To a solution of 20a-int (150 mg, 305.86 umol) in THF (2mL)/H₂O (2 mL) was added LiOH·H₂O (12.83 mg, 305.86 umol). This wasstirred for 12 hrs at 20° C. after which LCMS showed the desired productwas present and the reaction complete. The solvent was removed and thecrude material was purified by prep-HPLC to give Example 20.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 20%; at11.5 min: 40%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): 7.56 (d, J=7.2 Hz, 1H), 7.35-7.41 (m,3H), 6.60 (d, J=7.2 Hz, 1H), 5.52-5.63 (m, 1H), 4.60-4.64 (m, 1H),3.44-3.46 (m, 2H), 2.78-2.79 (m, 2H), 2.68-2.76 (m, 2H) 2.64-2.66 (m,1H), 2.05-2.08 (m, 2H), 1.89-1.92 (m, 2H), 1.65-1.67 (m, 2H), 1.43-1.46ppm (m, 2H); LCMS (ESI+): m/z=476.0 (M+H)+, RT=2.3 min; HPLC: RT=4.9min, purity: 90.9%; Chiral SFC purity: 100%, e.e. value: 100%, RT=3.3min.

Example 21 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methyl)azetidin-1-yl)phenyl)propanoicacid

Compound 21a-int: To 2-(1-tert-butoxycarbonylazetidin-3-yl)acetic acid(4.8 g, 22.3 mmol), HOBt (3.62 g, 26.76 mmol) and TEA (5.64 g, 55.75mmol, 7.73 mL) in DCM (100 mL) was added EDCI (5.13 g, 26.76 mmol) at 0°C. The mixture was stirred at 20° C. for 1 hr then N-methoxymethanaminehydrogen chloride salt (2.39 g, 24.53 mmol) was added. The mixture wasstirred at 20° C. for 2 hrs then poured into H₂O (50 mL). The organiclayer was separated, was washed with H₂O (50 mL), brine (50 mL) anddried over Na₂SO₄. The solvent was removed to give tert-butyl3-[2-[methoxy(methyl)amino]-2-oxo-ethyl]azetidine-1-carboxylate (5.5 g,19.36 mmol, 86.8% yield). To this material (5.5 g) in THF (100 mL) wasadded dropwise a THF solution of bromo(methyl)magnesium (3.55 g, 29.81mmol) at −78° C.; the reaction was stirred at −78° C. for 3 hrs. TLC(PE:EtOAc=3:1, R_(f)=0.5) indicated the reaction was complete. Themixture was quenched with sat. NH₄Cl (50 mL), extracted with EtOAc (100mL×2), then the combined organic layers were dried over Na₂SO₄ andconcentrated to give 21a-int.

Compound 21b-int: A mixture of 21a-int (5 g, 23.44 mmol),2-aminopyridine-3-carbaldehyde (2.86 g, 23.44 mmol) and L-proline (1.35g, 11.72 mmol) in EtOH (80 mL) was stirred at 80-90° C. for 12 hrs. TLC(PE:EtOAc=1:1, R_(f)=0.15) indicated the reaction was completed. Themixture was concentrated and the residue was poured into H₂O (50 mL)then extracted with EtOAc (100 mL×3). The combined organics layers weredried over Na₂SO₄, filtered and concentrated. The residue was purifiedby silica gel chromatography (PE:EtOAc=1:1) to give 21b-int.

Compound 21c-int: 21b-int (3.50 g, 11.69 mmol) in HCl/MeOH (4N, 40 mL)was stirred at 20° C. for 12 hrs. TLC (PE:EtOAc=10:1, R_(f)=0.15)indicated the reaction was complete. The mixture was concentrated togive compound 21c-int.

Compound 21d-int: To 21c-int (200 mg, 1 mmol) in DMSO (3 mL) was added(S)-methyl 3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate(610.13 mg, 1.51 mmol), CuI (38.23 mg, 200.75 umol), Cs₂CO₃ (654.09 mg,2.01 mmol) and L-proline (46.23 mg, 401.51 umol). The mixture wasstirred at 90° C. for 12 hrs under N₂. LCMS indicated the reaction wascomplete. The reaction mixture was diluted with H₂O (20 mL) andextracted with ethyl acetate (20 mL×3). The combined organic phases werewashed with brine (30 mL), dried with anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by silica gel chromatography(PE:EA=10:1, 0:1) to give 21d-int.

Compound 21e-int: To 21d-int (170 mg, 356.72 umol) in MeOH (10 mL) wasadded Pd/C (50 mg), then the mixture was stirred at 40° C. for 12 hrsunder H₂; TLC showed the starting material was consumed completely. Themixture was filtered and concentrated in vacuum to give 21e-int.

¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.19-7.37 (m, 1H), 7.15 (s, 1H),6.98 (br d, J=8.16 Hz, 2H), 6.42-6.48 (m, 2H), 4.01 (dt, J=14.44, 7.33Hz, 1H), 3.66-3.81 (m, 5H), 3.27-3.36 (m, 2H), 3.12 (d, J=1.10 Hz, 2H),2.96-3.05 (m, 2H), 2.71 (br t, J=6.28 Hz, 2H), 2.29-2.38 (m, 3H), 1.94(dt, J=11.42, 5.65 Hz, 2H), 1.43 (s, 9H).

Compound 21f-int: To 21e-int (160 mg, 332.92 umol) in DCM (5.00 mL) wasadded TFA (1.54 g, 13.51 mmol, 1.00 mL), then the mixture was stirred at25° C. for 12 hrs. LCMS showed the reaction was complete. The mixturewas concentrated to give 21f-int; LCMS (ESI+): m/z=381.3 (M+H)⁺, RT:0.59 min.

Compound 21g-int: To 2,6-dichlorobenzoic acid (60.24 mg, 315.40 umol) inDCM was added HOBt (35.51 mg, 262.83 umol) and EDCI (65.50 mg, 341.68umol), then the mixture was stirred 0.5 hrs. Compound 21f-int (100 mg,262.83 umol) and Et₃N (66.49 mg, 657.08 umol, 91.08 uL) was added to themixture and stirred at 25° C. for 12 h. LCMS showed the reaction wascomplete. The mixture was added to H₂O (10 mL) and extracted with ethylacetate (20 mL×2). The combined organic phases were washed with brine(20 mL×5), dried with anhydrous Na₂SO₄, filtered and concentrated. Afterpurification by prep-TLC (PE:EtOAc=0:1) there was obtained 21g-int; LCMS(ESI+): m/z=553.2 (M+H)⁺, RT: 0.72 min.

Example 21: To 21g-int (70 mg, 126.47 umol) in THF (5 mL)/H₂O (2 mL) wasadded LiOH·H₂O (15.92 mg, 379.42 umol). This mixture was stirred at 40°C. for 12 hrs whereupon LCMS showed the reaction was complete. Themixture was concentrated and purified by prep-HPLC to give Example 21.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 20%; atT=10 min: 40%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.88 (s, 1H), 7.31-7.36 (m, 3H),7.16 (d, J=8.60 Hz, 2H), 6.49 (d, J=8.38 Hz, 2H), 4.82-4.83 (m, 1H),4.22 (t, J=7.61 Hz, 2H), 3.99 (s, 1H), 3.73-3.79 (m, 2H), 3.45-3.49 (m,2H), 3.15 (d, J=5.73 Hz, 2H), 2.91 (dd, J=14.00, 9.15 Hz, 1H), 2.83 (t,J=6.17 Hz, 2H), 1.90-1.98 (m, 2H); LCMS (ESI+): m/z=539.0 (M+H)⁺, RT:2.2 min; HPLC purity: 96.3%, RT: 6.3 min; Chiral SFC: racemate.

Example 22 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoicacid

Compound 22a-int: To the solution of tert-butyl3-acetylazetidine-1-carboxylate (4.8 g, 24.09 mmol) in EtOH (70 mL) wasadded L-proline (1.39 g, 12.05 mmol) and 2-aminonicotinaldehyde (2.94 g,24.09 mmol). The mixture was stirred at 70° C. for 12 hrs after whichLCMS showed the reaction was completed. The mixture was concentrated invacuum and purified by silica gel chromatography (PE:EtOAc=5:1 to 0:1)to give 22a-int; ¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 9.10-9.22 (m,1H), 8.17-8.30 (m, 2H), 7.46-7.60 (m, 2H), 4.39 (br s, 4H), 4.03-4.29(m, 1H), 1.42-1.53 (m, 9H).

Compound 22b-int: 22a-int (1.50 g, 5.26 mmol, 1.00 eq) in HCl/EtOAc (50mL) was stirred at 25° C. for 12 hrs. LCMS and TLC showed the reactionwas completed. The mixture was concentrated to give 22b-int; ¹H NMR (400MHz, METHANOL-d₄): δ ppm 9.11-9.27 (m, 1H), 8.52-8.77 (m, 2H), 7.67-7.89(m, 2H), 4.51-4.64 (m, 3H), 4.10-4.33 (m, 1H), 3.73-4.00 (m, 1H).

Compound 22c-int: To 22b-int (500 mg, 2.70 mmol) in DMSO (10 mL) wasadded (S)-methyl 3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (1.64 g, 4.05 mmol) and Cs₂CO₃ (1.76 g, 5.40 mmol), CuI(102.82 mg, 540.00 umol) and L-proline (124.32 mg, 1.08 mmol). Themixture was stirred at 90° C. for 18 hrs under N₂; after this time LCMSshowed that the reaction was complete. The mixture was diluted with H₂O(20 mL) and extracted with ethyl acetate (20 mL×3). The combined organicphases were washed with brine (30 mL), dried with anhydrous Na₂SO₄,filtered and concentrated, then purified by silica gel chromatography(PE:EtOAc=1:1) to give 22c-int; ¹H NMR (400 MHz, CHLOROFORM-d): δ ppm9.10 (dd, J=4.41, 1.98 Hz, 1H), 8.15-8.24 (m, 2H), 7.62 (d, J=8.38 Hz,1H), 7.48 (dd, J=8.05, 4.30 Hz, 1H), 6.97 (d, J=8.38 Hz, 2H), 6.49 (d,J=8.16 Hz, 2H), 4.96 (br d, J=7.72 Hz, 1H), 4.36-4.38 (m, 2H), 4.26 (brd, J=2.87 Hz, 2H), 3.71 (s, 3H), 1.42 (s, 9H).

Compound 22d-int: To 22c-int (300 mg, 648.59 umol) in MeOH (7 mL) wasadded Pd/C (100 mg); the mixture was degassed with N₂ then saturatedwith H₂. The reaction was stirred under H₂ (50 psi) at 40° C. for 12hrs. TLC showed the starting material was consumed completely; themixture was filtered and concentrated to give 22d-int; LCMS (ESI+):m/z=467.3 (M+H)⁺, RT: 0.75 min.

Compound 22e-int: 22d-int was added to HCl/MeOH (10 mL) and stirred at25° C. for 12 hrs. After this time LCMS showed the reaction wascomplete. The mixture was concentrated to give 22e-int.

Compound 22f-int: To 2,6-dichlorobenzoic acid (175.13 mg, 916.88 umol)in DMF (5 mL) was added EDCI (190.41 mg, 993.29 umol) and HOBt (103.24mg, 764.07 umol); this mixture was stirred 0.5 h. Compound 22e-int (280mg, 764.07 umol) and Et₃N (193.29 mg, 1.91 mmol, 264.78 uL) were addedto the mixture and stirred at 25° C. for 2 hrs. LCMS showed the reactionwas complete. The mixture was diluted with H₂O (10 mL) and extractedwith ethyl acetate (20 mL×2). The combined organic phases were washedwith brine (20 mL×5), dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by prep-TLC (PE:EtOAc=1:1) togive 22f-int; LCMS (ESI+): m/z=539.2 (M+H)⁺, RT: 0.75 min.

Example 22: To 22f-int (100 mg, 185.37 umol) in THF (5 mL) was addedLiOH (13.32 mg, 556.12 umol) and H₂O (2 mL), then the mixture wasstirred at 40° C. for 12 hrs. After this time LCMS showed the reactionwas complete. The mixture was concentrated then purified by prep-HPLC togive Example 22.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 12%; at10.5 min: 34%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.63 (d, J=7.2 Hz, 1H), 7.32-7.36(m, 3H), 7.17 (d, J=8.4 Hz, 2H), 6.83 (d, J=7.5 Hz, 1H), 6.50 (d, J=8.4Hz, 2H), 4.81 (br s, 1H), 4.16-4.23 (m, 2H), 3.90 (br d, J=2.8 Hz, 2H),3.47-3.53 (m, 2H), 3.27-3.28 (m, 1H), 3.17 (dd, J=14.0, 5.52 Hz, 1H),2.92 (dd, J=14.2, 9.2 Hz, 1H), 2.83 (t, J=6.4 Hz, 2H), 1.92-2.00 (m,2H); LCMS (ESI+): m/z=525.0 (M+H)⁺, RT: 2.5 min; HPLC purity: 90.5%, RT:6.2 min; Chiral SFC purity: 87.3%, ee value: 74.5%, RT: 1.3 min.

Example 23 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(((1s,3R)-3-(pyridin-2-ylamino)cyclobutyl)methoxy)phenyl)propanoicacid

Compound 23a-int: See the procedure for compound 18a-int.

Compound 23b-int: To 23a-int (0.4 g, 1.09 mmol) in THF (20 mL) was addedtert-butyl ((1s,3s)-3-(hydroxymethyl)cyclobutyl)(pyridin-2-yl)carbamate(0.3 g, 1.09 mmol) and PPh₃ (0.63 mg, 2.4 mmol) at 0° C., then portionsof ADDP (0.6 g, 2.40 mmol) were added at 0° C. The mixture was stirredfor 12 hrs at 30° C. then concentrated. The crude product was purifiedby column chromatography (PE:EtOAc=5:1 to 1:1) to give 23b-int; LCMS(ESI+): m/z=628.2 (M+H)⁺, RT: 0.91 min.

Compound 23c-int: 23b-int (0.9 g) in HCl/MeOH (50 mL, 4M) was stirredfor 2 h at 15° C. The mixture was concentrated to give 23c-int; LCMS(ESI+): m/z=528.2 (M+H)⁺, RT: 0.75 min.

Example 23: To 23c-int (0.4 g) in THF (10 mL)/H₂O (10 mL) was addedLiOH·H₂O (0.16 g, 3.78 mmol). The mixture was stirred for 2 h at 30° C.then was concentrated and purified by prep-HPLC to give Example 23.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 30%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 2.03-1.97 (m, 2H) 2.59-2.49 (m,3H) 3.21 (t, J=10.4 Hz, 2H) 3.89 (d, J=5.2 Hz, 3H) 5.12-5.07 (m, 1H)5.42 (s, 1H) 6.38 (d, J=7.6 Hz, 1H) 6.69-6.63 (m, 2H) 6.77 (d, J=8.8 Hz,2H) 7.15 (d, J=8.8 Hz, 2H) 7.28-7.22 (m, 3H) 7.79-7.74 (m, 2H) 9.67 (s,1H); LCMS (ESI+): m/z=514.0 (M+H)⁺, RT: 2.2 min; HPLC purity: 95.3%, RT:6.2 min; Chiral SFC purity: 100%, ee value: 100%, RT: 3.4 min.

Example 24 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-((E)-2-((1s,4R)-4-(pyridin-2-ylamino)cyclohexyl)vinyl)phenyl)propanoicacid

Compound 24a-int: To a solution of tert-butylpyridin-2-yl((1s,4s)-4-vinylcyclohexyl)carbamate (1 g, 3.31 mmol) intoluene (15 mL) was added Pd(OAc)₂ (37.12 mg, 165.5 umol) and PPh₃(86.82 mg, 331.00 umol) under N₂, then (S)-methyl3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (2.37 g, 6.62mmol) and TEA (669.22 mg, 6.62 mmol, 916.74 uL) was added to themixture; the mixture was stirred at 70° C. under N₂ for 14 hrs. LCMSshowed the reaction was complete after this time. The mixture wasfiltered and concentrated, then partitioned between water (50 mL) andEtOAc (50 mL) then the organic layer was washed with saturated NH₄Claqueous solution (100 mL), brine (100 mL), dried over Na₂SO₄ (10 g) andconcentrated. The residue was purified by column chromatography (SiO₂,PE:EtOAc=5:1 to 1:1) to give 24a-int; ¹H NMR (400 MHz, CHLOROFORM-d): δppm 8.48 (dd, J=10.58, 4.41 Hz, 1H), 7.66-7.71 (m, 1H), 7.23 (d, J=7.94Hz, 2H), 7.12-7.18 (m, 2H), 7.00-7.06 (m, 3H), 6.25-6.35 (m, 1H),4.00-4.11 (m, 1H), 3.71-3.73 (m, 3H), 3.27 (d, J=7.06 Hz, 1H), 3.06 (br.s., 1H), 1.94-2.04 (m, 1H), 1.57-1.92 (in, 8H), 1.38-1.42 (in, 18H).

Compound 24b-int: To 24a-int (150 mg, 258.74 umol) in EtOAc (5 mL) wasadded HCl/EtOAc (4 M, 50 mL); the mixture was stirred at 20° C. for 2 hafter which LCMS showed the reaction was complete. The mixture wasconcentrated under reduced pressure and the crude compound 24b-int wasused into the next step without further purification; LCMS (ESI+):m/z=380.3, (M+H)⁺, RT: 0.63 min

Compound 24c-int: To a solution of 2,6-dichlorobenzoic acid (83.05 mg,434.80 umol) in DMF (8 mL) was added HOBt (58.75 mg, 434.80 umol) andEDCI (83.35 mg, 434.8 umol); the mixture was stirred at 20° C. for 0.5hr. Compound 24b-int (150 mg, 395.27 umol) in DMF (2 mL) and TEA (120mg, 1.19 mmol, 164.37 uL) was added; the mixture was stirred at 20° C.for 5.5 hr. LCMS showed the reaction was completed. H₂O (50 mL) andEtOAc (15 mL) were added into the mixture, separated, the organic layerwas dried over Na₂SO₄ and concentrated. The residue was purified byprep-TLC (SiO₂, PE:EtOAc=1:2) to give 24c-int; LCMS (ESI+): m/z=552.3,(M+H)⁺, RT: 0.78 min.

Example 24: To a solution of 24c-int in THF (10 mL) was added LiOH·H₂O(151.9 mg, 3.62 mmol). The mixture was stirred at 60° C. for 2 hours.The reaction mixture was concentrated under reduced pressure to removesolvent. The residue was purified by prep-HPLC to give Example 24.

HPLC purification method: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 12%; atT=12 min: 45%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.87-7.90 (m, 1H), 7.80-7.82 (m,1H), 7.25-7.39 (m, 6H), 7.10-7.13 (m, 1H), 7.05 (m, 1H), 6.85-6.87 (m,1H), 6.43 (s, 1H), 6.26-6.28 (m, 1H), 4.92 (m, 1H), 3.83 (m, 1H), 3.35(m, 1H), 3.25 (m, 1H), 2.97-3.03 (m, 2H), 2.44 (m, 1H), 1.73-1.87 (m,6H); LCMS (ESI+): m/z=538.1 (M+H)⁺, RT: 2.0 min; HPLC purity: 98.7%, RT:7.0; Chiral SFC purity: 79.3%, e.e. value: 58.6%, RT: 4.53.

Example 25 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(((1s,4R)-4-(pyridin-2-ylamino)cyclohexyl)methoxy)phenyl)propanoicacid

Compound 25a-int: To a mixture of methyl 4-aminocyclohexanecarboxylate(14 g, 68.67 mmol, HCl salt) in 2-fluoropyridine (99.75 g, 1.03 mol,88.27 mL) was added DIEA (8.88 g, 68.67 mmol, 11.99 mL). The mixture wasstirred at 120° C. for 16 hr; LCMS showed the reaction was complete. Themixture was concentrated and taken up in EtOAc (200 mL) dried andconcentrated. The residue was purified by silica gel chromatography(PE:EtOAc=1:1) to give 25a-int; LCMS (ESI+): m/z=235.1 (M+H)⁺, RT: 0.63min.

Compound 25b-int: To 25a-int (2 g, 8.11 mmol), TEA (2.46 g, 24.33 mmol,3.37 mL), DMAP (99.08 mg, 811.00 umol) in DCM (20 mL) was added Boc₂O(1.95 g, 8.92 mmol, 2.05 mL). The mixture was stirred at 15° C. for 19hrs; LCMS showed the reaction was complete. The mixture was washed withH₂O, dried over Na₂SO₄ and concentrated. This material was purified bysilica gel chromatography (PE:EtOAc=1:1) to give 25b-int; ¹H NMR (400MHz, METHANOL-d₄): δ 1.37 (d, J=0.88 Hz, 9H), 1.46-1.64 (m, 4H), 1.80(br d, J=13.01 Hz, 2H), 2.17 (br d, J=13.01 Hz, 2H), 2.60 (br s, 1H),3.58 (d, J=0.88 Hz, 3H), 4.03 (td, J=11.52, 2.98 Hz, 1H), 7.14-7.39 (m,2H), 7.85 (br t, J=7.72 Hz, 1H), 8.32-8.49 (m, 1H).

Compound 25c-int: To 25b-int (1.35 g, 3.84 mmol) in THF (8 mL) was addedLiBH4 (250.91 mg, 11.52 mmol). The mixture was stirred at 50° C. for 16hr; LCMS showed the reaction was complete. The mixture was quenched byH₂O (10 mL) and EtOAc (15 mL) was poured into the mixture. The organiclayer was separated, dried over Na₂SO₄ and concentrated. The crudematerial was purified by silica gel chromatography (PE:EtOAc=1:1) togive 25c-int; LCMS (ESI+): m/z=307.1 (M+H)⁺, RT: 0.93.

Compound 25d-int: To 25c-int (350 mg, 950.54 umol), 23a-int (270 mg,837.14 umol), PPh₃ (373.98 mg, 1.43 mmol) in THF (3 mL) was added DEAD(248.32 mg, 1.43 mmol, 258.67 uL) at 0° C. The mixture was stirred at45° C. for 76 hr; LCMS showed the reaction was complete. The mixture wasconcentrated to residue and purified by silica gel chromatography(PE:EtOAc=2:1), then by HPLC to give compound 25d-int; LCMS (ESI+):m/z=656.3 (M+H)⁺, RT: 0.98 min.

Compound 25e-int: To 25d-int (130.00 mg, 142.55 umol) in DCM (5 mL) wasadded HCl/EtOAc (4 M, 1.07 mL). The mixture was stirred at 30° C. for 1hr; LCMS showed the reaction was complete. The mixture was concentratedto give 25e-int; LCMS (ESI+): m/z=556.3 (M+H)⁺, RT: 0.80 min.

Example 25: To 25e-int (80 mg, 97.14 umol) in THF (3 mL) was addedLiOH·H₂O (4.08 mg, 97.14 umol). The mixture was stirred at 50° C. for 14hrs; LCMS showed the reaction was complete. The mixture was purified byprep-HPLC to give Example 25.

HPLC purification method: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 45%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.72-7.99 (m, 2H), 7.27-7.41 (m,3H), 7.22 (d, J=8.60 Hz, 2H), 7.13 (d, J=9.26 Hz, 1H), 6.81-6.90 (m,3H), 4.87-4.93 (m, 1H), 3.81-3.93 (m, 3H), 3.22 (dd, J=14.22, 5.18 Hz,1H), 2.95 (dd, J=14.11, 9.48 Hz, 1H), 2.01 (br s, 1H), 1.74-1.89 (m,6H), 1.54-1.73 (m, 2H); LCMS (ESI+): m/z=542.1 (M+H)⁺, RT: 2.6 min; HPLCpurity: 97.9%, RT: 6.8 min; Chiral SFC purity: 79.2%, e.e. value: 68.3%,RT: 3.2 min.

Example 26 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-((2-methyl-4-(pyridin-2-ylamino)butan-2-yl)amino)phenyl)propanoicacid

Compound 26a-int: To a solution of (S)-methyl2-(2,6-dichlorobenzamido)-3-(4-nitrophenyl)propanoate (5 g, 12.59 mmol)and 3-methylbut-2-en-1-ol (3.25 g, 37.76 mmol, 3.78 mL) in EtOH (50 mL)was added Fe(AcAc)₃ (1.33 g, 3.78 mmol) and PhSiH₃ (2.72 g, 25.18 mmol);this mixture was stirred at 60° C. for 1 hr. Zn metal (16.46 g, 251.76mmol) was added, followed by HCl (10 mL); the reaction was heated at 60°C. for 1 hr. When LCMS indicated the reaction was complete, the solventwas removed by evaporation under reduced pressure. The residue waspoured into sat. NaHCO₃ (50 mL) and DCM (100 mL) and was filtered thenwashed with DCM (100 mL). The organic layer was separated and dried overNa₂SO₄ then concentrated. The crude product was purified by columnchromatography on silica gel (PE:EtOAc=2:1) to give compound 26a-int; ¹HNMR (400 MHz, CHLOROFORM-d): δ ppm 1.25-1.32 (m, 8H) 1.76 (br t, J=5.62Hz, 1H) 1.87 (br s, 2H) 3.19 (br d, J=5.51 Hz, 2H) 3.76 (s, 2H)3.86-3.98 (m, 3H) 5.08-5.20 (m, 1H) 6.28 (br d, J=7.94 Hz, 1H) 6.80 (brd, J=7.94 Hz, 2H) 7.00-7.08 (m, 2H) 7.30-7.37 (m, 3H).

Compound 26b-int: 26a-int (1 g, 2.21 mmol),4-nitro-N-(pyridin-2-yl)benzenesulfonamide (1 g, 2.21 mmol), PPh₃ (1.39g, 5.29 mmol) and DEAD (1.38 g, 7.94 mmol, 1.44 mL) in THF (100 mL) wasstirred at 0-20° C. for 12 hrs; LCMS indicated the reaction wascomplete. The mixture was evaporated and purified by prep-HPLC to give26b-int; LCMS (ESI+): m/z=714.1 (M+H)⁺, RT=0.82 min.

Example 26: 26b-int (300 mg, 419.81 umol) and mercaptoacetic acid(193.36 mg, 2.10 mmol, 143.23 uL) and LiOH (50.27 mg, 2.10 mmol) in DMF(10 mL) was stirred at 50° C. for 3 hrs; LCMS indicated the reaction wascomplete. The mixture was poured into H₂O (50 mL), washed with TBME (50mL×2) and the aqueous layer was concentrated. The crude product waspurified by prep-HPLC to give Example 26.

HPLC purification method: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; at12 min: 45%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min; Monitorwavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d): δ ppm 7.92 (t, J=7.91 Hz, 1H), 7.86 (d,J=6.65 Hz, 1H), 7.58 (d, J=8.41 Hz, 2H), 7.34-7.39 (m, 5H), 7.04 (d,J=9.03 Hz, 1H), 6.91 (t, J=6.78 Hz, 1H), 5.01 (dd, J=10.23, 4.58 Hz,1H), 3.47-3.52 (m, 2H), 3.40 (d, J=5.02 Hz, 1H), 3.07 (dd, J=14.18,10.16 Hz, 1H), 2.06-2.13 (m, 2H), 1.49 (d, J=5.40 Hz, 6H); LCMS (ESI+):m/z=515.1 (M+H)⁺, RT: 1.7 min; HPLC purity: 100%, RT: 4.1 min; ChiralSFC purity: 100%, e.e. value: 100%, RT: 2.2 min.

Example 27 Synthesis of(2S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Compound 27a-int: To the solution of pent-4-yn-1-ol (4.67 g, 55.52 mmol)in DCM (50 mL) was added imidazole (4.91 g, 72.17 mmol), then there wasadded a solution of tert-butyl-chlorodiphenylsilane (15.56 g, 56.63mmol, 14.55 mL) in DCM (30 mL) drop-wise at 0° C. The mixture wasstirred at 25° C. for 12 hrs when TLC (Petroleum ether:Ethylacetate=10:1, Rf=0.5) indicated the reaction was complete. The mixturewas poured into HCl solution (0.5N, 50 mL) diluted with H₂O (50 mL),then extracted with DCM (100 mL×2). The combined organics layers weredried over Na₂SO₄, filtered and concentrated to give compound 27a-int;¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.70 (dd, J=7.89, 1.75 Hz, 4H)7.38-7.46 (m, 6H) 3.78 (t, J=6.14 Hz, 2H) 2.37 (td, J=7.02, 2.63 Hz, 2H)1.93 (t, J=2.63 Hz, 1H) 1.76-1.84 (m, 2H) 1.09 (s, 9H).

Compound 27b-int: To a solution of compound 27a-int (17.5 g, 54.26 mmol)in THF (150 mL) was added 2-chloropyridine-3-carbonyl chloride (9.55 g,54.26 mmol) and CuI (516.69 mg, 2.71 mmol), followed by Pd(PPh₃)₂Cl₂(1.90 g, 2.71 mmol) under N₂. The mixture was cooled to 0° C., then TEAwas added (5.49 g, 54.26 mmol, 7.52 mL) under N₂. The reaction mixturewas allowed to warm to 25° C. with stirring for 12 hrs. after which TLC(Petroleum ether:Ethyl acetate=5:1, Rf=0.25) indicated the reaction wascomplete. The mixture was eluted with EtOAc (100 mL), filtered. Thefiltrate was washed with H₂O (100 mL), brine (100 mL) and dried overNa₂SO₄. The mixture was filtered and concentrated in vacuo. The residuewas purified by column chromatography on silica gel (Petroleumether:Ethyl acetate=10:1) to give compound 27b-int (16.50 g, 35.71 mmol,65.81% yield) as a yellow oil; ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.52(dd, J=4.60, 1.97 Hz, 1H), 8.22 (dd, J=7.67, 1.97 Hz, 1H), 7.65 (dd,J=7.67, 1.53 Hz, 4H), 7.32-7.41 (m, 6H) 3.78 (t, J=5.92 Hz, 2H)2.70-2.71 (m, 1H) 2.67 (t, J=7.02 Hz, 1H) 1.89 (quin, J=6.47 Hz, 2H)1.06 (s, 9H).

Compound 27c-int: A mixture of compound 27b-int (17.5 g, 37.87 mmol) and(4-methoxyphenyl)methanamine (5.20 g, 37.87 mmol, 4.91 mL) in DMF (200mL) was added K₂CO₃ (10.47 g, 75.74 mmol) at 20° C. Then the reactionmixture was stirred at 100° C. TLC (Petroleum ether:Ethyl acetate=3:1,Rf=0.2) indicated the reaction was complete after 16 hrs. The mixturewas poured into H₂O (200 mL), then extracted with EtOAc (100 mL×3). Thecombined organics were dried over Na₂SO₄, filtered and concentrated. Theresidue was purified by column chromatography on silica gel (Petroleumether:Ethyl acetate=5:1 to 1:1) to give compound 27c-int; ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 8.74 (dd, J=7.83, 1.87 Hz, 1 H) 8.69 (dd,J=4.41, 1.76 Hz, 1H) 7.59-7.65 (m, 4H) 7.32-7.45 (m, 7H) 6.91 (d, J=8.60Hz, 2H) 6.78 (d, J=8.82 Hz, 2H) 3.71-3.77 (m, 5H) 2.79-2.87 (m, 2H)1.84-1.94 (m, 2H) 1.03 (s, 9H).

Compound 27d-int: To a solution of compound 27c-int (16.50 g, 29.32mmol) in EtOH (250 mL) was added NaBH₄ (13.31 g, 351.83 mmol) inportions. The mixture was stirred at 25° C. for 12 hrs. TLC (Petroleumether:Ethyl acetate=3:1, Rf=0.25) indicated the reaction was complete.The mixture was poured into H₂O (100 mL) and concentrated in vacuum. Themixture was extracted with EtOAc (200 mL×3), then the combined organicswere washed with brine (100 mL), dried over Na₂SO₄, filtered andconcentrated in vacuo. The residue was purified by column chromatographyon silica gel (Petroleum ether:Ethyl acetate=5:1) to give compound27d-int; LCMS (ESI+): m/z=567.5 (M+H)⁺, RT: 0.899 min.

Compound 27e-int: A mixture of compound 27d-int (12.00 g, 21.17 mmol)and Pd/C (500 mg) in MeOH (60 mL) and AcOH (20.00 mL) was degassed withN₂ three times and then with H₂ three times. The mixture washydrogenated under a H₂ (50 psi) atmosphere at 40° C. for 12 hrs. TLC(Petroleum ether:Ethyl acetate=5:1, R_(f)=0.35) indicated that thereaction was complete. The mixture was filtered to remove the catalyst,then the filtrate was concentrated by distillation under vacuum. Theresidue was purified by column chromatography on silica gel (Petroleumether:Ethyl acetate=5:1) to give compound 27e-int; LCMS (ESI+):m/z=551.5 (M+H)⁺, RT=0.943 min.

Compound 27f-int: To a mixture of compound 27e-int (2 g, 3.63 mmol) inTHF (30 mL) was added TBAF (1 M, 20 mL). The mixture was stirred at 20°C. for 16 hrs, then EtOAc (50 mL) was poured into the mixture. Themixture was washed with H₂O (3×20 mL), dried over Na₂SO₄ andconcentrated to a residue. The residue was purified by prep-HPLC to givecompound 27f-int; LCMS (ESI+): m/z=313.2 (M+H)⁺, RT=0.62 min; ChiralSFC: racemate. HPLC purification method: Shimadzu LC-8A preparative HPLCsystem; Mobile phase A: TFA/H₂O=0.09% v/v; B: AcN (gradient % B at T=0:5%; at 20 min: 35%); Column: Luna C18 250×50 10u; Flow rate: 80 mL/min;Monitor wavelength: 220 & 254 nm.

Compound 27g-int: To a mixture of compound 27f-int (150 mg, 480.14umol), (S)-methyl2-(2,6-dichlorobenzamido)-3-(4-hydroxyphenyl)propanoate (176.79 mg,480.14 umol) and tributylphosphine (145.71 mg, 720.21 umol, 177.70 uL)was added ADDP (181.72 mg, 720.21 umol) at 0° C. This mixture wasstirred at 45° C. for 16 hrs whereupon the reaction was complete byLCMS. EtOAc (50 mL) was poured into the mixture and the mixture waswashed with H₂O (3×20 mL), dried over Na₂SO₄, concentrated to give aresidue. This crude product was purified by TLC (Petroleum ether:Ethylacetate=1:1) to give 27g-int; LCMS (ESI+): m/z=662.2 (M+H)⁺, RT=2.26min.

Example 27: To a mixture of 27g-int (140 mg, 211.29 umol) in DCM (3 mL)was added TFA (24.1 mg, 211.29 umol, 15.64 uL). The mixture was stirredat 30° C. for 16 hrs then the solvent was removed. The residue wasdissolved in MeCN (1.5 mL) then H₂O (1.5 mL) and HCl (1N, 633.87 umol,22.66 uL) and AcOH (neat, 422.58 umol, 24.17 uL) were added. Thismixture was stirred at 70° C. for 16 hrs, the solvent was removed andthe residue was purified by prep-HPLC to give Example 27.

HPLC purification method: Gilson 281 semi-preparative HPLC system;Mobile phase: A: TFA/H₂O=0.075% v/v; B: ACN (gradient % B at T=0: 20%;at 3.1 min: 50%); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d⁴) δ ppm 7.63-7.74 (m, 2H), 7.35 (s, 3H),7.22 (d, J=8.60 Hz, 2H) 6.71-6.92 (m, 3H), 4.90-4.92 (m, 1H), 3.96-4.11(m, 2H), 3.70 (br s, 1H), 3.13-3.25 (m, 1H), 2.78-3.00 (m, 3H),2.03-2.15 (m, 1H), 1.66-1.98 (m, 5H). LCMS (ESI+): m/z=527.7 (M+H)⁺,RT=2.273 min; HPLC purity: 98.7%, RT: 4.9 min; Chiral SFC: twodiastereomers indicated.

Example 28 Synthesis of(+/−)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid

Compound 28a-int: To a mixture of benzyl3-hydroxyazetidine-1-carboxylate (0.17 g, 0.82 mmol) in toluene (5 mL)was added NaOH/H₂O (0.79 g, 9.84 mmol, 50% purity) and TBAB (0.07 g,0.21 mmol) at 10° C. under N₂. The mixture was stirred at 10° C. for 30min, then 2-(3-chloropropyl)-2-methyl-1,3-dioxolane (0.2 g, 1.22 mmol)was added and stirred at 60° C. for 16 hrs. The desired product wasdetected by LCMS. Nine batches run in parallel at this scale werecombined together and the solvent removed. The residue was diluted withH₂O (20 mL), then extracted with EtOAc (15 mL×3). The combined organicphase was washed with brine (20 mL), dried over anhydrous Na₂SO₄ andconcentrated in vacuum. This material was purified by columnchromatography (SiO₂, Petroleum ether:Ethyl acetate=6:1˜1:1) to affordcompound 28a-int; LCMS (ESI+): m/z=336.1 (M+H)⁺, RT=0.81 min. ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 7.28-7.39 (m, 5H), 5.10 (s, 2H), 4.20-4.28(m, 1H), 4.11-4.18 (m, 2H), 3.86-3.99 (m, 6H), 3.37 (t, J=5.51 Hz, 2H),1.70 (br s, 4H), 1.32 (s, 3H).

Compound 28b-int: To a mixture of 28a-int (1.00 g, 2.98 mmol) in MeOH(20 mL) was added Pd/C (30.00 mg, 0.3 mmol, 10%) at 20° C. The mixturewas stirred at 20° C. under H₂ (15 psi) for 16 hours. TLC (PetroleumEther:Ethyl Acetate=1:1, R_(f)=0.27) showed compound 28a-int wasconsumed completely. The reaction was purged with N₂, filtered through apad of Celite® then concentrated to give compound 28b-int; ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 4.23-4.39 (m, 1H), 3.88-4.00 (m, 5H), 3.55-3.76(m, 4H), 3.36 (br t, J=5.95 Hz, 2H), 1.72 (br d, J=5.73 Hz, 4H), 1.33(s, 3H).

Compound 28c-int: To a mixture of (R)-methyl2-((tert-butoxycarbonyl)amino)-3-iodopropanoate (1.01 g, 3.06 mmol) inCH₃CN (5 mL) was added 28b-int (0.56 g, 2.78 mmol) and DIEA (0.9 g, 6.96mmol). This mixture was stirred at 70° C. for 16 hours, then LCMSindicated the desired product was present and the reaction complete. Thesolvent was removed and the residue was poured into water (20 mL) andextracted with EtOAc (15 mL×3). The combined organic phases were washedwith brine (20 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated in vacuo. The residue was purified by column chromatography(SiO₂, Petroleum ether:Ethyl acetate=6:1˜1:1) to afford compound28c-int; LCMS (ESI+): m/z=403.2 (M+H)⁺, RT=1.5 min; ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 5.38-5.47 (m, 1H), 4.17-4.24 (m, 1H), 4.00-4.08 (m,1H), 3.87-4.00 (m, 4H), 3.74 (s, 2H), 3.52-3.66 (m, 2H), 3.28-3.37 (m,2H), 2.75-3.02 (m, 4H), 1.72-1.87 (m, 4H), 1.57-1.71 (m, 4H), 1.44 (s,9H), 1.31 (s, 3H).

Compound 28d-int: To a mixture of 28c-int (0.78 g, 1.94 mmol) in acetone(20 mL) and H₂O (1 mL) was added TsOH·H₂O (73.81 mg, 0.39 mmol) at 20°C. The mixture was stirred at 20° C. for 16 hrs after which TLC(Petroleum ether:Ethyl acetate=1:2, R_(f)=0.37) indicated that 28c-intwas consumed. NaHCO₃ solution was added to adjust to pH 8; the solventwas removed. This residue was poured into water (30 mL) and extractedwith DCM (20 mL×3). The combined organic phases were washed with brine(30 mL), dried over anhydrous Na₂SO₄, filtered, concentrated andpurified by prep-TLC (Petroleum ether:Ethyl acetate=1:2, R_(f)=0.37) togive 28d-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: ACN (gradient of B: 2% at T=0 to32% at T=10 min); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 5.40 (br s, 1H), 4.21 (br s, 1H),4.03 (t, J=5.92 Hz, 1H), 3.74 (s, 3H), 3.51-3.65 (m, 2H), 3.31 (t,J=6.14 Hz, 2H), 2.75-3.01 (m, 4H), 2.51 (t, J=7.02 Hz, 2H), 2.15 (s,3H), 1.81 (q, J=6.69 Hz, 2H), 1.45 (s, 9H).

Compound 28e-int: To 28d-int (0.35 g, 0.98 mmol) and2-aminonicotinaldehyde (0.16 g, 1.27 mmol) in MeOH (3 mL) was addedL-proline (56.21 mg, 0.49 mmol) under N₂. The mixture was stirred at 80°C. for 48 hrs, then TLC (Petroleum ether:Ethyl acetate=1:2, R_(f)=0.05)showed a new product and the 28d-int was consumed completely. Thesolvent was removed to give a residue and this material was poured intowater (30 mL) then extracted with EtOAc (20 mL×3). The combined organicphases were washed with brine (15 mL), dried with anhydrous Na₂SO₄,filtered, concentrated and purified by column chromatography (Petroleumether:Ethyl acetate=1:1˜1:5). There was obtained 150 mg of 28e-int whichwas purified further by prep-HPLC to give pure 28e-int.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: ACN (gradient of B: 2% at T=0 to32% at T=10 min); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 9.27 (br s, 1H), 8.43 (br d, J=8.38Hz, 1H), 8.30 (br d, J=8.16 Hz, 1H), 7.69 (br s, 1H), 7.57 (br d, J=7.72Hz, 1H), 6.14 (br s, 1H), 4.38-4.59 (m, 3H), 3.88 (br s, 1H), 3.78 (s,3H), 3.69 (br d, J=8.38 Hz, 1H), 3.57-3.65 (m, 1H), 3.52 (br s, 2H),3.24 (br t, J=6.06 Hz, 2H), 2.15-2.26 (m, 3H), 1.43 (s, 9H); LCMS(ESI+): m/z=445.2 (M+H)⁺; RT: 1.05 min.

Compound 28f-int: To 28e-int (80.00 mg, 0.18 mmol) in MeOH (10 mL) wasadded Pd/C (10.00 mg, 10%) under N₂. The suspension was degassed undervacuum and purged with H₂ several times. The mixture was stirred underH₂ (50 psi) at 50° C. for 5 hours. LCMS showed the starting material wasconsumed completely and had desired MS. The reaction was purged with N₂,then filtrated through a pad of diatomaceous earth and concentrated togive 28f-int which was used directly for next step. LCMS (ESI+):m/z=449.3 (M+H)⁺; RT: 1.1 min.

Compound 28g-int:28f-int (74 mg, 0.16 mmol) in HCl/EtOAc (30 mL, 4N) wasstirred at 20° C. for 16 hrs. LCMS showed that 28g-int was present andthe reaction complete; the solvent was removed to give 28g-int, whichwas used for next step without further processing; LCMS (ESI+): m/z349.2 (M+H)⁺, RT: 0.56 min.

Compound 28h-int: To a solution of 2, 6-dichlorobenzoic acid (0.1 g,0.52 mmol) in DCM (5 mL) was added DMF (3.83 mg, 52.35 umol) at 0° C.under N₂, then oxalyl dichloride (0.20 g, 1.57 mmol) was added drop-wiseat 0° C. and the reaction mixture was stirred at 0 to 20° C. for 2hours. TLC (Petroleum ether:Ethyl acetate=5:1, R_(f)=0.77) showed thestarting material was consumed completely. And the solvent was removedto give 2,6-dichlorobenzoyl chloride (0.11 g, 0.37 mmol, 70% yield)which was used for next step directly. To 28g-int (65 mg, 0.17 mmol, HClsalt) and DIEA (87.3 mg, 0.68 mmol) in DCM (10 mL), was added drop-wisea solution of 2,6-dichlorobenzoyl chloride (88.43 mg, 0.42 mmol) in DCM(5 mL) at 0° C. under N₂. The reaction mixture was stirred at 0-20° C.for 16 hrs after which LCMS indicated that 28h-int was present and28g-int was consumed. The solvent was removed and the residue waspurified by prep-HPLC to give pure 28h-int; LCMS (ESI+): m/z 521.3(M+H)⁺, RT: 1.1 min.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase: A: TFA/H₂O=0.075% v/v; B: ACN (gradient of B: 20% at T=0to 40% at T=12 min); Column: YMC-Actus Triart C18 150×30 5u; Flow rate:20 mL/min; Monitor wavelength: 220 & 254 nm.

Example 28: To 28h-int (10 mg, 19.18 umol) in THF (3 mL) and H₂O (1 mL)was added LiOH·H₂O (2.41 mg, 57.54 umol) at 20° C. and this mixture wasstirred at 20° C. for 2 hours. LCMS showed the reaction was complete,then 1N HCl was added to adjust the solution to pH 7 and the solvent wasremoved and the residue was purified by prep-HPLC to give Example 28.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase: A: TFA/H₂O=0.075% v/v; B: ACN (gradient of B: 15% at T=0to 40% at T=12 min); Column: YMC-Actus Triart C18 150×30 5u; Flow rate:25 mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d4) δ ppm 7.58 (d, J=7.28 Hz, 1H), 7.39-7.49(m, 3H), 6.64 (d, J=7.50 Hz, 1H), 4.72-4.77 (m, 1H), 4.57 (br dd,J=10.69, 5.40 Hz, 2H), 4.38-4.46 (m, 1H), 4.19 (br dd, J=10.03, 4.30 Hz,2H), 3.79 (dd, J=13.01, 7.50 Hz, 1H), 3.63 (dd, J=12.79, 5.29 Hz, 1H),3.54 (t, J=5.95 Hz, 2H), 3.45-3.51 (m, 2H), 2.78-2.87 (m, 4H), 1.91-2.04(m, 4H); LCMS (ESI+): m/z 506.9 (M+H)⁺, RT: 2.1 min; HPLC purity: 97.5%,RT: 4.8 min; Chiral SFC purity: 51.8%, e.e.: 3.7%, RT: 3.9 min.

Example 29 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoicacid trifluoroacetate

Compound 29a-int. To a stirred solution 4-iodobenzyl bromide (800 mg,2.69 mmol) in 8.0 mL dry DMF cooled to 0° C. in an ice bath was addedtert-butyl7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(12H)-carboxylate (825mg, 2.96 mmol), followed by sodium hydride (60% in mineral oil, 162 mg,4.04 mmol) and the reaction stirred at ambient temperature for 1 hour.The reaction mixture was diluted with water, extracted into diethylether, and the organics pooled and washed with brine, dried over sodiumsulfate, filtered, concentrated and purified over silica eluted with0-40% ethyl acetate in hexane to afford the compound 29a-int. ¹H NMR(400 MHz, DMSO-d₆) δ=7.68 (d, J=8.2 Hz, 2H), 7.41 (d, J=7.7 Hz, 1H),7.09 (d, J=8.3 Hz, 2H), 6.93 (d, J=7.5 Hz, 1H), 4.44 (s, 2H), 3.74 (t,J=6.9 Hz, 2H), 3.64-3.58 (m, 2H), 2.89 (t, J=7.0 Hz, 2H), 2.68 (t, J=6.6Hz, 2H), 1.80 (quin, J=6.3 Hz, 2H), 1.38 (s, 9H).

Compound 29b-int. To a sealed vial with a stir bar and zinc metal (140mg, 2.15 mmol) in 1 mL dry DMF under argon was added TMS-Cl (0.045 mL,0.354 mmol). The reaction was then heated to 50° C. for 15 min. Thereaction was allowed to cool to ambient temperature, stirring stoppedsuch that zinc dust settled, and the solvent was withdrawn by syringe.The zinc residue was washed 2×0.500 mL dry DMF using a syringe tointroduce and withdraw the solvent from the vial. After two washes, thesupernatant was clear. To the activated zinc, Fmoc-iodoalanine methylester (228 mg, 0.506 mmol) in 1.5 mL dry DMF was added at once, and themixture stirred and heated at 55° C. for 15 minutes. A separate solution29a-int (250 mg, 0.506 mmol) and palladium dichloridebistriphenylphosphine (10.7 mg, 0.015 mmol) in 1 mL dry DMF wasprepared, sealed and sparged with argon for 5 minutes. The organozincwas transferred under argon to the mixture of aryl iodide and catalyst,and heated to 55° C. overnight. The reaction was then allowed to cool toambient temperature, diluted 5 ml water, extracted into 1×5 mL EtOAc,washed 3×5 ml brine, organics pooled and dried over sodium sulfate,filtered, concentrated and purified over silica 0-30% ethyl acetate inhexane to yield the compound 29b-int. ¹H NMR (400 MHz, DMSO-d₆) δ=7.87(d, J=7.8 Hz, 3H), 7.63 (t, J=6.5 Hz, 2H), 7.43-7.35 (m, 3H), 7.34-7.26(m, 2H), 7.23-7.16 (m, 4H), 7.13-7.08 (m, 1H), 6.90 (d, J=7.5 Hz, 1H),4.42 (s, 2H), 4.27-4.18 (m, 3H), 4.18-4.12 (m, 1H), 3.72 (t, J=6.9 Hz,2H), 3.62 (s, 2H), 3.61-3.56 (m, 2H), 3.03 (dd, J=4.9, 13.6 Hz, 1H),2.92-2.84 (m, 3H), 2.66 (t, J=6.6 Hz, 2H), 1.79 (quin, J=6.3 Hz, 2H),1.39 (s, 9H).

Compound 29c-int. To a stirred solution 29b-int (90 mg, 0.130 mmol) inDMF (3.38 mL) and isopropanol (0.1 mL) was added a solution of 1 M TBAFin THF (0.267 mL, 0.267 mmol) in DMF (2.77 mL). The reaction stirred atambient temperature overnight, and was then diluted with EtOAc (10 mL),washed brine (2×10 mL), dried over magnesium sulfate, filtered andconcentrated. The residue was partitioned between acetonitrile andhexanes, and the acetonitrile layer concentrated to afford the 29c-int.

Compound 29d-int. To a stirred solution 29c-int (57 mg, 121 mmol) andTEA (24.6 mg, 0.243 mmol) in 1.7 mL dry THF at 0° C. 2,6-dichlorobenzoylchloride (25.4 mg, 12.6 mmol) in 1.7 mL dry THF. The reaction wasallowed to warm to ambient temperature over 1 hr. The reaction wasdiluted with water, extracted into ethyl acetate, separated and theorganics washed with 0.1N HCl, washed with brine, dried over sodiumsulfate, filtered, concentrated and purified over silica gel eluted with0-100% ethyl acetate in hexane to afford the 29d-int.

Compound 29e-int. 29d-int (44 mg, 0.685 mmol) was stirred at ambienttemperature in 4 ml HCl solution in dioxane (3.0 mL) overnight, and thenconcentrated. The sample was thrice redissolved in methanol andconcentrated to afford 29d-int. LCMS (+ESI, calc. M+H+=542.2, obs.542.2).

Example 29. A solution of 29e-int (36 mg, 0.064 mmol) in 0.5 mL THF and0.25 mL water with lithium hydroxide monohydrate (5.85 mg, 139 mmol) wasstirred at ambient temperature for one hour. The pH of the reaction wasadjusted to pH 5-6. A white solid precipitate was formed, washed withwater, and the material purified using preparative HPLC (Mobile Phase A:0.1% TFA in H₂O, B: ACN; Flow rate: 20 ml/min; Gradient: 0 min 10% B; 5min 10% B; 20 min 95% B; 32 min 95% B; 35 min 10% B Column: PhenomenexGemini 5 micron C18 110A, 150×21.20 mm 5 micron size), followed bylyophilization to afford the Example 29 as a white solid. ¹H NMR (400MHz, METHANOL-d4) δ=7.80 (s, 1H), 7.68 (br s, 1H), 7.59 (d, J=7.4 Hz,1H), 7.36-7.34 (m, 3H), 7.28 (d, J=7.9 Hz, 2H), 7.18 (d, J=8.0 Hz, 2H),6.64 (d, J=7.4 Hz, 1H), 4.95-4.91 (m, 2H), 4.54-4.45 (m, 2H), 3.77-3.69(m, 2H), 3.66-3.63 (m, 1H), 3.51-3.46 (m, 2H), 3.27 (br d, J=5.1 Hz,1H), 3.00 (dd, J=9.5, 14.1 Hz, 1H), 2.93 (t, J=5.9 Hz, 2H), 2.82 (t,J=6.2 Hz, 2H), 1.99-1.91 (m, 2H). LCMS (+ESI, calc. M+H+=528.1, obs.527.9).

Example 30 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)propoxy)methyl) phenyl) propanoic acid trifluoroacetate

Compound 30a-int. To a stirred solution 4-iodobenzylbromide (4.0 g, 13.5mmol) in 40 mL dry DMF was added tert-butyl((3-hydroxypropyl)pyridine-2-yl)carbamate (3.74 g, 14.8 mmol) and sodiumhydride (60% in mineral oil) (808 mg, 20.2 mmol) and the reactionstirred at ambient temperature for one hour. The reaction mixture wasdiluted with water, extracted into diethyl ether, and the organicspooled, washed with brine, dried over sodium sulfate, filtered,concentrated and purified over silica gel eluted with 0-40% ethylacetate in hexanes to provide 30a-int; ¹H NMR (400 MHz, DMSO-d6)δ=8.42-8.33 (m, 1H), 7.74 (ddd, J=2.0, 7.3, 8.3 Hz, 1H), 7.71-7.67 (m,2H), 7.52 (d, J=8.4 Hz, 1H), 7.13 (ddd, J=0.9, 4.9, 7.3 Hz, 1H), 7.08(d, J=8.4 Hz, 2H), 4.34 (s, 2H), 3.97-3.88 (m, 2H), 3.43 (t, J=6.2 Hz,2H), 1.90-1.77 (m, 2H), 1.43 (s, 9H).

Compound 30b-int. To a sealed vial with a stir bar and zinc metal (123mg, 1.89 mmol) in 0.2 mL dry DMF under argon was added TMS-Cl (0.039 mL,0.310 mmol) and the reaction was then heated to 50° C. for 15 min. Thereaction was allowed to cool to ambient temperature, stirring stoppedsuch that zinc dust settled, and the solvent was withdrawn by syringe.The zinc residue was washed 2×0.75 mL dry DMF using a syringe tointroduce and withdraw the solvent from the vial. After two washes, thesupernatant was clear. To the activated zinc, Fmoc-iodoalanine methylester (200 mg, 0.443 mmol) in 0.2 mL dry DMF was added at once, and themixture stirred and heated at 55° C. for 15 minutes. A separate solutionaryl iodide 1298.5 (208 mg, 0.443 mmol) and palladium dichloridebistriphenylphosphine (9.3 mg, 0.013 mmol) in 0.2 mL dry DMF wasprepared, sealed and sparged with argon for 5 minutes. The organozincwas transferred under argon to the mixture of aryl iodide and catalyst,and heated to 55° C. for 1 hr. The reaction was then allowed to cool toambient temperature, diluted 3 ml water, extracted into 1×2 mL EtOAc,washed 3×3 ml brine, organics pooled and dried over sodium sulfate,filtered, concentrated and purified over silica 0-30% ethyl acetate inhexane to afford 30b-int as a white solid. ¹H NMR (400 MHz, DMSO-d6)δ=8.39-8.33 (m, 1H), 7.92-7.83 (m, 3H), 7.77-7.70 (m, 1H), 7.63 (br t,J=6.5 Hz, 2H), 7.51 (br d, J=8.2 Hz, 1H), 7.40 (dt, J=4.4, 7.2 Hz, 2H),7.36-7.24 (m, 3H), 7.23-7.14 (m, 3H), 7.14-7.08 (m, 1H), 4.32 (s, 2H),4.28-4.19 (m, 3H), 4.20-4.11 (m, 1H), 3.95-3.85 (m, 2H), 3.62 (s, 3H),3.39 (br t, J=6.1 Hz, 2H), 3.08-3.00 (m, 1H), 2.92-2.84 (m, 1H),1.85-1.73 (m, 2H), 1.42 (s, 9H).

Compound 30c-int. To a stirred solution of 30b-int (80 mg, 0.120 mmol)in DMF (3.38 mL) and isopropanol (0.092 mL) was added a solution of 1 MTBAF in THF (0.246 mL, 0.246 mmol) in DMF (6.0 mL). The reaction wasstirred at ambient temperature overnight, and was then diluted withEtOAc. The organic layer was washed with water, dried over sodiumsulfate, filtered and concentrated. The residue was partitioned betweenacetonitrile and hexanes. The acetonitrile layer was washed 6× withhexanes and concentrated to afford 30c-int.

Compound 30d-int. To a stirred solution of 30c-int (53 mg, 120 mmol) andTEA (24.6 mg, 0.243 mmol) in 1.6 mL dry THF was added2,6-dichlorobenzoyl chloride (16.9 mg, 0.120 mmol) in 1.6 mL dry THF.The reaction was allowed to warm to ambient temperature over 1 hr. Thereaction was partitioned with aq. sodium bicarbonate and ethyl acetate.The organic layer was dried over sodium sulfate, filtered, andconcentrated. The crude residue was purified over 4 g silica eluted witha gradient of ethyl acetate in hexane to afford 30d-int.

Compound 30e-int. 30d-int (49 mg, 0.795 mmol) was stirred at ambienttemperature in 4 M HCl in dioxane at 40° C. for 1.5 hr. The mixture wasconcentrated, dissolved in MeOH and reconcentrated five times to affordthe crude hydrochloride salt of 30e-int.

Example 30. A solution of 30e-int (45 mg, 0.087 mmol) in 0.5 mL THF,0.25 mL methanol and 0.25 mL of water with lithium hydroxide monohydrate(11 mg, 261 mmol) was stirred at 50° C. for one hour. The pH of thereaction was adjusted to pH 5-6 and the product was extracted into DCM.The organic layer was dried over sodium sulfate, filtered, andconcentrated. The residue was purified using preparative HPLC (MobilePhase A: 0.1% TFA in H₂O, B: ACN; Flow rate: 20 ml/min; Gradient: 0 min10% B; 5 min 10% B; 20 min 95% B; 32 min 95% B; 35 min 10% B Column:Phenomenex Gemini 5 micron C18 110A, 150×21.20 mm 5 micron size),followed by lyophilization to afford Example 30. ¹H NMR (400 MHz,DMSO-d6) δ=13.25-13.01 (br s, 1H), 12.86-12.70 (br s, 1H), 9.08 (d,J=8.3 Hz, 1H), 8.66-8.49 (m, 1H), 7.92-7.87 (m, 1H), 7.84 (br t, J=7.9Hz, 1H), 7.47-7.37 (m, 3H), 7.28-7.20 (m, 3H), 6.98 (br d, J=8.9 Hz,1H), 6.82 (br t, J=6.6 Hz, 1H), 6.61-6.44 (br s, 1H), 4.71-4.62 (m, 1H),4.44 (s, 2H), 3.51 (br t, J=6.0 Hz, 2H), 3.41-3.35 (m, 2H), 3.16-3.08(m, 1H), 2.90 (br dd, J=9.7, 14.0 Hz, 1H), 1.92-1.82 (m, 2H). LCMS(+ESI, calc. M+H+=502.1, obs. 501.8).

Example 31 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-((((1s,4R)-4-(pyridin-2-ylamino)cyclohexyl)oxy) methyl)phenyl)propanoic acid trifluoroacetate

Compound 31a-int. To a stirred solution tert-butyl-L-serinate (2.5 g,12.6 mmol) and DIPEA (6.99 mL, 37.9 mmol) in 100 mL DCM at 0° C. in anice bath was added 2,6-dichlorobenzoyl chloride (1.81 mL, 12.6 mmol).The reaction was allowed to warm to ambient temperature over 1 hr. Thereaction was diluted with 100 mL 10% aqueous citric acid, separated andthe organics washed brine (1×100 mL), dried over sodium sulfate,filtered and concentrated to afford 31a-int. ¹H NMR (400 MHz, DMSO-d₆)δ=8.95 (d, J=7.9 Hz, 1H), 7.51-7.47 (m, 2H), 7.45-7.39 (m, 1H), 4.65(br. s, 1H) 4.42 (td, J=5.6, 7.9 Hz, 1H), 3.69 (d, J=5.6 Hz, 2H), 1.44(s, 9H).

Compound 31b-int. To a stirred solution of 31a-int (4.05 g, 12.1 mmol)in 50 mL DCM was added triphenylphosphine (3.81 g, 14.5 mmol) andimidazole (949 mg, 13.9 mmol), followed by iodine (3.54 g, 13.9 mmol). Abrief exotherm brought the reaction to reflux, and the orange colorquickly dissipated. After stirring 0.5 hours, the reaction was diluted1×100 mL water, organics separated and washed 1×100 mL 10% aqueouscitric acid, 1×100 mL brine, dried over sodium sulfate, filtered andconcentrated to afford a red-orange oil which was purified over silicagel eluted with 0-50% ethyl acetate in hexane to afford 31b-int. LCMS(+ESI, calc. M−tert-butyl+2H⁺=387.9, obs. 387.8; calc.M−tert-butyl+2H⁺+CH₃CN=428.9, obs. 428.8).

Compound 31c-int. To a stirred solution ofN-((1s,4s)-5-(tert-butyldiphenylsilyl)oxy)cyclohexyl)pyridine-2-amine(3.30 g, 8.20 mmol) in 33 mL of dry THF was added DMAP (100 mg, 0.820mmol), Boc anhydride (2.15 g, 9.84 mmol) and triethylamine (1.66 g, 16.4mmol) and the reaction stirred overnight at ambient temperature underargon. The reaction was concentrated and purified over silica gel elutedwith 0-25% ethyl acetate in hexane to afford 31c-int. ¹H NMR (400 MHz,DMSO-d₆) δ=8.48-8.40 (m, 1H), 7.82 (dt, J=1.9, 7.7 Hz, 1H), 7.61 (dd,J=1.9, 7.5 Hz, 1H), 7.57-7.51 (m, 4H), 7.46-7.38 (m, 6H), 7.29-7.26 (m,1H), 3.99-3.89 (m, 2H), 2.46-2.35 (m, 2H), 1.96-1.87 (m, 2H), 1.45-1.38(m, 1H), 1.35-1.34 (m, 9H), 1.34-1.31 (m, 1H), 1.00-0.98 (m, 1H),0.98-0.95 (m, 1H), 0.93-0.90 (m, 9H).

Compound 31d-int. 31c-int (4.4 g, 8.55 mmol) in 40 mL of THF under argonwas added 1.0 M TBAF solution in THF (13.2 mL, 13.2 mmol). The reactionwas heated in an oil bath at 50° C. for 24 hrs. The reaction was diluted1×100 mL water and extracted into 1×100 mL ethyl acetate. The organiclayer was washed 1×100 mL water, 1×100 mL brine, and then dried oversodium sulfate, filtered, concentrated and purified over silica geleluted with 0-50% ethyl acetate in hexanes to afford 31d-int. ¹H NMR(400 MHz, DMSO-d₆) δ=8.46 (dd, J=1.8, 4.9 Hz, 1H), 7.81 (dt, J=1.9, 7.7Hz, 1H), 7.29 (dd, J=4.9, 7.3 Hz, 1H), 7.19 (d, J=7.9 Hz, 1H), 3.97 (tt,J=3.4, 12.1 Hz, 1H), 3.75 (br d, J=2.3 Hz, 1H), 1.84-1.69 (m, 2H), 1.65(br d, J=14.0 Hz, 2H), 1.55-1.39 (m, 4H), 1.32 (s, 9H).

Compound 31e-int. To a stirred solution of 4-iodobenzyl bromide (400 mg,1.35 mmol) and 31d-int (197 mg, 0.674 mmol) in 3.5 mL of dry DMF, underargon, and cooled to 0° C. in an ice bath, was added sodium hydride (60%in mineral oil) (24.2 mg, 1.01 mmol). The reaction was stirred in thebath which was allowed to warm to ambient temperature overnight. Thereaction was quenched 1×5 mL water and extracted into 1×10 mL ethylacetate. The organic layer was washed 3×20 mL brine, dried over sodiumsulfate, filtered, and concentrated. The crude residue was purified oversilica eluted with 0-50% ethyl acetate in hexane to afford 31e-int. LCMS(+ESI, calc. M−tert-butyl+2H⁺=453.1, obs. 453.1; calc. M−Boc+2H⁺=409.1,obs. 409.0, calc. M+Na⁺=531.1, obs. 531.0).

Compound 31f-int. To a sealed vial with a stir bar and zinc metal (43.6mg, 0.670 mmol) in 0.3 mL of dry DMF under argon was added TMS-Cl (0.014mL, 0.110 mmol). The reaction was then heated to 50° C. for 15 min. Thereaction was allowed to cool to ambient temperature, and the solvent waswithdrawn by syringe. The zinc residue was washed 2×0.25 mL dry DMFusing a syringe to introduce and withdraw the solvent from the vial.After two washes, the supernatant was clear. To the activated zinc, 31b(140 mg, 0.315 mmol) in 1 mL dry DMF was added at once, and the mixturestirred and heated at 55° C. for 15 minutes. A separate solution of31e-int (80 mg, 0.157 mmol) and palladium dichloridebistriphenylphosphine (3.3 mg, 0.0047 mmol) in 1 mL dry DMF wasprepared, sealed and sparged with argon for 5 minutes. The organozincwas transferred under argon to the mixture of aryl iodide and catalyst,and heated to 55° C. for 1 hr. The reaction was then allowed to cool toambient temperature, diluted with 3 ml of water and extracted into 1×2mL EtOAc. The organic layer was washed 3×3 ml brine, dried over sodiumsulfate, filtered, concentrated and purified over silica 0-30% ethylacetate in hexane to afford 31f-int. ¹H NMR (400 MHz, DMSO-d₆)δ=9.14-9.10 (m, 1H), 8.49-8.44 (m, 1H), 7.85-7.76 (m, 1H), 7.48-7.40 (m,3H), 7.31-7.26 (m, 1H), 7.24-7.23 (m, 1H), 7.22-7.19 (m, 2H), 7.17-7.12(m, 2H), 4.66-4.56 (m, 1H), 4.33 (s, 2H), 4.09-3.98 (m, 1H), 3.08-3.02(m, 1H), 2.96-2.90 (m, 1H), 2.97-2.89 (m, 1H), 1.97-1.86 (m, 2H), 1.79(br d, J=12.8 Hz, 2H), 1.55 (br d, J=11.8 Hz, 2H), 1.45-1.39 (m, 2H),1.39-1.37 (m, 9H), 1.33 (s, 9H).

Example 31. Compound 31f-int (45 mg, 0.064 mmol) was stirred overnightin neat formic acid (1 mL). The solvent was removed under vacuum, andthe residue twice concentrated from acetonitrile (2 mL). The residue waspurified by prep. HPLC (Mobile Phase A: H₂O, B: 0.1% TFA in ACN; Flowrate: 20 ml/min; Gradient: 0 min 10% B; 5 min 10% B; 20 min 95% B; 32min 95% B; 35 min 10% B Column: Phenomenex Gemini 5 micron C18 110A,150×21.20 mm 5 micron size) and lyophilized to afford the Example 31. ¹HNMR (400 MHz, DMSO-d₆) δ=13.11 (br s, 1H), 12.77 (br s, 1H), 9.09 (d,J=8.3 Hz, 1H), 8.67 (br s, 1H), 7.95-7.75 (m, 1H), 7.51-7.33 (m, 2H),7.32-7.16 (m, 3H), 7.02 (br d, J=8.9 Hz, 1H), 6.83 (t, J=6.6 Hz, 1H),4.79-4.56 (m, 1H), 4.45 (s, 1H), 3.77 (br s, 4H), 3.68 (br s, 2H), 3.60(br s, 2H), 3.35 (br s, 1H), 3.26-3.03 (m, 1H), 2.92 (br dd, J=9.7, 14.0Hz, 1H), 2.77-2.52 (m, 1H), 2.47-2.21 (m, 1H), 2.07 (s, 1H), 1.92 (br d,J=11.1 Hz, 1H), 1.76-1.51 (m, 4H), 1.12 (br d, J=17.9 Hz, 1H), 0.85 (brs, 1H), 0.40 (br s, 1H), 0.07 (br s, 1H), −0.20 (br d, J=5.5 Hz, 1H).LCMS (+ESI, calc. M+H+=542.2, obs. 542.2).

Example 32 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(((1s,3R)-3-(pyridin-2-ylamino)cyclobutoxy)methyl)phenyl)propanoicacid trifluoroacetate

Compound 32a-int. To a solution of(1s,3s)-3-(pyridin-2-ylamino)cyclobutan-1-ol (1.00 equiv; 1.37 g, 8.34mmol) in DCM (41.1 mL) at 0° C., imidazole (2.00 equiv; 1.14 g, 16.7mmol) and tert-butyldiphenylsilyl chloride (TBDPSCl) (1.30 equiv; 2.98g, 10.8 mmol) were added and the mixture was stirred at 0° C. overnight.Then the reaction mixture was concentrated and purified by flashchromatography with 0-10% MeOH in DCM to give 32a-int. ¹H NMR (400 MHz,DMSO-d6) δ=7.93 (s, 1H), 7.90 (dd, J=1.3, 4.8 Hz, 1H), 7.62 (dd, J=1.8,7.5 Hz, 4H), 7.49-7.41 (m, 6H), 6.44 (dd, J=5.5, 6.6 Hz, 1H), 6.37 (d,J=8.4 Hz, 1H), 4.01 (quin, J=7.2 Hz, 1H), 3.75-3.61 (m, 1H), 2.64-2.54(m, 2H), 1.98-1.82 (m, 2H), 1.03-0.94 (m, 9H). LCMS (+ESI, calc.M+H+=403.21, obs. 403.6).

Compound 32b-int. To a solution of starting material 32a-int (1.00equiv; 3.30 g, 8.20 mmol), 4-(dimethylamino) pyridine (DMAP) (0.10equiv; 100 mg, 0.82 mmol), triethylamine (2.00 equiv; 1.66 g, 16.4 mmol)in THF (33 mL), Boc anhydride (1.20 equiv; 2.15 g, 9.84 mmol) was addedand the mixture was stirred at room temperature overnight under argon.The reaction mixture was concentrated and purified by flashchromatography with 0-30% ethyl acetate in hexane to give 32b-int. LCMS(+ESI, calc. M+H+=503.27, obs. M−t-butyl+2H+=447.1, M−Boc+H+=403.1).

Compound 32c-int. To a solution of starting material 32b-int (1.00equiv; 2.30 g, 4.85 mmol) in THF (23 mL), tetrabutylammonium fluoridesolution (TBAF) 1.0 M in THF (5.03 mL) was added and the mixture wasstirred for 2 hours at room temperature. The reaction mixture wasconcentrated and purified by flash chromatography with 0-50% ethylacetate in hexane to give 32c-int. LCMS (+ESI, calc. M+H+=265.15, obs.M−t-butyl+2H+=209.1, M−Boc+H+=165.1).

Compound 32d-int. To a solution of 1-(bromomethyl)-4-iodobenzene (1.00equiv; 920 mg, 3.10 mmol) in DMF (9.2 mL), starting material 32c-int(1.10 equiv; 901 mg, 3.41 mmol) and sodium hydride (1.00 equiv; 74.4 mg,3.10 mmol) were added and the mixture was stirred at room temperatureovernight. Then the reaction mixture was diluted with water andextracted with ether. The organic layer was washed with brine, driedover sodium sulphate, filtered and concentrated to obtain 32d-int. ¹HNMR (400 MHz, DMSO-d6) δ=8.52-8.40 (m, 1H), 7.82 (dt, J=2.1, 7.7 Hz,1H), 7.67 (d, J=8.2 Hz, 2H), 7.34-7.21 (m, 2H), 7.06 (d, J=8.2 Hz, 2H),4.25 (s, 2H), 4.16-4.06 (m, 1H), 3.77-3.64 (m, 1H), 2.57-2.51 (m, 2H),1.85-1.69 (m, 2H), 1.41-1.21 (m, 9H). LCMS (+ESI, calc. M+H+=481.09,obs. M−t-butyl+2H+=425.7, M−Boc+H+=381.0).

Compound 32e-int. To a mixture of zinc dust (4.26 equiv; 116 mg, 1.77mmol) and anhydrous DMF (0.2 mL) under argon, trimethyl silyl chloride(0.70 equiv; 37.0 μL, 0.291 mmol) was added. The mixture was heated to55° C. and stirred for 20 min. Then allowed the reaction mixture tosettle down, DMF was removed. The activated zinc powder was washed withanhydrous DMF under argon until it stopped giving brown color. To theactivated zinc powder, 31b-int (2.00 equiv; 370 mg, 0.833 mmol) in 200μL anhydrous DMF was added. After 5 min, the reaction mixture was heatedup to 50° C. and then allowed to cool down to room temperature for 20min. The supernatant of the above mixture was added to a solution of32d-int (1.00 equiv; 200 mg, 0.416 mmol) andbis(triphenylphosphine)palladium(II) dichloride (0.030 equiv; 8.77 mg,12.5 μmol) in anhydrous DMF (200 μL). The reaction mixture was stirredat 50° C. and monitored by TLC and LCMS. After the reaction wascompleted, the reaction mixture was partitioned with aqueous sodiumbicarbonate and ethyl acetate. The organic layer was dried over sodiumsulphate, then filtered and concentrated under vacuum. The product waspurified by flash chromatography with 0-30% ethyl acetate in hexane togive 32e-int. LCMS (+ESI, calc. M+H+=670.24, obs. 670.2,M−Boc+H+=570.2).

Example 32. A reaction mixture of 32e-int (1.00 equiv; 200 mg, 0.298mmol) and formic acid (2 mL) was stirred at 40° C. for 2 hours. Then themixture was concentrated under vacuum. Example 32 was purified byPrep-HPLC (Mobile Phase A: 0.1% TFA in H₂O, B: ACN; Flow rate: 20ml/min; Gradient: 0 min 1% B; 5 min 1% B; 18 min 65% B, 20 min 95% B, 32min 95% B, Column: Phenomenex Gemini 5 micron C18 110A, 150×21.20 mm 5micron size).

Example 32 was obtained by combining the pure fractions andlyophilizing. ¹H NMR (400 MHz, DMSO-d6) δ=12.87 (br, 1H), 12.69 (br,1H), 9.08 (br d, J=8.3 Hz, 1H), 7.91 (br d, J=5.4 Hz, 1H), 7.86-7.73 (m,1H), 7.47-7.35 (m, 4H), 7.31-7.19 (m, 3H), 6.97-6.85 (m, 2H), 6.81 (brs, 1H), 4.66 (dt, J=4.9, 8.9 Hz, 1H), 4.37 (s, 2H), 3.87-3.69 (m, 2H),3.12 (br dd, J=4.7, 14.1 Hz, 1H), 2.91 (br dd, J=9.8, 13.9 Hz, 1H),2.83-2.73 (m, 2H), 1.98-1.84 (m, 2H). LCMS (+ESI, calc. M+H+=514.12,obs. 514.1).

Example 33 Synthesis of(2S)-2-(2,6-dichlorobenzamido)-3-(4-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)phenyl)propanoicacid

Compound 33a-int. To a solution of 1-bromo-1-(4-iodophenyl)ethane (1.00equiv; 500 mg, 1.61 mmol), tert-butyl7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(12H)-carboxylate(1.00 equiv; 448 mg, 1.61 mmol), and 18-crown-6 (0.10 equiv; 42.5 mg,0.161 mmol) in DMF (1 mL) at 0° C., sodium hydride (2.00 equiv; 129 mg,3.22 mmol) was added. The reaction mixture was then heated at 55° C.After one hour, the reaction mixture was cooled to 0° C., diluted withether, quenched by cautious addition of saturated ammonium chloride.Then the mixture was poured into water, washed with brine, dried oversodium sulphate and concentrated under vacuum to give 33a-int. ¹H NMR(400 MHz, DMSO-d6) δ=7.67 (d, J=8.3 Hz, 2H), 7.40 (d, J=7.7 Hz, 1H),7.08 (d, J=8.3 Hz, 2H), 6.90 (d, J=7.7 Hz, 1H), 4.43 (q, J=6.4 Hz, 1H),3.68-3.49 (m, 4H), 2.92-2.75 (m, 2H), 2.67 (t, J=6.6 Hz, 2H), 1.85-1.72(m, 2H), 1.32 (s, 9H), 1.28 (d, J=6.5 Hz, 3H). LCMS (+ESI, calc.M+H+=509.12, obs. M−t-butyl+2H+=452.8, M−Boc+H+=409.0).

Compound 33b-int. To a mixture of zinc dust (4.5 equiv; 57.9 mg, 0.885mmol) and anhydrous DMF (0.1 mL) under argon, trimethyl silyl chloride(0.75 equiv; 18.7 μL, 0.148 mmol) was added. The mixture was heated to55° C. and stirred for 20 min. Then allowed the reaction mixture tosettle down, DMF was removed. The activated zinc powder was washed withanhydrous DMF under argon until it stopped giving brown color. To theactivated zinc powder, 31b-int (2.00 equiv; 175 mg, 0.393 mmol) in 100μL anhydrous DMF was added. After 5 min, the reaction mixture was heatedup to 50° C. and then allowed to cool down to room temperature for 20min. The supernantant of the above mixture was added to a solution of33a-int (1.00 equiv; 100 mg, 0.197 mmol) andbis(triphenylphosphine)palladium(II) dichloride (0.030 equiv; 4.14 mg,5.90 μmol) in anhydrous DMF (100 μL). The reaction mixture was stirredat 50° C. and monitored by TLC and LCMS. After the reaction wascompleted, the reaction mixture was partitioned with aqueous sodiumbicarbonate and ethyl acetate. The organic layer was dried over sodiumsulphate, then filtered and concentrated under vacuum. The product33b-int was purified by flash chromatography with 0-70% ethyl acetate inhexane. The compound was further purified by prep-HPLC (Mobile Phase A:0.1% TFA in H₂O, B: ACN; Flow rate: 20 ml/min; Gradient: 0 min 10% B; 5min 10% B; 35 min 60% B, 37 min 90% B, 47 min 90% B, 50 min 10% B. LCMS(+ESI, calc. M+H+=698.27, obs. M−t-butyl+2H+=642.2). The fractions fromthe prep run containing the desired product were combined, partiallyconcentrated, and taken onto the next step as a solution.

Example 33. The reaction mixture of 33b-int (1.00 equiv; 53 mg, 0.076mmol) and formic acid (2 mL) was stirred at 40° C. for 2 hours. Then themixture was concentrated under vacuum and purified by flashchromatography with 0-30% water in acetonitrile. Example 33 was obtainedby lyophilization. ¹H NMR (400 MHz, DMSO-d6) δ=8.97-8.58 (m, 1H),8.35-8.03 (m, 1H), 7.45-7.34 (m, 3H), 7.23 (d, J=8.0 Hz, 2H), 7.19-7.09(m, 2H), 7.01 (br d, J=7.3 Hz, 1H), 6.37-6.27 (m, 1H), 6.27-6.23 (m,1H), 4.57 (br s, 1H), 4.38 (q, J=6.4 Hz, 1H), 3.20 (br s, 2H), 3.13 (brdd, J=4.8, 13.9 Hz, 2H), 2.92 (br dd, J=9.3, 13.7 Hz, 2H), 2.71-2.61 (m,2H), 2.58 (br t, J=6.2 Hz, 2H), 1.77-1.67 (m, 2H), 1.27 (d, J=6.5 Hz,3H). LCMS (+ESI, calc. M+H+=542.15, obs. 542.1).

Example 34 Synthesis of(2S)-2-[(4-cyclopropylbenzoyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 34 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by4-cyclopropylbenzoyl chloride in the reaction with intermediate 1f-int.

m/z [M+H] for C₃₀H₃₄N₃O₄: theoretical: 500.25; found: 500.2.

¹H NMR (500 MHz, Methanol-d4) δ 7.70-7.59 (m, 2H), 7.53 (m, 1H),7.22-7.16 (m, 2H), 7.16-7.09 (m, 2H), 6.83-6.75 (m, 2H), 6.61 (d, J=7.4Hz, 1H), 4.85-4.76 (m, 1H), 4.02 (m, 2H), 3.49 (t, J=5.7 Hz, 2H), 3.28(dd, J=13.9, 5.0 Hz, 1H), 3.04 (dd, J=14.0, 9.6 Hz, 1H), 2.88 (t, J=7.5Hz, 2H), 2.81 (t, J=6.2 Hz, 2H), 2.22-2.07 (m, 2H), 2.04-1.89 (m, 3H),1.05 (m, 2H), 0.79-0.71 (m, 2H).

Example 35 Synthesis of(2S)-2-[(3,5-dichlorobenzoyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 35 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by 3,5-dichlorobenzoylchloride in the reaction with intermediate 1f-int.

m/z [M+H] for C₂₇H₂₈Cl₂N₃O₄: theoretical: 528.14; found: 528.1.

¹H NMR (500 MHz, Methanol-d4) δ 7.68 (d, J=1.9 Hz, 2H), 7.64 (t, J=1.9Hz, 1H), 7.56 (dd, J=7.4, 1.2 Hz, 1H), 7.23-7.16 (m, 2H), 6.85-6.78 (m,2H), 6.63 (d, J=7.4 Hz, 1H), 4.84-4.76 (m, 1H), 4.03 (t, J=5.8 Hz, 2H),3.54-3.46 (m, 2H), 3.30-3.26 (m, 1H), 3.01 (dd, J=14.0, 10.2 Hz, 1H),2.94-2.85 (m, 2H), 2.82 (t, J=6.2 Hz, 2H), 2.21-2.10 (m, 2H), 2.03-1.91(m, 2H).

Example 36 Synthesis of(2S)-2-[(2-chloro-5-fluoro-benzoyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 36 was prepared by the same procedure used to prepare Example 1except that benzoic acid was replaced with2-chloro-5-fluorobenzoylchloride in the reaction with 1f-int.

m/z [M+H] for C₂₇H₂₈ClFN₃O₄: theoretical: 512.17; found: 512.2.

¹H NMR (500 MHz, Methanol-d4) δ 7.58 (dd, J=7.3, 1.1 Hz, 1H), 7.45 (m,1H), 7.25-7.16 (m, 3H), 7.03 (dd, J=8.3, 3.0 Hz, 1H), 6.88-6.80 (m, 2H),6.65 (d, J=7.3 Hz, 1H), 4.83 (m, 1H), 4.05 (t, J=5.8 Hz, 2H), 3.51 (t,J=5.7 Hz, 2H), 3.32-3.23 (m, 1H), 3.00-2.91 (m, 3H), 2.83 (t, J=6.3 Hz,2H), 2.18 (m, 2H), 1.98 (m, 2H).

Example 37 Synthesis of(2S)-2-((2,6-dichlorobenzoyl)amino)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Compound 37a-int. To a mixture of methyl(2S)-2-amino-3-(3-hydroxyphenyl)propanoate hydrochloride (100. mg,0.4300 mmol) in DCM (2.1581 mL) at r. t. was added diisopropylethylamine(0.38 mL, 2.16 mmol) followed by 2,6-dichlorobenzoyl chloride (0.06 mL,0.4300 mmol) dropwise. The resulting mixture was stirred at r. t. for 1hr. The reaction was concentrated, the residue was then partitionedbetween EtOAc (5.0 mL) and 1N HCl (2.0 mL). the layers were separatedand the organic layer was washed with saturated sodium bicarbonate (2.0mL) followed by brine (2.0 mL), dried over sodium sulfate, filtered andconcentrated to give 37a-int.

Compound 37b-int. To the mixture of methyl(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-(3-hydroxyphenyl)propanoate (158.mg, 0.4300 mmol) and tert-butyl7-(3-hydroxypropyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate(100.37 mg, 0.3400 mmol) in THF (1.4303 mL) at r.t. was added ADDP(129.92 mg, 0.5100 mmol). The resulting mixture was sonicated to aiddissolving, tributylphosphine (0.13 mL, 0.5100 mmol) was added dropwiseto the reaction mixture. The newly formed mixture was stirred at r.t.for 2 hrs. TLC showed starting material still present. Additional ADDP(129.92 mg, 0.5100 mmol) was added and the reaction was heated at 60°C., and tributylphosphine (0.13 mL, 0.5100 mmol) was added dropwise tothe warm mixture. The reaction was stirred at 60° C. for another 2 hrsand then at ambient temperature for 2 days. The reaction was thendiluted with EtOAc (10.0 mL) and washed with water (2.0 mL). The organiclayer was concentrated to give a purplish solid, retreated with EtOAc(5.0 mL), mixed with silica gel, concentrated down with rotavapor,purified by combiflash (12 g silica gel, 0-50% EtOAc/Hexanes, dryloading). Desired fractions were combined and concentrated to 37b-int.m/z [M+H] for C₃₃H₃₈Cl₂N₃O₆: theoretical: 642.21; found: 642.7.

Example 37. tert-Butyl7-(3-(3-((2S)-2-((2,6-dichlorobenzoyl)amino)-3-methoxy-3-oxo-propyl)phenoxy)propyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate(85. mg, 0.1300 mmol) was treated with 4N HCl in 1,4-dioxane (1.0 mL) atr.t. for overnight. The reaction was concentrated, coevaporated withEtOAc (3×1.0 mL). The resulting residue was then dissolved in a mixtureof MeOH (2.0 mL) and water (0.8 mL) and then was treated with lithiumhydroxide (19.01 mg, 0.7900 mmol). The resulting mixture was stirred atr.t. for 1 hour before it was concentrated. The resulting residue wasthen redissolved in 1:1 AcOH:H₂O (3.0 mL), filtered and purified byreverse phase prep HPLC (50 g C18 Gold column, 10-60% ACN/H₂O with 0.1%TFA). Desired fractions were combined and frozen dried to Example 37.m/z [M+H] for C₂₇H₂₈Cl₂N₃O₄: theoretical: 528.14; found: 528.1.

¹H NMR (500 MHz, Methanol-d4) δ 7.59 (dt, J=7.4, 1.2 Hz, 1H), 7.41-7.33(m, 3H), 7.19 (dd, J=8.7, 7.5 Hz, 1H), 6.92-6.84 (m, 2H), 6.76 (ddd,J=8.4, 2.6, 1.1 Hz, 1H), 6.67 (d, J=7.4 Hz, 1H), 5.00 (dd, J=9.8, 5.1Hz, 1H), 4.09 (q, J=5.7 Hz, 2H), 3.50 (q, J=5.2 Hz, 2H), 3.31-3.25 (m,1H), 3.00 (dd, J=14.2, 9.9 Hz, 1H), 2.92 (t, J=7.5 Hz, 2H), 2.83 (t,J=6.3 Hz, 2H), 2.26-2.17 (m, 2H), 1.99-1.94 (m, 2H).

Example 38 Synthesis of(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-cis-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid

Compound 38a-int. 2-Fluoropyridine (1 g, 10 mmol),4-trans-aminocyclohexanol (1.42 g, 12.36 mmol) and triethylamine (2.15mL, 15.45 mmol) were stirred in isopropanol (5 mL) at 100° C. for sevendays. The reaction mixture was evaporated and purified by combiflashchromatography (EtOAc in Hexanes=20-100%) to give 38a-int.

Compound 38b-int. To a reaction solution of 38a-int (300 mg, 1.56 mmol),23a-int (689 mg, 1.87 mmol) and tributylphosphine (631 mg, 3.12 mmol) inTHF (10 mL) at 60° C., was added 1,1-(azodicarbonyl)dipiperidine (787mg, 3.12 mmol) portion-wise. The reaction mixture was stirred at 60° C.for two hours. It was then evaporated and purified by combiflashchromatography (EtOAc in Hexanes=20-100%) to give 38b-int. ¹H NMR (500MHz, Chloroform-d) δ 8.03 (dd, J=5.1, 1.9 Hz, 1H), 7.38 (td, J=8.7, 1.9Hz, 1H), 7.32-7.19 (m, 3H), 7.12 (d, J=10 Hz, 2H), 6.83 (d, J=10 Hz,2H), 6.61 (d, J=10 Hz, 1H), 6.52 (m, 1H), 6.37 (d, J=8.5 Hz, 1H), 5.15(m, 1H), 4.64 (d, J=8.0 Hz, 1H), 4.45 (br, 1H), 3.75 (s, 3H), 3.71 (m,1H), 3.19 (m, 2H), 2.00 (m, 2H), 1.87 (m, 2H), 1.73 (m, 4H). LCMS[M+H⁺]: 543.

Example 38. Compound 38b-int (100 mg, 0.18 mmol) and lithium hydroxide(60 mg, 2.5 mmol) were stirred in methanol (2 mL) at room temperaturefor three hours. The reaction mixture was evaporated and purified byreverse-phase combiflash chromatography (CH₃CN (0.1% TFA) in water (0.1%TFA)=10-100%) to Example 38. ¹H NMR (500 MHz, Methanol-d₄) δ 7.90 (ddd,J=8.9, 6.9, 1.7 Hz, 1H), 7.82 (dd, J=6.5, 1.6 Hz, 1H), 7.41-7.31 (m,3H), 7.26 (m, 2H), 7.07 (d, J=9.1 Hz, 1H), 6.95-6.85 (m, 3H), 4.96-4.89(m, 1H), 4.62 (br, 1H), 3.70 (p, J=7.9 Hz, 1H), 3.25 (m, 1H), 2.97 (dd,J=14.1, 9.7 Hz, 1H), 2.13 (m, 2H), 1.93-1.74 (m, 6H). LCMS [M+H⁺]: 529.

Example 39 Synthesis of(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-trans-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid

Example 39 was prepared by the same procedure used to prepare Example 38with the exception that trans-4-aminocyclohexanol was replaced bycis-4-aminocyclohexanol in the reaction with 2-fluoropyridine. ¹H NMR(500 MHz, Methanol-d₄) δ 7.90 (t, J=9 Hz, 1H), 7.83 (d, J=5 Hz, 1H),7.40-7.35 (m, 3H), 7.25 (d, J=10 Hz, 1H), 7.14 (d, J=10 Hz, 1H), 7.06(d, J=5 Hz, 1H), 6.91-6.88 (m, 2H), 6.72 (m, 1H), 4.93-4.88 (m, 1H),4.35 (m, 1H), 3.67 (m, 1H), 3.33 (m, 1H), 2.97 (m, 1H), 2.20 (m, 2H),1.63 (m, 6H). LCMS [M+H⁺]: 529.

Example 40 Synthesis of(2S)-2-(1H-indazole-6-carbonylamino)-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 40 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by1H-indazole-6-carboxylic acid in the reaction with intermediate 1f-int.¹H NMR (500 MHz, Methanol-d₄) δ 8.19 (s, 1H), 8.05 (s, 1H), 7.83 (d,J=7.5 Hz, 1H), 7.50 (d, J=7.5 Hz, 2H), 7.24 (d, J=7.5 Hz, 2H), 6.81 (d,J=7.5 Hz, 2H), 6.59 (d, J=7.2 Hz, 1H), 4.10 (t, J=3.3 Hz, 2H), 3.49 (t,J=3.5 Hz, 2H), 3.16-2.99 (m, 1H), 2.89 (t, J=3.2 Hz, 2H), 2.77 (t, J=3.0Hz, 2H), 2.22-2.08 (m, 2H), 1.98-1.85 (m, 2H); LCMS [M+H⁺]: 500.

Example 41 Synthesis of(2S)-2-[(1-methylindazole-6-carbonyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 41 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by1-methylindazole-6-carboxylic acid in the reaction with intermediate1f-int. ¹H NMR (500 MHz, Methanol-d₄) δ 8.14 (s, 1H), 8.03 (s, 1H), 7.81(d, J=7.5 Hz, 1H), 7.52 (d, J=7.5 Hz, 2H), 7.24 (d, J=7.5 Hz, 2H), 6.82(d, J=7.5 Hz, 2H), 6.61 (d, J=7.2 Hz, 1H), 4.14 (s, 3H), 4.10 (t, J=3.9Hz, 2H), 3.49 (t, J=3.5 Hz, 2H), 3.17-3.00 (m, 1H), 2.90 (t, J=3.0 Hz,2H), 2.78 (t, J=3.0 Hz, 2H), 2.22-2.06 (m, 2H), 2.02-1.86 (m, 2H); LCMS[M+H⁺]: 514.

Example 42 Synthesis of(2S)-2-(1H-indazole-5-carbonylamino)-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 42 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by1H-indazole-5-carboxylic acid in the reaction with intermediate 1f-int.¹H NMR (500 MHz, Methanol-d₄) δ 8.26 (s, 1H), 8.16 (s, 1H), 7.81 (d,J=7.3 Hz, 1H), 7.61 (d, J=5.5 Hz, 1H), 7.50 (d, J=5.4 Hz, 1H), 7.24 (d,J=7.4 Hz, 2H), 6.81 (d, J=7.4 Hz, 2H), 6.60 (d, J=7.1 Hz, 1H), 4.02 (t,J=3.8 Hz, 2H), 3.49 (t, J=3.5 Hz, 2H), 3.16-3.04 (m, 1H), 2.89 (t, J=3.0Hz, 2H), 2.77 (t, J=3.0 Hz, 2H), 2.22-2.06 (m, 2H), 2.02-1.86 (m, 2H);LCMS [M+H⁺]: 500.

Example 43 Synthesis of(2S)-2-[(1-methylindazole-5-carbonyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 43 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by1-methylindazole-5-carboxylic acid in the reaction with intermediate1f-int. ¹H NMR (500 MHz, Methanol-d₄) δ 8.24 (s, 1H), 8.12 (s, 1H), 7.84(d, J=7.3 Hz, 1H), 7.63 (d, J=5.9 Hz, 1H), 7.51 (d, J=5.7 Hz, 1H), 7.23(d, J=7.5 Hz, 2H), 6.81 (d, J=7.6 Hz, 2H), 6.61 (d, J=7.1 Hz, 1H), 4.12(s, 3H), 4.01 (t, J=3.1 Hz, 2H), 3.49 (t, J=3.5 Hz, 2H), 3.16-2.99 (m,1H), 2.89 (t, J=3.0 Hz, 2H), 2.77 (t, J=2.9 Hz, 2H), 2.22-2.06 (m, 2H),1.99-1.87 (m, 2H); LCMS [M+H⁺]: 514.

Example 44 Synthesis of(2S)-2-[(2-methylindazole-6-carbonyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 44 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by2-methylindazole-6-carboxylic acid in the reaction with intermediate1f-int. ¹H NMR (500 MHz, Methanol-d₄) δ 8.27 (s, 1H), 8.10 (s, 1H), 7.76(d, J=7.2 Hz, 1H), 7.53 (d, J=5.6 Hz, 1H), 7.42 (d, J=5.8 Hz, 1H), 7.24(d, J=7.3 Hz, 2H), 6.81 (d, J=7.2 Hz, 2H), 6.61 (d, J=7.1 Hz, 1H), 4.27(s, 3H), 4.03 (t, J=3.8 Hz, 2H), 3.48 (t, J=3.7 Hz, 2H), 3.10-3.00 (m,1H), 2.89 (t, J=3.1 Hz, 2H), 2.77 (t, J=3.0 Hz, 2H), 2.20-2.10 (m, 2H),2.00-1.90 (m, 2H); LCMS [M+H⁺]: 514.

Example 45 Synthesis of(2S)-2-[(2-methylindazole-5-carbonyl)amino]-3-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]phenyl]propanoicacid

Example 45 was prepared by the same procedure used to prepare Example 1with the exception that benzoic acid was replaced by2-methylindazole-5-carboxylic acid in the reaction with intermediate1f-int. ¹H NMR (500 MHz, Methanol-d₄) δ 8.38 (s, 1H), 8.23 (s, 1H),7.71-7.57 (m, 2H), 7.51 (d, J=6.0 Hz, 1H), 7.23 (d, J=7.5 Hz, 2H), 6.80(d, J=7.5 Hz, 2H), 6.60 (d, J=7.2 Hz, 1H), 4.26 (s, 3H), 4.02 (t, J=3.8Hz, 2H), 3.49 (t, J=3.8 Hz, 2H), 3.15-2.98 (m, 1H), 2.89 (t, J=3.0 Hz,2H), 2.77 (t, J=2.9 Hz, 2H), 2.22-2.05 (m, 2H), 2.02-1.86 (m, 2H); LCMS[M+H⁺]: 514.

Example 46 Synthesis of(2S)-2-((2,6-dichlorobenzoyl)amino)-3-(4-((1-((2-pyridylamino)methyl)cyclopropyl)methoxy)phenyl)propanoicacid

Compound 46a-int. To the mixture of 18a-int (206.59 mg, 0.56 mmol) and(1-((2-pyridylamino)methyl)cyclopropyl)methanol (100. mg, 0.56 mmol) ina mixture of DMF (0.5 mL) and THF (2.5 mL) at r.t. was addedtributylphosphine (0.28 mL, 1.12 mmol) followed by ADDP (283.13 mg, 1.12mmol) slowly. The resulting mixture was then heated at 60° C. for 2 hrs.The reaction was cooled to room temperature and diluted with EtOAc (10mL). The mixture was then mixed with silica gel, concentrated, purifiedby combiflash (dry load, 0-100% EtOAc/Hexanes). Desired fractions werecombined and concentrated to give 46a-int. m/z [M+H] for C₂₇H₂₇C₂N₃O₄:theoretical: 528.14 Found: 528.1.

Example 46. 46a-int (42.6 mg, 0.08 mmol) (8) was dissolved in a mixtureof methanol (2 mL) and water (1.6 mL) at r.t. To this stirred mixturewas added lithium hydroxide (11.58 mg, 0.48 mmol). The resulting mixturewas stirred for 1 hr at r.t. The reaction was then concentrated,redissolved in 50% AcOH/H₂O (3.0 mL), filtered and purified by reversephase prep HPLC (C18 Gold reusable column, 30 g, 10-70% ACN/H₂O with0.1% TFA). Desired fractions were combined and frozen dried to Example46. m/z [M+H] for C₂₆H₂₅Cl₂N₃O₄: theoretical: 514.12, found: 514.1. ¹HNMR (500 MHz, Methanol-d₄) δ 7.87-7.84 (m, 1H), 7.74-7.73 (m, 1H),7.37-7.36 (m, 3H), 7.21-7.20 (m, 2H), 7.13-7.11 (m, 1H), 6.84-6.8 (m,3H), 4.83-4.81 (m, 1H), 3.9 (s, 2H), 3.55-3.48 (m, 2H), 3.23-3.19 (m,1H), 2.97-2.92 (m, 1H), 0.82-0.77 (m, 4H).

Example 47 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid

Compound 47a-int: To a solution of tert-butyl3-oxopiperazine-1-carboxylate (2 g, 10 mmol) in THF (50 mL) was addedP₂S₅ (2.25 g, 10 mmol). The reaction is stirred at 60° C. for 12 hrs.TLC (PE:EA=4:1, Rf=0.6) indicated the reaction was complete. Theprecipitate was removed by filtration and the filtrate was concentratedin vacuum to give compound 47a-int.

Compound 47b-int: A mixture of 47a-int (2 g), methyl iodide (41.8 ml)and dichloromethane (50 ml) was stirred at 20° C. for 12 hrs. Thereaction mixture was concentrated under reduced pressure and was pouredinto H₂O (20 mL). The organic layer was separated, washed with sat.NaHCO₃ (20 mL), H₂O (20 mL) and brine (20 mL) then dried over Na₂SO₄.After filtration, the solvent was removed under reduced pressure to givecompound 47b-int; ¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 4.00 (bs, 2H),3.68-3.76 (m, 2H), 3.42 (t, J=5.2 Hz, 2H), 2.33 (s, 3H), 1.46 (s, 9H).

Compound 47c-int: Methyl (2S)-2-aminopent-4-enoate (45 g, 348.41 mmol)in DCM (500 mL) was added dropwise to TEA (88.14 g, 871.03 mmol, 120.74mL) and 2,6-dichlorobenzoyl chloride (21 g, 100.26 mmol, 14.38 mL) inDCM at 20° C. The mixture was stirred at 20-40° C. for 12 hrs and waspoured into H₂O (500 mL). The organic layer was separated and washedwith 1N HCl (200 mL), sat. NaHCO₃ (200 mL), brine (200 mL) and driedover Na₂SO₄. The solvent was removed by evaporation under reducedpressure and dried in vacuo to give 47c-int.

Compound 47d-int: To a mixture of compound 47c-int (13.3 g, 44.02 mmol)and hept-6-en-1-ol (5.03 g, 44.02 mmol) in DCM (1.2 L) was added theGrubbs II catalyst (5.61 g, 6.60 mmol) in one portion at 25° C. underN₂. The mixture was stirred at 40° C. for 24 hours. LC-MS showed 43c-intwas consumed completely and one main peak with desired MS was detected.TLC (PE:EtOAc=2/1, R_(f)=0.2) indicated 47c-int was consumed completely,and one major new spot with higher polarity was detected. The reactionmixture was concentrated and purified by column chromatography (SiO₂,PE:EtOAc=10/1 to 2/1) to give 47d-int.

Compound 47e-int: To 47d-int (7 g, 18.03 mmol) and PPh₃ (4.73 g, 18.03mmol) in DCM (70 mL) was added CBr₄ (5.98 g, 18.03 mmol) in one portionat 0° C. The mixture was stirred at 25° C. for 12 hrs. LC-MS showed43d-int was consumed completely; TLC (PE:EtOAc=1/1, R_(f)=0.8) indicated43d-int was consumed; this material was evaporated then dissolved in DMFand NaN₃ (3 equivalents) added. The reaction was heated at 50° C. untilthe starting bromide was consumed; then the reaction was diluted withwater and extracted with EtOAc (3×). The combined organic extracts werewashed with water (5×) dried (Na₂SO₄) and evaporated. This material waspurified by column chromatography (SiO₂, PE:EtOAc=10/1 to 6/1) to give47e-int; ¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.21-7.38 (m, 3H),6.26-6.41 (m, 1H), 5.30-5.61 (m, 2H), 4.81-4.98 (m, 1H), 3.73-3.85 (m,3H), 3.30-3.44 (m, 2H), 2.53-2.78 (m, 1H), 1.97-2.19 (m, 3H), 1.76-1.92(m, 2H), 1.30-1.52 (m, 3H).

Compound 47f-int: To a solution of compound 47e-int (3.5 g, 8.47 mmol)in EtOAc (200 mL) was added Pd/C (350 mg). The suspension was degassedunder vacuum and purged with H₂ several times. The mixture was stirredunder H₂ (20 psi) at 25° C. for 5 hours. LC-MS showed 47e-int wasconsumed completely and one main peak with desired MS was detected. Thereaction mixture was filtered and the filter was concentrated. Theresidue was purified by prep-HPLC to give compound 47f-int.

Compound 47g-int: To compound 47f-int (200 mg, 513.72 umol) in THF (5mL) and H₂O (1 mL) was added LiOH·H₂O (43.11 mg, 1.03 mmol). The mixturewas stirred at 20° C. for 2 hours. LC-MS showed 43f-int was consumedcompletely and 47g-int was detected. The mixture was concentrated andadjusted to pH 6 with aq. HCl (1N). The mixture was concentrated to givecompound 47g-int. The crude product was used into the next step withoutfurther purification.

Compound 47h-int: To a mixture of compound 47g-int (90 mg, 239.81 umol)and 47b-int (165.71 mg, 719.43 umol) in EtOH (10 mL) was added TEA(72.80 mg, 719.43 umol, 99.73 uL). The mixture was stirred at 80° C. for12 hours. LC-MS showed ˜5% of 47b-int remained and several new peaks onLC-MS with ˜17% of 47h-int was detected. TLC (EtOAc/MeOH=10/1) indicatedsome 47b-int remained, and one major new spot with lower polarity wasdetected. The reaction mixture was concentrated and was purified byprep-TLC (SiO₂, EtOAc/MeOH=10/1) to give compound 47h-int.

Example 47: 47h-int (70.00 mg, 125.56 umol) in HCl/EtOAc (15 mL) wasstirred at 25° C. for 2 hours. LC-MS showed 47h-int was consumedcompletely and Example 47 was detected. The reaction mixture wasconcentrated and was purified by prep-HPLC to give Example 47.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 5%; atT=10 min: 35%); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.37-7.48 (m, 3H), 4.63 (dd,J=9.48, 4.63 Hz, 1H), 4.10 (br s, 2H), 3.60-3.64 (m, 2H), 3.42 (br s,2H), 3.26 (t, J=7.17 Hz, 2H), 1.90-2.00 (m, 1H), 1.79 (ddt, J=13.75,9.34, 6.86, 6.86 Hz, 1H), 1.63-1.71 (m, 2H), 1.50-1.58 (m, 2H), 1.40 (brs, 8H); LCMS (ESI+): m/z=457.2 (M+H)⁺, RT: 2.1 min; HPLC purity: 79.1%,RT: 4.8 min; Chiral SFC purity: 100%, ee value: 100%, RT: 2.6 min.

Example 48 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrooxazol-2-yl)amino)decanoicacid

Compound 48a-int: To a solution of 2-aminoethanol (6.1 g, 0.1 mol) inEtOH (250 mL) was added of K₂CO₃ (6.9 g, 50 mmol) and carbon disulfide(15.2 g, 0.2 mol). The mixture was heated to 40° C. and H₂O₂ (30% w/w,15.3 mL, 150 mmol) was slowly added over 1 hr. The reaction was thenallowed to cool to 20° C., and stirred for an additional 4 hrs. Sat.NH₄Cl (10 mL) was added and concentrated in vacuo. The mixture wasextracted with EtOAc (3×150 mL). The combined organic layers were driedwith Na₂SO₄, concentrated to give compound 48a-int, which was useddirectly for next step without any further purification.

Compound 48b-int: To a solution of 48a-int (5 g, 48 mmol) in EtOH (100mL) was added methyl iodide (14.2 g, 0.1 mol); this was stirred at 80°C. for 12 hrs. The reaction was then allowed to cool to 20° C. andconcentrated in vacuo. The mixture was poured into H₂O (50 mL),extracted with EtOAc (3×50 mL). The combined organic layers were driedwith Na₂SO₄, then concentrated to give 48b-int, which was used directlyfor next step without any further purification.

Compound 48c-int: To a mixture of compound 47f-int (130 mg, 258.27 umol)and 48b-int (60.52 mg, 516.55 umol) in EtOH (5 mL) was added TEA (78.4mg, 774.82 umol, 107.4 uL). The mixture was stirred at 80° C. for 12hrs. LCMS showed that the reactants were consumed completely and MS for48c-int was detected. TLC (EtOAc/MeOH=10/1) indicated the reaction wascompleted. The reaction mixture was concentrated and the residue waspurified by prep-TLC (SiO₂, EtOAc/MeOH=10/1) to give compound 48c-int.

Example 48: To a mixture of compound 48c-int (100 mg, 218.16 umol) inTHF (5 mL) and H₂O (1 mL) was added LiOH·H₂O (18.31 mg, 436.32 umol).The mixture was stirred at 25° C. for 2 hours. LCMS showed the majorpeak to be Example 48. The mixture was adjusted to pH 6 with aq. HCl(1N) then concentrated in vacuo. The residue was purified by prep-HPLCto give Example 48.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: 10 mM NH₄HCO₃ in H₂O; B: ACN (gradient % B at T=0: 25%;at T=12 min: 45%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.33-7.48 (m, 3H), 4.75-4.84 (m,2H), 4.63 (dd, J=9.26, 4.63 Hz, 1H), 3.84-3.95 (m, 2H), 3.24 (t, J=7.17Hz, 2H), 1.90-2.00 (m, 1H), 1.73-1.84 (m, 1H), 1.62 (br d, J=6.62 Hz,2H), 1.52 (br d, J=5.73 Hz, 2H), 1.38 (br d, J=3.31 Hz, 8H); LCMS(ESI+): m/z=444.2 (M+H)⁺, RT: 2.4 min; HPLC purity: 93.6%, RT: 4.3 min;Chiral SFC purity: 100%, ee value: 100%, RT: 2.9 min.

Example 49 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrothiazol-2-yl)amino)decanoicacid

Compound 49a-int: A solution of 2-aminoethanol (6.1 g, 0.1 mol) andchlorosulfuric acid (11.7 g, 0.1 mol) in CCl₄ (100 mL) was stirred at25° C. for 12 hrs. To the mixture was added CS₂ (7.6 g, 99.85 mmol, 6.03mL) and NaOH (5 g) in EtOH/H₂O (20 mL/10 mL) in one portion at 25° C.This mixture was stirred at 40° C. for an additional 4 hrs. Saturatedaqueous NH₄Cl (10 mL) was added and then the solution was concentrated.The mixture was extracted with EtOAc (3×150 mL). The combined organiclayers were dried with Na₂SO₄, and concentrated in vacuo to give49a-int. This was used directly for next step without any furtherpurification.

Compound 49b-int: To a solution of 49a-int (5 g, 48 mmol) in EtOH (100mL) was added Mel (14.2 g, 0.1 mol); this was stirred at 80° C. for 12hrs. The reaction was allowed to cool to 20° C. and concentrated. Themixture was poured into H₂O (50 mL), extracted with EtOAc (3×50 mL). Thecombined organic layers were dried with Na₂SO₄ and concentrated to give49b-int which was used directly for next step without any furtherpurification.

Compound 49c-int: To a solution of compound 47f-int (70 mg, 0.16 mmol)in EtOH (1 mL) was added compound 49b-int (21 mg, 0.16 mmol). Themixture was stirred for 1 hr at 80° C. The mixture was concentrated andwas purified by Prep-TLC (DCM:MeOH=10:1) to give 49c-int.

Example 49: To a solution of 49c-int (35 mg, 66.74 umol) in THF (1mL)/H₂O (1 mL) was added LiOH·H₂O (2.80 mg, 66.74 umol). The mixture wasstirred for 2 h at 20° C. then was concentrated and purified byPrep-HPLC to give Example 49.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: 10 mM NH₄HCO₃ in H₂O; B: AcN (gradient % B at T=0: 30%;at T=12 min: 50%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 1.84-1.80 (m, 4H) 2.96-2.90 (m, 1H)3.32-3.17 (m, 1H) 3.54-3.52 (m, 2H) 3.60-3.56 (m, 2H) 4.01-3.97 (m, 4H)4.87-4.85 (m, 1H) 6.81 (d, J=8.8 Hz, 2H) 7.20 (d, J=8.8 Hz, 2H)7.36-7.30 (m, 3H); LCMS (ESI+): m/z=460.3 (M+H)⁺, RT: 2.4 min; HPLCpurity: 95.1%, RT: 4.3 min; Chiral SFC purity: 97.5%, ee value: 95%, RT:2.9 min.

Example 50 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)decanoicacid

Compound 50a-int: A mixture of isothiocyanatomethane (7.3 g, 0.1 mol),methyl glycinate hydrochloride (12.5 g, 0.1 mol), and TEA (14 mL, 0.1mol) in EtOH (100 mL) was heated to 80° C. for 14 hours. After coolingto ambient temperature, the solvent was removed under reduced pressure.The residue was crystallized from EtOH (20 mL) to give 50a-int.

Compound 50b-int: To a mixture of 50a-int (1 g, 7.68 mmol) in MeCN (10mL) was added Mel (1.64 g, 11.52 mmol, 717.17 uL) at 25° C. The mixturewas stirred at 40° C. for 12 hrs. LC-MS showed 50a-int was consumed and50b-int was detected. TLC (PE:EtOAc=1/1, R_(f)=0.3) indicated thereaction was complete. The reaction mixture was concentrated in vacuoand the residue was purified by column chromatography (SiO₂,PE:EtOAc=10/1 to 3/1) to give 50b-int; ¹H NMR (400 MHz, CHLOROFORM-d): δppm 4.14 (s, 2H), 3.04-3.10 (m, 3H), 2.57 (s, 3H).

Compound 50c-int: A solution of 47f-int (100 mg, 256.86 umol) and50b-int (48.15 mg, 333.92 umol) in pyridine (3 mL) under microwave wasstirred at 120° C. for 3 hr. LCMS showed that the desired product wasdetected. The solvent was removed in vacuum and the residue was purifiedby prep-TLC (DCM:MeOH=10:1, R_(f)=0.4) to give 50c-int; this product wasused directly in the next step; LCMS (ESI+): m/z 485.1 (M+H)⁺, RT: 0.71min.

Example 50: A solution of 50c-int (60 mg, 123.61 umol), HCl (0.1 mL,2.5N, 247.22 umol) and AcOH (7.42 mg, 123.61 umol) in H₂O (3 mL) wasstirred at 70° C. for 10 hrs. LCMS showed that Example 50 was detected.The reaction mixture was purified by prep-HPLC to give Example 50.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 15%; atT=15 min: 45%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.35-7.46 (m, 3H), 4.64 (dd,J=9.48, 4.63 Hz, 1H), 4.21 (s, 2H), 3.38 (t, J=7.39 Hz, 2H), 3.15 (s,3H), 1.90-2.01 (m, 1H), 1.75-1.86 (m, 1H), 1.66-1.75 (m, 2H), 1.49-1.58(m, 2H), 1.41 (br s, 8H); LCMS (ESI+): m/z 471.0 (M+H)⁺, RT: 2.4 min;HPLC purity: 87.1%, RT: 3.9 min; Chiral SFC purity: 96.3%, ee value:92.6%, RT: 4.0 min.

Example 51 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)decanoicacid

Compound 51a-int: To a mixture of 3-aminopropan-1-ol (5 g, 66.57 mmol,5.15 mL) and TEA (6.74 g, 66.57 mmol, 9.23 mL) in MeOH (66 mL) was addedCS₂ (7.6 g, 99.85 mmol, 6.03 mL) in one portion at 0° C. The mixture wasstirred at 20° C. for 0.5 hrs. 30% H₂O₂ (15.09 g, 133.14 mmol, 12.79 mL)was added at such a rate that the solvent was at reflux. The reactionmixture was then cooled to 20° C., filtered and concentrated underreduced pressure. NaOH solution (80 mL, 1N) was added to free the TEAthat was subsequently removed in vacuo. The mixture was neutralized withaqueous HCl (5N) and the aqueous phase was extracted with ethyl acetate(100 mL×5). The combined organic phase was dried with anhydrous Na₂SO₄,filtered and concentrated in vacuum to give 51a-int, which was used intothe next step without further purification.

Compound 51b-int: To a mixture of 51a-int (2 g, 17.07 mmol) in EtOH (6mL) was added CH₃I (3.15 g, 22.19 mmol, 1.38 mL) in one portion at 20°C. The mixture was stirred at 90° C. for 1 hour. TLC (Petroleumether/Ethyl acetate=1/1, R_(f)=0.8) indicated the reaction was complete.The mixture was concentrated and the residue was purified by columnchromatography (SiO₂, PE:EtOAc=10/1 to 8/1) to give compound 51b-int; ¹HNMR (400 MHz, CHLOROFORM-d): δ ppm 3.41 (q, J=6.40 Hz, 2H), 3.20 (t,J=6.78 Hz, 2H), 2.33-2.39 (m, 3H), 2.06 (quin, J=6.68 Hz, 2H).

Compound 51c-int: To 51b-int (200 mg, 513.72 umol) and 47f-int (67.4 mg,513.72 umol) in dioxane (6 mL) was added TEA (155.95 mg, 1.54 mmol,213.63 uL). The mixture was stirred at 110° C. for 4 hours; LC-MS showedthe reactants were consumed and the MS of 51c-int was detected. TLC(EtOAc/MeOH=10/1, R_(f)=0.4) one major new spot was detected. Thereaction mixture was concentrated and the residue was purified byprep-TLC (EtOAc/MeOH=10/1) to give 51c-int.

Example 51: To 51c-int (100 mg, 211.69 umol) in THF (5 mL) and H₂O (2mL) was added LiOH·H₂O (17.77 mg, 423.38 umol); the mixture was stirredat 25° C. for 2 hours. LCMS showed 51c-int was consumed completely andone main peak with desired MS was detected. The mixture was concentratedand adjusted to pH 6 with aq. HCl (1N) and was concentrated in vacuum.The residue was purified by prep-HPLC to give Example 51.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: 10 mM NH₄HCO₃ in H₂O; B: AcN (gradient % B at T=0: 25%;at T=12 min: 45%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.33-7.47 (m, 3H), 4.56 (dd,J=8.27, 4.74 Hz, 1H), 3.21-3.30 (m, 6H), 1.86-2.00 (m, 3H), 1.71-1.84(m, 1H), 1.45-1.58 (m, 4H), 1.26-1.42 (m, 7H), 1.25-1.26 (m, 1H); LCMS(ESI+): m/z=458.0 (M+H)⁺, RT: 2.5 min; HPLC purity: 100%, RT: 6.5 min;Chiral SFC purity: 100%, ee value: 100%, RT: 3.0 min.

Example 52 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid

Compound 52a-int: A mixture of 2-(tert-butoxycarbonylamino)acetic acid(4.01 g, 22.92 mmol), EDCI (4.79 g, 25 mmol HOBt (3.38 g, 25 mmol) andTEA (5.27 g, 52.08 mmol) in DCM (100 mL) was stirred for 10 min, thenethyl 2-(methylamino)acetate (3.20 g, 20.83 mmol) was added, theresulting mixture was stirred at 15° C. for 12 hrs. LCMS showed thedesired MS; TLC (PE:EtOAc=1:1, R_(f)=0.35) showed a new spot. Themixture was concentrated and the residue was purified by silica columnchromatography (PE:EtOAc=2:1) to give 52a-int; ¹H NMR (400 MHz,CHLOROFORM-d): δ ppm 5.46 (br s, 1H), 4.17-4.28 (m, 2H), 4.04 (d, J=4.27Hz, 2H), 3.04 (s, 3H), 1.44-1.46 (m, 9H), 1.26-1.31 (m, 3H).

Compound 52b-int: A solution of compound 52a-int (3.9 g, 14.22 mmol) inHCl/EtOAc (60 mL) was stirred at 20° C. for 1 hr. TLC (PE:EtOAc=1:1,R_(f)=0) showed the reaction was complete; the mixture was concentratedto give the crude product compound 52b-int (3 g).

Compound 52c-int: 52b-int (1.2 g, 6.89 mmol) and K₂CO₃ (2.86 g, 20.67mmol) in EtOH (20 mL) was heated to 80° C. for 12 hrs. LCMS showed52c-int was present; then the mixture was filtered and the filtrate wasconcentrated in vacuum. The residue was dissolved in EtOAc/MeOH=10:1 (40mL). The mixture was filtered and the filtrate was concentrated invacuum to give 52c-int; ¹H NMR (400 MHz, DMSO-d₆): δ ppm 8.10 (br s,1H), 3.84 (s, 2H), 3.73 (s, 2H), 2.78 (s, 3H).

Compound 52d-int: 52c-int (1.90 g, 14.83 mmol) and Lawesson's Reagent(3.00 g, 7.42 mmol) in toluene (50 mL) was heated to 60° C. for 1 hr.LCMS showed product 52d-int; after cooling the mixture was filtered, thefilter cake was dissolved in DCM (100 mL) then filtered and the filtratewas concentrated. This was purified by silica column chromatography(DCM:MeOH=30:1) to give 52d-int.

Compound 52e-int: A mixture of compound 52d-int (570 mg, 3.95 mmol, 1.00eq), K₂CO₃ (1.09 g, 7.9 mmol) and CH₃I (1.12 g, 7.90 mmol, 491.81 uL) inCH₃CN (10 mL) was stirred at 20° C. for 12 hrs. LCMS showed 52e-int. Themixture was filtered and the filtrate was concentrated in vacuo; theresidue was purified by prep-TLC (EtOAc) to give compound 52e-int; ¹HNMR (400 MHz, CHLOROFORM-d): δ ppm 4.29 (t, J=2.82 Hz, 2H), 4.03 (t,J=2.89 Hz, 2H), 2.99 (s, 3H), 2.37 (s, 3H).

Compound 52f-int: 52e-int (200 mg, 513.72 umol) and 47f-int (81.28 mg,513.72 umol) in EtOH (5 mL) was heated to 80° C. for 12 hrs. LCMS showedthe desired product; the reaction mixture was concentrated and theresidue was purified by prep-HPLC to give 52f-int.

Example 52: 52f-int (40 mg, 80.09 umol) and LiOH·H₂O (10.08 mg, 240.27umol) in THF (2 mL)/H₂O (500 uL) was stirred at 20° C. for 12 hrs. LCMSshowed the reaction was complete. The mixture was concentrated in vacuumand the residue was purified by prep-HPLC to give Example 52.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system:Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 11%; atT=10 min: 41%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.31-7.48 (m, 3H), 4.63 (dd,J=9.48, 4.63 Hz, 1H), 4.39 (s, 2H), 4.03 (s, 2H), 3.23-3.29 (m, 2H),3.00 (s, 3H), 1.89-2.00 (m, 1H), 1.73-1.84 (m, 1H), 1.62-1.73 (m, 1H),1.68 (quin, J=7.06 Hz, 1H), 1.50-1.59 (m, 2H), 1.40 (br s, 8H); LCMS(ESI+): m/z=485.1 (M+H)⁺, RT: 2.0 min; HPLC purity: 95.4%, RT: 5.6 min;Chiral SFC purity: 100%, ee value: 100%, RT: 2.7 min.

Example 53 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid

Compound 53a-int: To N-methylethane-1,2-diamine (7.41 g, 100 mmol, 8.72mL) in EtOH (100 mL) was added dropwise diethyl oxalate (14.61 g, 100mmol, 13.65 mL) at 20° C. The mixture was stirred at 90° C. for 13 hrs.The solvent was removed under reduced pressure and dried under vacuum.The residue was recrystallized from EtOH (50 mL) to give compound53a-int.

Compound 53b-int: To a mixture of Lawesson's Reagent (3.16 g, 7.81 mmol)in dry toluene (30 mL) was added compound 53a-int (2 g, 15.6 mmol) at 0°C. The mixture was heated to 45-50° C. for 1.5 hrs and stirred at 15° C.for 3 hrs. LCMS showed the desired product. After cooling, the mixturewas filtered and the filtrate cake was dissolved in DCM (100 mL) thenstirred for 30 min. This mixture was filtered, the filtrate wasconcentrated and the residue was purified column chromatography onsilica gel to give 53b-int.

Compound 53c-int: 53b-int (2 g, 13.9 mmol), CH₃I (2.95 g, 20.8 mmol) andK₂CO₃ (2.11 g, 15.3 mmol) in CH₃CN (30 mL) was stirred at 15° C. for 12hrs. LCMS showed 53c-int was present. The mixture was filtered and thefiltrate was concentrated. The residue was dissolved in DCM:MeOH=10:1(40 mL), then filtered and the filtrate was concentrated to give53c-int; ¹H NMR (400 MHz, CHLOROFORM-d): δ ppm 3.77-3.81 (m, 2H),3.39-3.43 (m, 2H), 3.03 (s, 3H), 2.23 (s, 3H).

Compound 53d-int: 53c-int (200 mg, 513.72 umol, 1.00 eq) and 47f-int(81.28 mg, 513.72 umol) in dioxane (10 mL) was heated to 110° C. for 12hr. LCMS showed 53d-int was present; TLC (DCM:MeOH=10:1, R_(f)=0.2)showed a new spot. The mixture was concentrated and the residue waspurified by prep-TLC (DCM:MeOH=10:1) to give 53d-int.

Example 53: A mixture of compound 53d-int (100 mg, 200.23 umol) andLiOH·H₂O (8.40 mg, 200.23 umol) in THF (5 mL)/H₂O (1 mL) was stirred at20° C. for 1 hr. LCMS showed desired MS; the mixture was concentratedand the residue was purified by prep-HPLC (TFA) to give Example 53.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 25%; atT=12 min: 55%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.30-7.50 (m, 3H), 4.62 (dd,J=9.26, 4.63 Hz, 1H), 3.59-3.74 (m, 4H), 3.33 (s, 2H), 3.11 (s, 3H),1.87-2.01 (m, 1H), 1.72-1.85 (m, 1H), 1.60-1.71 (m, 2H), 1.47-1.59 (m,2H), 1.38 (br s, 8H); LCMS (ESI+): m/z=485.2 (M+H)⁺, RT: 2.4 min; HPLCpurity: 90.6%, RT: 5.8 min; Chiral SFC purity: 100%, ee value: 100%, RT:2.6 min.

Example 54 Synthesis of(S)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)decanoicacid

Compound 54a-int: To a mixture of 3-aminopropan-1-ol (5 g, 66.57 mmol,5.15 mL) in CCl₄ (15 mL) was added dropwise chlorosulfonic acid (7.76 g,66.57 mmol, 4.43 mL) through an addition funnel at 0° C. under N₂. Thiswas stirred at 15° C. for 12 hrs. The mixture was concentrated to givethe crude product, which was suspended in MeOH (40 mL), filtered,triturated with MeOH, and dried, under high vacuum to give 3-aminopropylhydrosulfate (as a white solid). To a suspension of the white solid (6g, 38.6 mmol) and CS₂ (2.8 mL, 46.4 mmol) in 50% aqueous (v/v) EtOH (18mL) at 0° C. was slowly added a solution of NaOH (3.4 g, 85 mmol) in 50%aqueous (v/v) EtOH (8 mL). The reaction was heated at reflux for 1 hourthen cooled down to 15° C., resulting in the formation of off-whitecrystals. TLC (PE:EtOAc=1/1, R_(f)=0.2) indicated 3-aminopropylhydrosulfate was consumed completely and one major new spot with lowerpolarity was detected. The off-white crystals were filtered, washed withice-cold water and dried under high vacuum to yield 54a-int. The productwas used in the next step without further purification.

Compound 54b-int: To 54a-int (2 g, 15.01 mmol) in EtOH (6 mL) was addedCH₃I (4.26 g, 30.02 mmol, 1.87 mL) in one portion at 25° C.; thismixture was stirred at 90° C. for 1 hr. TLC (PE:EtOAc=1/1, R_(f)=0.8)indicated that 54a-int was consumed completely and one major new spotwith lower polarity was detected. The mixture was filtered and washedwith EtOH (3 mL) to give compound 54b-int; ¹H NMR (400 MHz, DMSO-d₆): δppm 3.61-3.70 (m, 2H), 3.26-3.35 (m, 2H), 2.62 (s, 3H), 2.04 (br d,J=4.63 Hz, 2H).

Compound 54c-int: 54b-int (200 mg, 513.72 umol) and 43f-int (90.78 mg,616.46 umol) were taken up in pyridine (2 mL) and heated at 120° C. for5 hours in a microwave reactor. LCMS showed 54b-int was consumedcompletely and 54c-int was detected. The reaction mixture wasconcentrated and the residue was purified by prep-HPLC to give 54c-int.

Example 54: To 54c-int (65 mg, 133.07 umol) in THF (3 mL)/H₂O (1 mL) wasadded LiOH·H₂O (11.17 mg, 266.14 umol). The mixture was stirred at 25°C. for 12 hours. LCMS showed 54c-int was consumed and one main peak forExample 54 was detected. The mixture was adjusted to pH 6 with aqueousHCl (1N) then concentrated and purified by prep-HPLC to give Example 54.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: 10 mM NH₄HCO₃ in H₂O; B: AcN (gradient % B at T=0: 30%;at T=12 min: 50%); Column: YMC-Actus Triart C18 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.32-7.47 (m, 3H), 4.62 (dd,J=9.15, 4.74 Hz, 1H), 3.51 (br t, J=5.51 Hz, 2H), 3.20-3.29 (m, 4H),2.13-2.22 (m, 2H), 1.88-2.00 (m, 1H), 1.71-1.84 (m, 1H), 1.57-1.68 (m,2H), 1.48-1.56 (m, 1H), 1.48-1.49 (m, 1H), 1.38 (br s, 8H); LCMS (ESI+):m/z=474.0 (M+H)⁺, RT: 2.5 min; HPLC purity: 97.6%, RT: 6.3 min; ChiralSFC purity: 99.1%, ee value: 98.2%, RT: 3.0 min.

Example 55 Synthesis of(S)-3-(4-(4-((4-acetyl-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6-dichlorobenzamido)propanoicacid

Compound 55a-int: To a solution of piperazin-2-one (500 mg, 4.99 mmol)and TEA (606.41 mg, 5.99 mmol, 830.70 uL) in DCM (10 mL) was added Ac₂O(509.84 mg, 4.99 mmol, 467.74 uL); this was stirred at 20° C. for 12hrs. The mixture was concentrated to give crude 55a-int; ¹H NMR (400MHz, DMSO-d₆): δ ppm 3.98 (s, 2H), 3.54 (m, 2H), 3.22 (m, 1H), 3.20 (m,1H), 2.01 (s, 3H).

Compound 55b-int: To 55a-int (370 mg, 2.6 mmol) in DCM (10 mL) was addedtrimethyloxonium tetrafluoroborate (961.42 mg, 6.50 mmol); the mixturewas stirred at 20° C. for 12 hrs. TLC (PE:EtOAc=1:1, R_(f)=0.24) showeda new spot. The mixture was added to ice water (10 mL) and adjusted topH 7 with NaHCO₃ solution; this was extracted with DCM (20 mL×3). Theorganic phases were combined, dried and concentrated to give 55b-int.

Compound 55c-int: See the procedure for 18a-int.

Compound 55d-int: To 55c-int (9 g, 24.4 mmol), tert-butyl(4-hydroxybutyl)carbamate (5.09 g, 26.9 mmol) and tributylphosphane(5.93 g, 29.3 mmol, 7.24 mL) in DCM (200 mL) was added ADDP (7.4 g, 29.3mmol); this mixture was stirred at 15° C. for 12 hrs. TLC (PE:EtOAc=2:1,R_(f)=0.52) showed a new spot and LCMS confirmed that 55d-int waspresent. The mixture was concentrated and purified by silica columnchromatography (PE:EtOAc=3:1) to give 55d-int.

Compound 55e-int: A solution 55d-int (1 g, 1.85 mmol) in HCl/EtOAc (20mL) was stirred at 20° C. for 30 min. TLC (PE:EtOAc=1:1) showed thereaction was complete; the mixture was concentrated to give 55e-int (900mg).

Compound 55f-int: To a solution of compound 55e-int (370 mg, 2.6 mmol)in DCM (10 mL) was added trimethyloxonium tetrafluoroborate (961.42 mg,6.5 mmol). The mixture was stirred at 20° C. for 12 hrs. TLC(PE:EtOAc=1:1, R_(f)=0.24) showed a new product. The mixture was pouredinto ice water (10 mL) and adjusted to pH 7 with NaHCO₃ solution; thiswas extracted with DCM (20 mL×3). The combined organic phases were driedand concentrated to give 55f-int.

Example 55: 55f-int (60 mg, 141.08 umol), 51b-int (110.17 mg, 705.38umol) and TEA (28.55 mg, 282.15 umol, 39.11 uL) in EtOH (5 mL) washeated to 80° C. for 5 hrs. LCMS showed Example 55 was present then themixture was concentrated and purified by prep-HPLC (TFA) to give Example55.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 5%; atT=11.5 min: 35%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.28-7.43 (m, 3H), 7.24 (d, J=8.60Hz, 2H), 6.78 (d, J=8.38 Hz, 2H), 4.70 (br t, J=5.95 Hz, 1H), 4.58 (brs, 3H), 4.48-4.52 (m, 1H), 3.99 (br s, 2H), 3.75-3.82 (m, 2H), 3.57 (brt, J=5.40 Hz, 2H), 3.49 (br d, J=5.51 Hz, 1H), 3.14-3.22 (m, 1H),3.00-3.09 (m, 1H), 2.09-2.19 (m, 3H), 1.83 (br s, 4H); LCMS (ESI+):m/z=549.0 (M+H)⁺, RT: 2.1 min; HPLC purity: 92.0%, RT: 3.8 min; ChiralSFC purity: 100%, ee value: 100%, RT: 2.9 min.

Example 56 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 56a-int: A mixture of compound 47b-int (30 mg, 70.54 umol),55f-int (48.74 mg, 211.62 umol) and TEA (14.28 mg, 141.08 umol, 19.56uL) in EtOH (5 mL) was heated to 80° C. for 12 hrs. LCMS showed desiredproduct and the mixture was concentrated. The residue was purified byprep-HPLC to give 56a-int.

Example 56: A solution of 56a-int (27 mg, 44.44 umol) in HCl/EtOAc (5mL) was stirred at 20° C. for 2 hr when LCMS showed the reaction wascomplete. The mixture was concentrated and the residue was purified byprep-HPLC (TFA) to give Example 56.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 1%: atT=11.5 min: 35%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.34-7.38 (m, 3H), 7.22 (d, J=8.77Hz, 2H), 6.84 (d, J=8.77 Hz, 2H), 4.87-4.89 (m, 1H), 4.02 (s, 4H), 3.59(t, J=5.70 Hz, 2H), 3.32-3.38 (m, 4H), 3.22 (dd, J=14.03, 5.26 Hz, 1H),2.95 (dd, J=14.47, 9.21 Hz, 1H), 1.86 (br s, 4H); LCMS (ESI+): m/z=507.2(M+H)⁺, RT: 2.1 min; HPLC purity: 98.065%, RT: 2.7 min; Chiral SFCpurity: 100%, ee value: 100%, RT: 2.8 min.

Example 57 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 57a-int: A solution of 55e-int (200 mg, 455.24 umol, 1.00 eq)and 50b-int (65.64 mg, 455.24 umol) in pyridine (2 mL) was stirred at120° C. for 3 hrs in a microwave reactor. LCMS showed that the desiredproduct was present. The solvent was removed to give 57a-int.

Example 57: To a solution of 58a-int (80 mg, 149.42 umol) in H₂O (800uL) was added HCl (12 N, 12.45 uL) and AcOH (8.97 mg, 149.42 umol, 8.54uL). The mixture was stirred at 70° C. for 12 hrs. LC-MS showed 57a-intwas consumed completely and one main peak with desired MS for Example 57was detected. The reaction mixture was concentrated and was purified byprep-HPLC to give Example 57.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 14%; atT=10.5 min: 34%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.32-7.39 (m, 3H), 7.22 (d, J=8.60Hz, 2H), 6.82-6.85 (m, 2H), 4.87-4.89 (m, 1H), 4.22 (s, 2H), 4.00-4.05(m, 2H), 3.47 (br t, J=6.73 Hz, 2H), 3.21 (dd, J=14.22, 5.40 Hz, 1H),3.12-3.15 (m, 3H), 2.96 (dd, J=14.22, 9.15 Hz, 1H), 1.85-1.93 (m, 4H);LCMS (ESI+): m/z=521.0 (M+H)⁺, RT: 2.3 min; HPLC purity: 97.2%, RT: 5.5min; Chiral SFC: purity: 100%, ee value: 100%, RT: 2.8 min.

Example 58 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 58a-int: A mixture of 55e-int (200 mg, 455.24 umol), 52e-int(79.23 mg, 500.76 umol) and TEA (138.20 mg, 1.37 mmol, 189.31 uL) inEtOH (5 mL) was heated to 80° C. for 12 hrs. LCMS showed desired MS for58a-int; the mixture was concentrated to give 58a-int.

Example 58: 58a-int (250 mg, 455 umol) and LiOH·H₂O (38.18 mg, 910 umol)in THF (5 mL)/H₂O (1 mL) was stirred at 20° C. for 12 hrs. LCMS showedExample 58 was present; the mixture was adjusted to pH 7 with 1N HCl andconcentrated. The residue was purified by prep-HPLC to give Example 58.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 30%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.29-7.37 (m, 3H), 7.20 (d, J=8.60Hz, 2H), 6.80-6.84 (m, 2H), 4.87-4.89 (m, 1H), 4.36 (s, 2H), 4.03 (s,2H), 4.00 (s, 2H), 3.33 (br d, J=7.06 Hz, 2H), 3.20 (dd, J=14.11, 5.29Hz, 1H), 2.99 (s, 3H), 2.93 (dd, J=14.11, 9.26 Hz, 1H), 1.82-1.89 (m,4H); LCMS (ESI+): m/z=535.0 (M+H)⁺, RT: 2.3 min; HPLC purity: 96.4%, RT:7.3 min; Chiral SFC purity: 100%, ee value: 100%, RT: 2.9 min.

Example 59 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 59a-int: To 55e-int (200 mg, 420.35 umol) and 51b-int (55.15mg, 420.35 umol) in dioxane (6 mL) was added TEA (127.61 mg, 1.26 mmol,174.81 uL); the mixture was stirred at 110° C. for 4 hours. LC-MS showed55e-int was consumed completely. The reaction mixture was concentratedto give then was purified by prep-HPLC to give 59a-int.

Example 59: 59a-int (100 mg, 191.42 umol) in THF (5 mL) and H₂O (2 mL)was added LiOH·H₂O (16.06 mg, 382.84 umol) in one portion at 20° C. Themixture was stirred at 20° C. for 2 hours. LCMS showed 59a-int wasconsumed completely and one main peak with desired MS for Example 59 wasdetected. The mixture was concentrated and adjusted to pH 6 with aqueousHCl (1N). The mixture was concentrated and the residue was purified byprep-HPLC to give Example 59.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 10%; atT=12 min: 70%); Column: Luna C18 100×30 5u; Flow rate: 20 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, DMSO-d₆): δ ppm 12.69 (br s, 1H), 9.03 (br d, J=8.16Hz, 1H), 7.35-7.46 (m, 3H), 7.18 (br d, J=8.60 Hz, 2H), 6.82 (br d,J=8.60 Hz, 2H), 6.09 (br s, 1H), 4.57-4.65 (m, 1H), 3.94 (br t, J=6.06Hz, 2H), 3.23 (br t, J=6.84 Hz, 2H), 3.18 (br t, J=5.73 Hz, 2H),3.01-3.11 (m, 3H), 2.86 (br dd, J=13.67, 9.48 Hz, 1H), 1.73-1.82 (m,2H), 1.52-1.67 (m, 4H); LCMS (ESI+): m/z=508.0 (M+H)⁺, RT: 2.7 min; HPLCpurity: 100%, RT: 8.0 min; Chiral SFC: purity: 100%, ee value: 100%, RT:3.2 min.

Example 60 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 60a-int: 55e-int (200 mg, 420.35 umol) and 54b-int (74.28 mg,504.42 umol) were taken up in a microwave tube in pyridine (2 mL). Thesealed tube was heated at 120° C. for 5 hours under microwave. LC-MSshowed 55e-int was consumed completely and desired product was detected.The reaction mixture was concentrated and the residue was purified byprep-TLC (SiO₂, EtOAc:MeOH=10/1) to give 60a.

Example 60: To 60a-int (100 mg, 185.70 umol) in THF (5 mL) and H₂O (2mL) was added LiOH·H₂O (15.58 mg, 371.41 umol). The mixture was stirredat 15° C. for 2 hours. LCMS showed 60a-int was consumed completely. Themixture was concentrated and adjusted to pH 6 with aqueous HCl (1N). Themixture was concentrated and the residue was purified by prep-HPLC togive Example 60.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 19%; atT=10 min: 49%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, DMSO-d₆): δ ppm 7.31-7.39 (m, 3H), 7.22 (d, J=8.82 Hz,2H), 6.82-6.86 (m, 2H), 4.89 (d, J=5.29 Hz, 1H), 3.98-4.02 (m, 2H), 3.52(br t, J=5.40 Hz, 2H), 3.35 (br s, 2H), 3.19-3.27 (m, 3H), 2.96 (dd,J=14.11, 9.26 Hz, 1H), 2.15-2.21 (m, 2H), 1.80-1.85 (m, 3H), 1.79-1.86(m, 1H); LCMS (ESI+): m/z=524.0 (M+H)⁺, RT: 2.5 min; HPLC purity: 98.6%,RT: 6.1 min; Chiral SFC purity: 100%, ee value: 100%, RT: 3.2 min.

Example 61 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 61a-int: To 55e-int (270 mg, 0.61 mmol) in EtOH (5 mL) wasadded 48b-int (72 mg, 0.61 mmol). The mixture was stirred at 80° C. for6 hrs then concentrated. The crude product was purified by Prep-TLC(DCM:MeOH=10:1) to give 61a-int.

Example 61: To 61a-int (200 mg, 393 umol) in THF (2 mL)/H₂O (2 mL) wasadded LiOH·H₂O (16.5 mg, 393 umol). The mixture was stirred for 2 hrs at20° C., then was concentrated and purified by Prep-HPLC to give Example61.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 5%; atT=10 min: 35%); Column: Luna C18 100×30 5u; Flow rate: 25 mL/min;Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 1.84-1.75 (m, 4H) 3.01-2.95 (m, 1H)3.26-3.21 (m, 1H) 3.40-3.45 (m, 4H) 4.03-3.91 (m, 4H) 4.80-4.75 (m, 1H)6.85 (d, J=8.8 Hz, 2H) 7.24 (d, J=8.8 Hz, 2H) 7.40-7.35 (m, 3H); LCMS(ESI+): m/z=494.0 (M+H)⁺, RT: 2.4 min; HPLC purity: 91.8%, RT: 5.8 min;Chiral SFC purity: 100%, ee value: 100%, RT: 6.0 min.

Example 62 Synthesis of(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoicacid

Compound 62a-int: To 55e-int (70 mg, 0.16 mmol) in EtOH (1 mL) was added49b-int (21 mg, 0.16 mmol). The mixture was stirred for 1 h at 80° C.then concentrated. The crude product was purified by Prep-TLC(DCM:MeOH=10:1) to give 62a-int.

Example 62: To 62a-int (35 mg, 66.74 umol) in THF (1 mL)/H₂O (1 mL) wasadded LiOH·H₂O (2.8 mg, 66.74 umol); the mixture was stirred for 2 h at20° C. The reaction was concentrated and purified by Prep-HPLC to giveExample 62.

HPLC purification conditions: Gilson 281 semi-preparative HPLC system;Mobile phase A: TFA/H₂O=0.075% v/v; B: AcN (gradient % B at T=0: 20%; atT=11.5 min: 50%); Column: Boston Green ODS 150×30 5u; Flow rate: 25mL/min; Monitor wavelength: 220 & 254 nm.

¹H NMR (400 MHz, METHANOL-d₄): δ ppm 7.36-7.30 (m, 3H), 7.20 (d, J=8.8Hz, 2H), 6.81 (d, J=8.8 Hz, 2H), 4.87-4.85 (m, 1H), 4.01-3.97 (m, 4H),3.60-3.56 (m, 2H), 3.54-3.52 (m, 2H), 3.32-3.17 (m, 1H), 2.96-2.90 (m,1H), 1.84-1.80 (m, 4H); LCMS (ESI+): m/z=510.0 (M+H)⁺, RT: 2.4 min; HPLCpurity: 99.5%, RT: 5.9 min; Chiral SFC purity: 99.2%, ee value: 98.4%,RT: 3.3 min.

Example 63 (Compound 98a) Synthesis of(2S)-2-(1H-indazole-6-carbonylamino)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid

Preparation of ethyl(2S)-2-(1H-indazole-6-carbonylamino)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoate(98-a-int): Ethyl(S)-2-amino-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoatebis-HCl salt (50 mg, 0.123 mmol), 1H-indazole-6-carboxylic acid (24 mg,0.147 mmol), HATU (70 mg, 0.184 mmol) and N,N-diisopropylethylamine (75uL, 0.43 mmol) were stirred in THF (5 mL) at room temperature for twohours. The reaction mixture was evaporated and purified by combiflashchromatography (2.0 M NH₃-MeOH in DCM=0-30%) to give ethyl(2S)-2-(1H-indazole-6-carbonylamino)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoate(35 mg, 59%). LCMS [M+H⁺]: 478.3.

Preparation of 98a:(2S)-2-(1H-indazole-6-carbonylamino)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid:Ethyl(2S)-2-(1H-indazole-6-carbonylamino)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoate(35 mg, 0.073 mmol) and LiOH (50 mg) were stirred in methanol (5 mL) atroom temperature for two hours. The reaction mixture was evaporated andpurified by reserve phase combiflash chromatography (CH₃CN in water(0.1% TFA)=10-100%) to give(2S)-2-(1H-indazole-6-carbonylamino)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid (25 mg, 72%). LCMS [M+H⁺]: 450.2; Purity: 95.7%.

Example 64 (Compound 99a)(S)-2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid

Preparation of ethyl3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propanoate (99-1b-int)

Compound 99-1a-int: To a mixture of 2-aminonicotinaldehyde (50 g, 409.4mmol, 1 equivalent) in EtOH (600 mL) was added ethyl 4-oxopentanoate(59.02 g, 409.4 mmol, 58.44 mL, 1 equivalent) and L-proline (23.57 g,204.7 mmol, 0.50 equivalent). The reaction was refluxed at 80° C. for 12hrs. TLC (petroleum ether:EtOAc=0:1, R_(f)=0.5) showed that compound99-1a-int was formed. The reaction mixture was concentrated to give aresidue. The residue was purified by column chromatography (SiO₂,Petroleum ether:Ethyl acetate=3:1 to 1:1) to obtain a pure productcompound 99-1a-int (39.00 g, 169.37 mmol, 41.37% yield) as an off-whitesolid; LCMS (ESI+): m/z=231.0 (M+H)⁺, RT=0.723 min.

Compound 99-1b-int: To a solution of compound 99-1a-int (39 g, 169.37mmol, 1 equivalent) in MeOH (500 mL) was added Pd/C (12 g) under N₂. Thesuspension was degassed under vacuum and purged with H₂ several times.The mixture was stirred under H₂ (50 psi) at 50° C. for 6 hrs. TLC(Ethyl acetate, R_(f)=0.6) indicated that 1a was consumed. The catalystwas removed by filtration and washed with MeOH (2×500 mL). The mixtureconcentrated under reduced pressure to give 99-1b-int (36 g, 153.66mmol, 91% yield) as a white solid. This material was used in the nextstep without further purification.

Preparation of tert-butyl7-(3-hydroxypropyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(99-1d-int)

Compound 99-1c-int: Compound 99-1b-int (36 g, 153.66 mmol, 1 equivalent)was added to Boc₂O (300 mL) at 25° C. The reaction mixture was stirredat 50° C. for 12 hrs; after this time, the desired product was detectedby LCMS and the reaction was complete. The crude product was purified bycolumn chromatography (SiO₂, Petroleum ether:Ethyl acetate=10:1 to 1:1)to give a pure 99-1c-int (47 g, 140.55 mmol, 91% yield) as colorlessoil; LCMS (ESI+): m/z=335.2 (M+H)⁺, RT=0.641 min.

Compound 99-1d-int: To a solution of 99-1c-int (20 g, 59.81 mmol, 1equivalent) in THF (200 mL) was added LiBH₄ (2.61 g, 119.62 mmol, 2equivalents) at 0° C. The reaction was stirred at 30° C. for 30 min thenat 40° C. for 5 hrs. TLC (Ethyl acetate, R_(f)=0.5) indicated that99-1c-int was consumed. The desired product was detected by LCMS. Thereaction mixture was poured into saturated NH₄Cl (500 mL) and wasextracted with EtOAc (500 mL). The organic layer was washed with brine(200 mL), dried over solid NaSO₄ then was concentrated under vacuum. Theresidue was purified by column chromatography (SiO₂, Petroleumether:Ethyl acetate=10:1 to 1:1) to give 99-1d-int (16 g, 54.73 mmol,92% yield) as colorless oil; LCMS (ESI⁺): m/z=335.2 (M+H)⁺, RT=0.695min.

¹H NMR (400 MHz, CHLOROFORM-d) δ: 7.34 (d, J=7.45 Hz, 1H), 6.86 (d,J=7.45 Hz, 1H), 4.25 (br s, 1H), 4.19-4.33 (m, 1H), 3.75-3.82 (m, 2H),3.66-3.74 (m, 2H), 2.92 (t, J=6.58 Hz, 2H), 2.75 (t, J=6.58 Hz, 2H),1.92-1.99 (m, 4H), 1.54-1.57 (m, 1H), 1.56 (s, 8H), 1.29 (t, J=7.02 Hz,1H) ppm.

Preparation of(S)-2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)-propanoicacid

Compound 99-1e-int: To a solution of 99-1d-int (3 g, 10.26 mmol, 1equivalent) and methyl(2S)-2-(benzyloxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (4.06 g,12.31 mmol, 1.2 equivalents) in dry THF (10 mL) was added ADDP (6.47 g,25.65 mmol, 2.5 equivalents) at 0° C. under N₂. Bu₃P (5.19 g, 25.65mmol, 6.33 mL, 2.5 equivalents) was added drop-wised to the reactionmixture at 0° C. Following the addition, the reaction mixture was warmedto 20° C. and stirred for 2 hours; then it was heated to 40° C. andstirred for an additional 12 hours at this temperature. TLC (Ethylacetate:Petroleum ether=2:1, R_(f)=0.2) indicated that some 99-1d-intremained, but a new product spot was also detected. Formation of thedesired product (99-1e-int) was confirmed by LCMS. The reaction mixturewas concentrated to give crude 99-1e-int. Column chromatography (SiO₂,Petroleum ether:Ethyl acetate=10:1 to 1:1) was used to isolate 99-1e-int(3.25 g, 5.38 mmol, purity 50%); LCMS (ESI+): m/z=604.3 (M+H)⁺; RT: 2.36min.

Compound 99-1f-int: To a solution of 99-1e-int (3.00 g, 4.97 mmol, 1equivalent) in MeOH (30 mL) was added Pd/C (10%, 0.5 g). The suspensionwas degassed under vacuum and was purged with H₂ several times. Themixture was stirred under H₂ (15 psi) at 30° C. for 3 hrs. TLC (Ethylacetate, R_(f)=0.3) indicated that compound 99-1e-int was consumed; thedesired product (99-1f-int) was detected by LCMS. The reaction mixturewas filtered and concentrated under reduced pressure. The crude productwas purified by column chromatography (SiO₂, Petroleum ether:Ethylacetate=1:1 to 0:1) followed by preparative scale HPLC (basicconditions) to give 99-1f-int (1.1 g, 1.76 mmol, 33.02% yield, 75%purity) as a brown oil; LCMS (ESI⁺): m/z=470.2 (M+H)⁺; RT=0.63 min.

Preparation of 2,6-dichloro-4-(1H-imidazol-5-yl)benzoic acid

Compound 99-1g-int: A mixture of methyl2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1g, 3.02 mmol), 5-bromo-1H-imidazole (666 mg, 4.53 mmol), Pd(dppf)Cl₂(44.21 mg, 60.42 μmol), K₂CO₃ (835.11 mg, 6.04 mmol) and Boc₂O (1.32 g,6.04 mmol, 1.39 mL) in dioxane (10 mL) and H₂O (2 mL) was stirred at 90°C. for 10 hrs. After this time, the desired coupling product 99-1g-intwas detected by LCMS. The reaction mixture was diluted with water (20mL) then extracted with ethyl acetate (3×20 mL). The organic layers werecombined, then were washed with brine (30 mL) and concentrated undervacuum. The crude product was purified by chromatography on silica gel(Petroleum ether:Ethyl acetate=10:1 to 1:1, R_(f)=0.3) to give compound99-1g-int (600 mg) as an off-white solid.

Compound 99-1h-int: A solution of 99-1g-int (600 mg, 2.21 mmol, 1equivalent) and LiOH H₂O (185.46 mg, 4.42 mmol) in H₂O (2 mL) and THF(10 mL) was stirred at 100° C. for 10 hours. After this time 99-1h-intwas detected by LCMS. The reaction solution was adjusted to 5-6 pH unitswith citric acid; then the solution was evaporated under reducedpressure. The crude 99-1h-int was purified by preparative scale HPLC(TFA, Phenomenex Luna C18 250×50 mm×10 μm; mobile phase: [solution A: 10mM NH₄HCO₃ and B: AcN]; with a gradient of B %: 0%-5% over 20 min.) togive compound 99-1h-int (50 mg, 194.5 μmol) as an off-white solid.

Preparation of Example 64 (Compound 99a): tert-butyl(S)-7-(3-(4-(2-amino-3-methoxy-3-oxopropyl)phenoxy)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

Compound 99-1i-int: To a solution of 99-1h-int (24 mg, 93.36 μmol) andDMF (682.37 mg, 9.34 μmol) in DCM (20 mL) was added oxalyl chloride(59.25 mg, 466.80 μmol, 40.86 μL) at 0° C. under N₂; then this reactionwas stirred at 25° C. for 1 hour. After this time, the solvent wasremoved under vacuum to give the acyl chloride, which was used directlyin the next step.

A solution of the acyl chloride (25.72 mg, 93.35 μmol), 99-1f-int (43.83mg, 93.35 μmol) and TEA (28.34 mg, 280.05 μmol, 38.82 μL) in THF (10 mL)was stirred at 25° C. for 10 hours. The desired coupling product,99-1i-int, was detected by LCMS. The reaction mixture was diluted withwater (10 mL) then was extracted with ethyl acetate (2×10 mL). Theorganic layers were combined, were washed with brine (15 mL) andevaporated under reduced pressure to give 99-1i-int (30 mg) as a yellowoil. This material was used in the next step without futurepurification.

Example 64 (Compound 99a), tert-butyl(S)-7-(3-(4-(2-amino-3-methoxy-3-oxopropyl)phenoxy)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate:A solution of 99-1i-int (30 mg, 42.34 μmol), AcOH (2.54 mg, 42.34 umol,2.42 μL, 1 equivalent) and HCl (12 M, 10.6 μL, 3 equivalents) in H₂O (5mL) was stirred at 70° C. for 10 hrs; after this time the reaction wascomplete by LCMS. The solvent was removed under vacuum and the productwas isolated by semi-preparative scale HPLC (TFA, Luna C18 [100×30×5μ];mobile phase A: water (0.1% TFA) and mobile phase B: AcN; with agradient of B %: 15%-35% over 12 min.) to give Example 64 (Compound99a), tert-butyl(S)-7-(3-(4-(2-amino-3-methoxy-3-oxopropyl)phenoxy)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate,(5.7 mg, 9.6 μmol, 23% yield) as an off-white solid; LCMS (ESI⁺):m/z=595 (M+H)⁺, RT: 1.95 min.; HPLC purity (15 min.): 94.2%, RT: 3.31min.; chiral purity [SFC]: 100%, RT: 3.35 min.

¹H NMR (400 MHz, METHANOL-d₄) δ: 8.38 (s, 1H), 7.85 (s, 1H), 7.78 (s,1H), 7.58-7.56 (d, J=7.20 Hz, 2H), 7.23-7.21 (d, J=8.80 Hz, 2H),6.81-6.79 (d, J=8.80 Hz, 2H), 6.64-6.62 (d, J=7.2 Hz, 1H), 4.89 (dd,J=9.48, 4.85 Hz, 1H), 4.02 (t, J=5.73 Hz, 2H), 3.47-3.51 (m, 2H), 3.20(m, 1H), 2.97 (m, 1H), 2.90 (t, J=7.50 Hz, 2H), 2.81 (t, J=6.28 Hz, 2H),2.16-2.17 (m, 2H) and 1.94 (m, 2H) ppm.

BIOLOGICAL EXAMPLES Example B1—Cell Adhesion Assay

In order to determine the potency, the compounds were assessed for theirability to inhibit αvβ1 expressing CHO cells attach to TGFβ1LAP.Microplates were coated overnight with 2 ug/ml TGFβ1LAP at 4° C., andblocked with 2% BSA/PBS for 30 min before the assay. Cells were detachedand washed in PBS. After that the cells were resuspended in DMEM at1.0×10⁶ cells/ml, fifty microliter of cell suspension and fiftymicroliter of compound solution were added into the plate. The plateswere incubated for one hour at 37° C. in humidified 5% carbon dioxide.Non-adherent cells were removed by centrifugation top side down at 58 gfor 5 min. The attached cells were fixed and stained with 0.5% crystalviolet (in 20% methanol and 1% formaldehyde) and the wells washed withPBS. Crystal violet was dissolved in 2% Triton-X in PBS. The relativenumber of cells in each well was evaluated by the absorbance at 595 nmin a microplate reader (Tecan). IC₅₀ values were determined bynon-linear regression with four parameters (Graphpad Prism 7.01,Y=Bottom+(Top−Bottom)/(1+10{circumflex over ( )}((LogIC50−X)*HillSlope)).

The IC50 values obtained for αvβ1 integrin inhibition for exemplarycompounds are shown in Table B-1. The compounds tested were compoundsamples prepared according to procedures described in the SyntheticExamples section, with the stereochemical purity as indicated in theExamples indicated for Example or Compound No. 1-62. The compoundstested were predominantly S-configuration at the alpha carbon of theamino acid scaffold, except for compounds 123, 124, and 125 which werepredominantly R-configuration at the alpha carbon of the amino acidscaffold. “Example or Compound No.” in Table B-1 refers to the compoundillustrated in the examples for Example or Compound Nos. 1-62 (thecompounds of Examples 1-62 are labeled as Compounds 1-62 in Table 1).“Example or Compound No.” in Table B-1 refers to the compound number asindicated in Table 1 or Table 2 for Example or Compound Nos. 63-126.

TABLE B-1 Example or αvβ1 Inhibition Compound No. IC₅₀ (nM)-range 1 <502 <50 3 <50 4 >1000 5 <50 6 <50 7 <50 8 50-250 9 50-250 10 <50 11 50-25012 <50 13 <50 14 <50 15 <50 16 <50 17 >1000 18 <50 19 <50 20 <5021 >1000 22 <50 23 <50 24 50-250 25 50-250 26 >1000 27 <50 28 250-100029 <50 30 250-1000 31 50-250 32 50-250 33 <50 34 <50 34 <50 35 <50 36<50 37 250-1000 38 <50 39 >1000 40 <50 41 <50 42 <50 43 <50 44 <50 45<50 46 50-250 47 >1000 48 >1000 49 50-250 50 >1000 51 >1000 52 >100053 >1000 54 250-1000 55 50-250 56 250-1000 57 >1000 58 >1000 59 >1000 60<50 61 50-250 62 <50 65 <50 74 250-1000 81 50-250 82 50-250 86 50-250 9850-250 (Example 63) 99 <50 (Example 64) 100 <50 101 <50 102 50-250 10350-250 104 50-250 105 250-1000 106 250-1000 107 250-1000 108 50-250 10950-250 110 50-250 111 250-1000 112 50-250 113 50-250 114 <50 115250-1000 116 <50

Example B2—Solid Phase Integrin αvβ1 Binding Assay

Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml)in PBS (100 ul/well 4° C., overnight). The coating solution was removed,washed with PBS. Plate was blocked with 200 ul/well of Block Buffer (2%BSA in PBS) at 37° C. for 1 h. Dilutions of testing compounds andrecombinant fibronectin (2 ug/ml) in binding and washing buffer (50 mMTris-HCl, ph7.5; 0.1% BSA, 1 mM MnCl2; NaCl 150 mM; 0.02% Tween-20; 1 mMCaCl2); 1 mM MgCl2) were added. The plate was incubated for 2 hours at25° C., washed, and incubated for 1 hour with Biotin-Anti-fibronectin.Bound antibody was detected by peroxidase-conjugated streptavidin. TheIC₅₀ values for testing compounds were calculated by a four-parameterlogistic regression.

The IC₅₀ values obtained for αvβ1 integrin inhibition for exemplarycompounds are shown in Table B-2. The compounds tested were compoundsamples prepared according to procedures described in the SyntheticExamples section, with the stereochemical purity as indicated in theExamples. The compounds tested were predominantly S-configuration at thealpha carbon of the amino acid scaffold, except for compounds 123, 124,and 125 which were predominantly R-configuration at the alpha carbon ofthe amino acid scaffold. “Compound No.” in Table B-2 refers to thecompound number as indicated in Table 1 or Table 2.

Solid Phase Assay

TABLE B-2 Compound αvβ1 Inhibition No. IC₅₀ (nM)-range 65 <50 75250-1000 81 <50 87 <50 88 <50 89 <50 90 <50 91 <50 92 <50 93 <50 94 <5095 <50 96 <50 97 <50 117 <50 118 <50 119 <50 121 <50 122 <50 123 >1000124 >1000 125 >1000 126 50-250

All references throughout, such as publications, patents, patentapplications and published patent applications, are incorporated hereinby reference in their entireties.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it is apparent to those skilled in the art that certainminor changes and modifications will be practiced. Therefore, thedescription and examples should not be construed as limiting the scopeof the invention.

1.-58. (canceled)
 59. A method of treating a fibrotic disease in anindividual in need thereof comprising administering to the individual atherapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein: R¹ is C₆-C₁₄aryl or 5- to 10-membered heteroaryl, wherein the C₆-C₁₄ aryl and 5- to10-membered heteroaryl of R¹ are independently optionally substituted byR¹⁰; R² is 5- to 10-membered heteroaryl containing at least 2 ringnitrogen atoms, 3- to 12-membered heterocyclyl containing at least 2ring nitrogen atoms, —NH—R³, —R³-R¹⁰, or —R³—NR^(3a)R^(3b), wherein the5- to 10-membered heteroaryl and 3- to 12-membered heterocyclyl of R²are independently optionally substituted by R¹⁰; R³ is 5- to 10-memberedheteroaryl containing at least 1 ring nitrogen atom, or 3- to12-membered heterocyclyl containing at least 1 ring nitrogen atom,wherein the 5- to 10-membered heteroaryl and 3- to 12-memberedheterocyclyl of R³ are independently optionally substituted by R¹⁰;-A-L- is A³; or -A-L- is -A¹-L¹- or -A²-L²-, and R² is 5- to 10-memberedheteroaryl, 3- to 12-membered heterocyclyl, —NH-(5- to 10-memberedheteroaryl), or —NH-(3- to 12-membered heterocyclyl), wherein the 5- to10-membered heteroaryl and 3- to 12-membered heterocyclyl of R² containat least 2 ring nitrogen atoms and are independently optionallysubstituted by R¹⁰; A¹ is C₃-C₅ cycloalkylene, C₃-C₈ cycloalkenylene,C₆-C₁₄ arylene, 5- to 10-membered heteroarylene or 3- to 12-memberedheterocyclylene, wherein the C₃-C₈ cycloalkylene, C₃-C₈ cycloalkenylene,C₆-C₁₄ arylene, 5- to 10-membered heteroarylene and 3- to 12-memberedheterocyclylene of A¹ are independently optionally substituted by R¹⁰;A² is C₃-C₅ alkylene or C₃-C₅ alkenylene, wherein the C₃-C₈ alkylene andC₃-C₈ alkenylene of A² are independently optionally substituted by R⁹;A³ is C₅-C₁₀ alkylene or C₅-C₁₀ alkenylene, wherein the C₅-C₁₀ alkyleneand C₅-C₁₀ alkenylene of A³ are independently optionally substituted byR⁹; L¹ is —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Y¹—X¹—, —O—Z—Y¹—, —O—Z—Y¹—X¹—,—O—Z—X¹—Y¹—, —O—Z—X¹—Y¹—X¹—, —Z—O—Z—, —X¹—Z—O—Z—, —Z—O—Z—X¹—,—X¹—Z—O—Z—X¹—, —Z—O—Y¹—, —Z—O—Y¹—X¹—, —X¹—Z—O—Y¹—, —X¹—Z—O—Y¹—X¹—,—N(R⁴)—Z—, —N(R⁴)—Z—X¹—, X², —X²—Y¹—, Y², or —Y²—X²—; L² is C₃-C₆cycloalkylene optionally substituted by R¹⁰; each X¹ is independentlyC₁-C₆ alkylene or C₂-C₆ alkenylene, wherein the C₁-C₆ alkylene and C₂-C₆alkenylene of X¹ are independently optionally substituted by R¹⁰; eachX² is independently C₁-C₆ alkylene or C₂-C₆ alkenylene, wherein theC₁-C₆ alkylene and C₂-C₆ alkenylene of X² are independently optionallysubstituted by R⁹; each Y¹ is independently C₃-C₆ cycloalkyleneoptionally substituted by R¹⁰; each Y² is independently saturated 3- to4-membered heterocyclylene optionally substituted by R¹⁰; each Z isindependently —CR^(5a)R^(5b)—; each R^(3a), R^(3b), R⁴, R^(5a) andR^(5b) is independently H or C₁-C₆ alkyl; each R⁹ is independently C₁-C₆alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, —CN, —OR¹¹, —SR¹¹,—NR¹²R¹³, —NO₂, —C═NH(OR¹¹), —C(O)R¹¹, —OC(O)R¹¹, —C(O)OR¹¹,—C(O)NR¹²R¹³, —NR¹¹C(O)R¹², —NR¹¹C(O)OR¹², —NR¹¹C(O)NR¹²R¹³, —S(O)R¹¹,—S(O)₂R¹¹, —NR¹¹ S(O)R¹², —NR¹¹S(O)₂R¹², —S(O)NR¹²R¹³, —S(O)₂NR¹²R¹³,—P(O)(OR¹²) (OR¹³), C₃-C₈ cycloalkyl, 3- to 12-membered heterocyclyl, 5-to 10-membered heteroaryl or C₆-C₁₄ aryl, wherein each R⁹ isindependently optionally substituted by halogen, oxo, —OR¹⁴, —NR¹⁴R¹⁵,—C(O)R¹⁴, —CN, —S(O)R¹⁴, —S(O)₂R¹⁴, —P(O)(OR¹⁴)(OR¹⁵), C₃-C₅ cycloalkyl,3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C₆-C₁₄aryl, or C₁-C₆ alkyl optionally substituted by oxo, —OH or halogen; eachR¹⁰ is independently oxo or R⁹; R¹¹ is independently hydrogen, C₁-C₆alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄ aryl, 5-to 6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein theC₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄aryl, 5- to 6-membered heteroaryl and 3- to 6-membered heterocyclyl areindependently optionally substituted by halogen, oxo, —CN, —OR¹⁶,—NR¹⁶R¹⁷, —P(O)(OR¹⁶)(OR¹⁷), or C₁-C₆ alkyl optionally substituted byhalogen, —OH or oxo; R¹² and R¹³ are each independently hydrogen, C₁-C₆alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄ aryl, 5-to 6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein theC₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆-C₁₄aryl, 5- to 6-membered heteroaryl and 3- to 6-membered heterocyclyl areindependently optionally substituted by halogen, oxo, —CN, —OR¹⁶,—NR¹⁶R¹⁷ or C₁-C₆ alkyl optionally substituted by halogen, —OH or oxo;or R¹² and R¹³ are taken together with the atom to which they attachedto form a 3- to 6-membered heterocyclyl optionally substituted byhalogen, oxo, —OR¹⁶, —NR¹⁶R¹⁷ or C₁-C₆ alkyl optionally substituted byhalogen, oxo or —OH; R¹⁴ and R¹⁵ are each independently hydrogen, C₁-C₆alkyl optionally substituted by halogen or oxo, C₂-C₆ alkenyl optionallysubstituted by halogen or oxo, or C₂-C₆ alkynyl optionally substitutedby halogen or oxo; or R¹⁴ and R¹⁵ are taken together with the atom towhich they attached to form a 3- to 6-membered heterocyclyl optionallysubstituted by halogen, oxo or C₁-C₆ alkyl optionally substituted byhalogen or oxo; and R¹⁶ and R¹⁷ are each independently hydrogen, C₁-C₆alkyl optionally substituted by halogen or oxo, C₂-C₆ alkenyl optionallysubstituted by halogen or oxo, or C₂-C₆ alkynyl optionally substitutedby halogen or oxo; or R¹⁶ and R¹⁷ are taken together with the atom towhich they attached to form a 3-6 membered heterocyclyl optionallysubstituted by halogen, oxo or C₁-C₆ alkyl optionally substituted by oxoor halogen; provided that the compound is other than: L-Tyrosine,N-[(5-chloro-1,3-benzodioxol-4-yl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[(3-chloro-1-methyl-1H-indol-2-yl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]-O-(1H-tetrazol-5-ylmethyl)-;L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methyl]-;L-Tyrosine,N-(2-chloro-4-methoxybenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;L-Tyrosine,N-(2-chloro-6-methylbenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;L-Tyrosine,N-(2-fluoro-6-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[(2-ethyl-3-thienyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tryptophan, N-benzoyl-5-[4-(1-piperazinyl)butoxyl-; L-Tyrosine,N-(2-chlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[(3-chloro-2-thienyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,a-[(2,6-dichlorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2-chloro-6-fluorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-Tyrosine,N-[(3-chloro-4-pyridinyl)carbonyl]-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;L-Tyrosine,O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-N-(2,4,6-trimethylbenzoyl)-;L-Tyrosine,N-[(3,5-dichloro-4-pyridinyl)carbonyl]-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;L-Tyrosine,N-(2,4-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,α-[(2-chloro-4-methoxybenzoyl)amino]-5-[2(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; 2-Pyridinepropanoic acid,α-[(2-chlorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2-chloro-6-fluoro-3-methylbenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;3-Pyridinepropanoic acid,α-[(2-chlorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-(2-chloro-6-fluorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;L-Tyrosine,N-(2-chloro-5-fluorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;2-Naphthalenepropanoic acid,α-(benzoylamino)-6-[2-(1-piperazinyl)ethoxy]-; L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2-ethyl-4-fluorobenzoyl)-;L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-5-methyl-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,α-[[(3-chloro-2-thienyl)carbonyl]amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(1,2,3,4-tetrahydro-1-methylpyrido[2,3-b]pyrazin-6-yl)ethyl]-;L-Tryptophan,N-benzoyl-5-[3-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]propoxy]-;L-Tyrosine,N-(2,6-dimethylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-[(3-methyl-4-pyridinyl)carbonyl]-;L-Tyrosine,N-(2-chloro-6-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[(3-chloro-2-thienyl)carbonyl]-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;2-Thiophenepropanoic acid,α-[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2-chloro-3,6-difluorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,α-[(2-fluoro-4-methylbenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-4-methyl-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,α-[(2-chloro-4-fluorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;3-Pyridinepropanoic acid,α-[(2-chloro-4-fluorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2-chlorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2-ethyl-5-fluorobenzoyl)-;1-Piperazinecarboxylic acid,4-[2-[[6-[2-(benzoylamino)-2-carboxyethyl]-2-naphthalenyl]oxy]ethyl]-,1-(1,1-dimethylethyl) ester; L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2,4,6-trimethylbenzoyl)-;L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-(2,6-dimethylbenzoyl)-;3-Pyridinepropanoic acid,α-[[(3-chloro-2-thienyl)carbonyl]amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tryptophan,N-benzoyl-5-[4-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]butoxy]-;L-Tyrosine,N-(2-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[(3,5-dichloro-4-pyridinyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tryptophan, N-benzoyl-5-[3-(1-piperazinyl)propoxy]-; L-Tyrosine,N-(6-chloro-2-fluoro-3-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-[(4-methoxy-3-thienyl)carbonyl]-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;L-Tyrosine,N-(2-chloro-4-fluorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-L-Tyrosine,O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-N-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-;L-Tyrosine,N-(2-chloro-5-methylbenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,α-[(2-ethyl-4-fluorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,αS)-; L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-7-methyl-1,8-naphthyridin-2-yl)ethyl]-;2-Pyridinepropanoic acid,α-[(2-chloro-6-fluorobenzoyl)amino]-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxyl-,(αS)-; 3-Pyridinepropanoic acid,α-(2-chloro-6-fluorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2-chloro-4-fluorobenzoyl)-O-[2-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)ethyl]-;3-Pyridinepropanoic acid,α-[(2,6-dichlorobenzoyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-,(αS)-; L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl];L-Tyrosine,N-(2,6-dichlorobenzoyl)-O-[2-methyl-2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-;L-Tyrosine,O-[3-(4-pyrimidinylamino)propyl]-N-(2,4,6-trimethylbenzoyl)-;L-Tyrosine,N-benzoyl-O-[4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]butyl]-;L-Tyrosine, O-[2-(2-benzothiazolylamino)ethyl]-N-(2,6-dichlorobenzoyl)-;L-Tyrosine,O-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]-N-(2,4,6-trimethylbenzol)-;L-Tyrosine,O-[3-(2-pyrimidinylamino)propyl]-N-(2,4,6-trimethylbenzoyl)-;L-Tyrosine,O-[2-(1H-benzimidazol-2-ylamino)ethyl]-N-(2,6-dichlorobenzoyl)-;L-Tyrosine, N-benzoyl-O-[4-(2-pyrimidinylamino)butyl]-; L-Tyrosine,O-[3-[(1,4,5,6-tetrahydro-2-pyrazinyl)amino]propyl]-N-(2,4,6-trimethylbenzoyl)-;L-Tyrosine, O-[3-(2-pyrazinylamino)propyl]-N-(2,4,6-trimethylbenzol)-;2-Thiophenepropanoic acid,α-[(2-chloro-4-fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 2-Pyridinepropanoic acid,α-[(2-chlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 3-Pyridinepropanoic acid,α-[(2-chloro-4-fluorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 2-Thiophenepropanoic acid,α-[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; L-Phenylalanine,N-(2-chloro-4-fluorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]-;2-Thiophenepropanoic acid,α-[(2-chloro-6-fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl],(αS)-; 2-Pyridinepropanoic acid,α-[(2-fluoro-6-methylbenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 3-Pyridinepropanoic acid,α-[(2-chloro-6-fluorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl-,(αS)-; L-Phenylalanine,N-(2,6-dichlorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]-;2-Thiophenepropanoic acid,α-(2,6-dichlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl-,(αS)-; 2-Pyridinepropanoic acid,α-(2-chloro-4-fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 2-Pyridinepropanoic acid,α-[[(3-chloro-2-thienyl)carbonyl]amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; L-Phenylalanine,N-(2-chlorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-;L-Phenylalanine,N-(2-chloro-6-fluorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-;2-Pyridinepropanoic acid,α-[(2-chloro-6-fluorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 2-Pyridinepropanoic acid,α-[(2,6-dichlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; L-Phenylalanine,N-(2,6-dichlorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-;3-Pyridinepropanoic acid,α-[(2,6-dichlorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; L-Phenylalanine,N-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-;L-Phenylalanine,N-(2-chlorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]-;2-Thiophenepropanoic acid,α-[[3-[(dimethylamino)methyl]benzoyl]amino]-5-[(8-methyl-6,10-dioxo-7,9-diazaspiro[4.5]dec-7-en-9-yl)methyl]-;2-Thiophenepropanoic acid,α-[(2-chlorobenzoyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; L-Phenylalanine,N-(2-chloro-4-fluorobenzoyl)-4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-;3-Pyridinepropanoic acid,α-[(2-chlorobenzoyl)amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; 2-Thiophenepropanoic acid,α-[[(3,5-dimethyl-4-isoxazolyl)carbonyl]amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; L-Phenylalanine,N-(2-chloro-6-fluorobenzoyl)-4-[3-(3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)propyl]-;3-Pyridinepropanoic acid,α-[[(3-chloro-2-thienyl)carbonyl]amino]-6-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-,(αS)-; or 1,8-Naphthyridine-2-nonanoic acid,α-(benzoylamino)-5,6,7,8-tetrahydro-, (αS)-, or a pharmaceuticallyacceptable salt thereof, and wherein the fibrotic disease is selectedfrom the group consisting of: idiopathic pulmonary fibrosis, cirrhosis,biliary tract fibrosis, diabetic nephrosclerosis, hypertensivenephrosclerosis, focal segmental glomerulosclerosis, acute kidney injuryfrom contrast induced nephropathy, systemic and local sclerosis orscleroderma, keloids and hypertrophic scars, post-surgical adhesions,atherosclerosis, restenosis, Crohn's disease, post-myocardial infarctioninduced fibrosis, and inherited cardiomyopathy.
 60. The method of claim59, wherein R¹ is a fused bicyclic C₉-C₁₄ aryl optionally substituted byR¹⁰ or a fused bicyclic 7- to 10-membered heteroaryl optionallysubstituted by R¹⁰.
 61. The method of claim 60, wherein R¹ is the fusedbicyclic 7- to 10-membered heteroaryl optionally substituted by R¹⁰, andwherein R¹ is indazolyl optionally substituted by R¹⁰, benzimidazolyloptionally substituted by R¹⁰, or benzoxazolyl optionally substituted byR¹⁰.
 62. The method of claim 59, wherein R¹ is phenyl optionallysubstituted by R¹⁰.
 63. The method of claim 59, wherein R¹ is amonocyclic 5- or 6-membered heteroaryl optionally substituted by R¹⁰.64. The method of claim 59, wherein the -A-L-moiety is -A¹-L¹-.
 65. Themethod of claim 64, wherein A¹ is selected from the group consisting of:1,4-phenylene, 1,3-phenylene, 1,1-cyclopropylene, 1,2-cyclopropylene,1,3-cyclobutylene, 1,4-cyclohexylene, 1,3-azetidinylene,1,3-pyrrolidinylene, and 2,5-benzo[d]oxazolylene.
 66. The method ofclaim 64, wherein L¹ is —O—Z—, —O—Z—X¹—, —O—Y¹—, —O—Z—Y¹—, —O—Z—X¹—Y¹—,—Z—O—Z—, —X¹—Z—O—Z—, —Z—O—Z—X¹—, —X¹—Z—O—Z—X¹—, —Z—O—Y¹—, or—X¹—Z—O—Y¹—.
 67. The method of claim 66, wherein Z is —CR^(5a)R^(5b)—,and wherein each of R^(5a) and R^(5b) is independently H.
 68. The methodof claim 66, wherein L¹ is selected from the group consisting of:—O—(CH₂)₃—, —O—(CH₂)₄—, —CH₂—O—(CH₂)₃—, —CH₂—O—(CH₂)₂—,—CH(CH₃)—O—(CH₂)₂—, —CH₂—O—(C H₂)₃—,

and wherein the wavy lines denote attachment points to the parentmolecule.
 69. The method of claim 64, wherein L¹ is —N(R⁴)—Z— or—N(R⁴)—Z—X¹—.
 70. The method of claim 69, wherein R⁴ is H and Z is—CR^(5a)R^(5b)—, wherein each of R^(5a) and R^(5b) is independently H,and wherein L¹ is —NH—C(CH₃)₂—(CH₂)₂—.
 71. The method of claim 64,wherein L¹ is X² or —X²—Y¹—, wherein L¹ is selected from the groupconsisting of: —(CH₂)₂—, —(CH₂)₄—, —(CH₂)₅—, —CF₂—(CH₂)₃— and

and wherein the wavy lines denote attachment points to the parentmolecule.
 72. The method of claim 64, wherein L¹ is Y² or —Y²—X²—. 73.The method of claim 72, wherein Y² is saturated 4-memberedheterocyclylene optionally substituted by R¹⁰.
 74. The method of claim72, wherein L¹ is selected from the group consisting of:

and wherein the wavy lines denote attachment points to the parentmolecule.
 75. The method of claim 59, wherein the -A-L- moiety is-A²-L²-, and wherein A² is C₃-C₈ alkylene optionally substituted by R⁹.76. The method of claim 59, wherein the -A-L- moiety is A³, and whereinA³ is C₅-C₁₀ alkenylene optionally substituted by R⁹.
 77. The method ofclaim 59, wherein the -A-L- moiety is -A²-L²- or A³, wherein the-A-L-moiety is selected from the group consisting of: —CH₂(CH₂)₅CH₂—,—CH₂(CH₂)₄CH₂—, —CH═CH—(CH₂)₃CH₂—, and

and wherein the wavy lines denote attachment points to the parentmolecule.
 78. The method of claim 59, wherein R² is 5- to 10-memberedheteroaryl containing at least 2 ring nitrogen atoms optionallysubstituted by R¹⁰, or 3- to 12-membered heterocyclyl containing atleast 2 ring nitrogen atoms optionally substituted by R¹⁰.
 79. Themethod of claim 78, wherein R² is selected from the group consisting of:5,6,7,8-tetrahydro-naphthyridinyl,1,2,3,4-tetrahydro-1,8-naphthyridinyl,3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, and2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl.
 80. The method of claim 59,wherein R² is —NH—R³ and -A-L- is -A³-.
 81. The method of claim 80,wherein R³ is 5- to 10-membered heteroaryl containing at least 1 ringnitrogen atom optionally substituted by R¹⁰, and wherein R³ is selectedfrom the group consisting of: 4,5-dihydro-1H-imidazolyl,5,6-dihydro-4H-1,3-oxazinyl, 4,5-dihydrothiazolyl,3,4,5,6-tetrahydropyrazinyl, and 5,6-dihydro-4H-1,3-thiazinyl.
 82. Themethod of claim 80, wherein R³ is pyridinyl optionally substituted byR¹⁰, and wherein R³ is selected from the group consisting of:4,5-dihydro-1H-imidazolyl, 5,6-dihydro-4H-1,3-oxazinyl,4,5-dihydrothiazolyl, 3,4,5,6-tetrahydropyrazinyl, and5,6-dihydro-4H-1,3-thiazinyl.
 83. The method of claim 59, whereinR²—R³—NR^(3a)R^(3b) and -A-L- is -A³-.
 84. The method of claim 83,wherein R² is —R³—NHR^(3a).
 85. The method of claim 83, wherein R³ ispyridyl optionally substituted by R¹⁰.
 86. The method of claim 59,wherein the compound is selected from the group consisting of:2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-benzamido-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(1-methyl-1H-benzo[d]imidazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(1-methyl-1H-benzo[d]imidazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(1-methyl-1H-benzo[d]imidazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(5-(difluoromethyl)pyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(5-(difluoromethyl)pyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(5-(difluoromethyl)pyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(6-phenylpyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(6-phenylpyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(6-phenylpyrazine-2-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichloro-4-cyanobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2,6-dichloro-4-cyanobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2,6-dichloro-4-cyanobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2-fluoro-6-(trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2-fluoro-6-(trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2-fluoro-6-(trifluoromethyl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2,6-difluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2-methylpyrimidine-4-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2-methylpyrimidine-4-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2-methylpyrimidine-4-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(1-methyl-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(1-methyl-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(1-methyl-1H-benzo[d]imidazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(benzo[d]oxazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(benzo[d]oxazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(benzo[d]oxazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(3-amino-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(3-formamido-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(3-formamido-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(3-formamido-4-hydroxybenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(isonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(isonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(isonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(nicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(nicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(nicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(3,5-dichloroisonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(3,5-dichloroisonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(3,5-dichloroisonicotinamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-((S)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-((R)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-((R)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-((S)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(E)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)non-4-enoicacid; (S,E)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)non-4-enoicacid; (R,E)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)non-4-enoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methyl)azetidin-1-yl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methyl)azetidin-1-yl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methyl)azetidin-1-yl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)azetidin-1-yl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)cyclobutyl)methoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)cyclobutyl)methoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)cyclobutyl)methoxy)phenyl)propanoicacid;(E)-2-(2,6-dichlorobenzamido)-3-(4-(2-(4-(pyridin-3-ylamino)cyclohexyl)vinyl)phenyl)propanoicacid; (S,E)-2-(2,6-dichlorobenzamido)-3-(4-(2-(4-(pyridin-3-ylamino)cyclohexyl)vinyl)phenyl)propanoicacid; (R,E)-2-(2,6-dichlorobenzamido)-3-(4-(2-(4-(pyridin-3-ylamino)cyclohexyl)vinyl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((4-(pyridin-2-ylamino)cyclohexyl)methoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-((4-(pyridin-2-ylamino)cyclohexyl)methoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-((4-(pyridin-2-ylamino)cyclohexyl)methoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((2-methyl-4-(pyridin-2-ylamino)butan-2-yl)amino)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-((2-methyl-4-(pyridin-2-ylamino)butan-2-yl)amino)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-((2-methyl-4-(pyridin-2-ylamino)butan-2-yl)amino)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(+/−)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-((2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)methyl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)propoxy)methyl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)propoxy)methyl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)propoxy)methyl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(((4-(pyridin-2-ylamino)cyclohexyl)oxy)methyl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(((4-(pyridin-2-ylamino)cyclohexyl)oxy)methyl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(((4-(pyridin-2-ylamino)cyclohexyl)oxy)methyl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)cyclobutoxy)methyl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)cyclobutoxy)methyl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-((3-(pyridin-2-ylamino)cyclobutoxy)methyl)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)phenyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(4-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)phenyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(4-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy)ethyl)phenyl)propanoicacid;2-(4-cyclopropylbenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(4-cyclopropylbenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(4-cyclopropylbenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(3,5-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(3,5-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(3,5-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2-chloro-5-fluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2-chloro-5-fluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2-chloro-5-fluorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-cis-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid;(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-cis-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid;(2R)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-cis-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid;2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-trans-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid;(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-trans-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid;(2R)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[4-trans-(2-pyridylamino)cyclohexoxy]phenyl]propanoicacid;2-(1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(1-methyl-1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(1-methyl-1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(1-methyl-1H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(1-methyl-1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(1-methyl-1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(1-methyl-1H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2-methyl-2H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2-methyl-2H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2-methyl-2H-indazole-6-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2-methyl-2H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2-methyl-2H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2-methyl-2H-indazole-5-carboxamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-((1-((pyridin-2-ylamino)methyl)cyclopropyl)methoxy)phenyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(4-((1-((pyridin-2-ylamino)methyl)cyclopropyl)methoxy)phenyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(4-((1-((pyridin-2-ylamino)methyl)cyclopropyl)methoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-10-((3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((4,5-dihydrooxazol-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrooxazol-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrooxazol-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((4,5-dihydrothiazol-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrothiazol-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((4,5-dihydrothiazol-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((4-methyl-3-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)decanoicacid;2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)decanoicacid;(S)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)decanoicacid;(R)-2-(2,6-dichlorobenzamido)-10-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)decanoicacid;3-(4-(4-((4-acetyl-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6-dichlorobenzamido)propanoicacid;(S)-3-(4-(4-((4-acetyl-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6-dichlorobenzamido)propanoicacid;(R)-3-(4-(4-((4-acetyl-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)-2-(2,6-dichlorobenzamido)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((1-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4-methyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-oxazin-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((5,6-dihydro-4H-1,3-thiazin-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrooxazol-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(4-((4,5-dihydrothiazol-2-yl)amino)butoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(2,6-dichlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(2,6-dichlorobenzamido)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)nonanoicacid;(2S)-2-(2,6-dichlorobenzamido)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)nonanoicacid;(2R)-2-(2,6-dichlorobenzamido)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)nonanoicacid;2-(2,6-dichlorobenzamido)-7-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)cyclopropyl)heptanoicacid;(2S)-2-(2,6-dichlorobenzamido)-7-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)cyclopropyl)heptanoicacid;(2R)-2-(2,6-dichlorobenzamido)-7-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)cyclopropyl)heptanoicacid;2-(2,6-dichlorobenzamido)-3-(2-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)cyclopropyl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(2-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)cyclopropyl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(2-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)cyclopropyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(1-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)cyclopropyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(1-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)cyclopropyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(1-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentyl)cyclopropyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)cyclobutyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)cyclobutyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)cyclobutyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)cyclobutyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)cyclobutyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)cyclobutyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)cyclohexyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)cyclohexyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)cyclohexyl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)azetidin-1-yl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)azetidin-1-yl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(3-((3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)methyl)azetidin-1-yl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)azetidin-1-yl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)propanoicacid;(2S)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)propanoicacid;(2R)-2-(2,6-dichlorobenzamido)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pyrrolidin-1-yl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)benzo[d]oxazol-5-yl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)benzo[d]oxazol-5-yl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(2-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)benzo[d]oxazol-5-yl)propanoicacid;2-(2,6-dichlorobenzamido)-3-(4-(1,1-difluoro-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)phenyl)propanoicacid;(S)-2-(2,6-dichlorobenzamido)-3-(4-(1,1-difluoro-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)phenyl)propanoicacid;(R)-2-(2,6-dichlorobenzamido)-3-(4-(1,1-difluoro-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)phenyl)propanoicacid;9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-5-carboxamido)nonanoicacid;(2S)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-5-carboxamido)nonanoicacid;(2R)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-5-carboxamido)nonanoicacid;2-(1-methyl-1H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(2S)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(2R)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-6-carboxamido)nonanoicacid;(2S)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-6-carboxamido)nonanoicacid;(2R)-9-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-3-yl)-2-(1-methyl-1H-indazole-6-carboxamido)nonanoicacid;2-(1-methyl-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-methyl-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(1-methyl-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(1-methyl-1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(1-methyl-1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(1-(tert-butyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-(tert-butyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(1-(tert-butyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(1-(cyclopropylmethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-(cyclopropylmethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(1-(cyclopropylmethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(2-methyl-2H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(2S)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(2R)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(2-methyl-2H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(2-methyl-2H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(4-chlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(4-fluorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(4-methoxybenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(4-cyanobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(3-chlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(3-fluorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(3-methoxybenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(3-cyanobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(2-fluorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(2-chlorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxamido)nonanoicacid;2-(1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;2-(2,6-dichloro-4-(1H-imidazol-5-yl)benzamido)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)phenyl)propanoicacid;(S)-2-(2-chloro-5-cyanobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(4-cyano-2-fluorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-(difluoromethyl)-1H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2-(difluoromethyl)-2H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-(difluoromethyl)-1H-indazole-5-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2-(difluoromethyl)-2H-indazole-6-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(5-phenyl-1H-pyrazole-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(4-(pyridin-3-yl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(4-(pyridin-4-yl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(4-(1-methyl-1H-pyrazol-4-yl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-methyl-1H-indazole-7-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1-methyl-1H-indazole-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(1H-indazole-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2-chloro-4-isopropoxybenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2-chloro-5-(trifluoromethoxy)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(3-(3,5-dimethyl-1H-pyrazol-1-yl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-benzamido-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(2-chloro-3-fluorobenzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(S)-2-(3-fluoro-5-(trifluoromethyl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-2-(3-(1-methyl-1H-pyrazol-4-yl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid;(R)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(3-(thiazol-5-yl)benzamido)nonanoicacid;(R)-2-(3-fluoro-5-(trifluoromethyl)benzamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoicacid; and(S)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(3-(thiazol-5-yl)benzamido)nonanoicacid, or a pharmaceutically acceptable salt thereof.
 87. The method ofclaim 59, wherein the fibrotic disease is idiopathic pulmonary fibrosis.88. The method of claim 59, wherein the fibrotic disease is cirrhosis.89. The method of claim 59, wherein the fibrotic disease is biliarytract fibrosis.
 90. The method of claim 59, wherein the fibrotic diseaseis diabetic nephrosclerosis.
 91. The method of claim 59, wherein thefibrotic disease is hypertensive nephrosclerosis.
 92. The method ofclaim 59, wherein the fibrotic disease is focal segmentalglomerulosclerosis.
 93. The method of claim 59, wherein the fibroticdisease is acute kidney injury from contrast induced nephropathy. 94.The method of claim 59, wherein the fibrotic disease is systemic andlocal sclerosis or scleroderma.
 95. The method of claim 59, wherein thefibrotic disease is keloids and hypertrophic scars.
 96. The method ofclaim 59, wherein the fibrotic disease is post-surgical adhesions. 97.The method of claim 59, wherein the fibrotic disease is atherosclerosis.98. The method of claim 59, wherein the fibrotic disease is restenosis.99. The method of claim 59, wherein the fibrotic disease is Crohn'sdisease.
 100. The method of claim 59, wherein the fibrotic disease ispost-myocardial infarction induced fibrosis.
 101. The method of claim59, wherein the fibrotic disease is inherited cardiomyopathy.